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The human prion protein (PrP) gene (PRNP) codon 129 (M/V) 
polymorphism is a susceptibility factor for variant Creutzfeldt-Jakob Disease (vCJD) 
and a major determinant of clinico-pathological phenotype in sporadic CJD.  The 
role of codon 129 in defining susceptibility and strain transmission properties has 
been investigated in three lines of transgenic mice that express human PrP.  The 
human PRNP gene has directly replaced the murine version, by gene targeting, and 
variation at codon 129 has given the three genotype lines (HuMM, HuMV, and 
HuVV).  The genetics of these three mouse lines are otherwise identical, and 
therefore differences in transmission properties can be directly attributable to the 
codon 129 genotype.   
vCJD inoculation has shown that all three codon 129 genotype mice are 
susceptible with a ranking of transmission efficiency of HuMM>HuMV>HuVV.  
HuMM mice develop the most widespread neuropathology with features similar to 
human vCJD.  Subclinical infection was noted in each mouse line.  These data 
suggest that the vCJD strain is transmissible to humans of each of the three codon 
129 genotypes, implying that non-MM cases of human infection with bovine 
spongiform encephalopathy (BSE) may exist but with long subclinical incubation 
periods.  Inoculation of material from blood transfusion associated vCJD showed no 
change in transmission properties suggesting that the threat of a future epidemic of 
human-to-human vCJD infection has not been increased by adaptation of the vCJD 
strain.  However the route of infection, for example via blood transfusion or surgery, 
may be more efficient that the original oral route of BSE infection.   
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sCJD is classified into six subgroups according to clinico-pathological 
features, and defined by codon 129 genotype and electrophoretic mobility type (1 or 
2) of disease associated PrPSc (MM1, MM2, MV1, MV2, VV1, VV2).  Typical cases 
from each subgroup have shown specific transmission properties suggesting that the 
subgrouping is defining separate disease strains.  The commonest subgroup (MM1) 
was the most transmissible and the HuVV mouse line the most susceptible host.  
These data outline the transmission risk from all sCJD types to recipients of each 
codon 129 genotype should an infection event occur, and show the significant role of 
recipient codon 129 genotype in defining the clinical or subclinical state and the 
success or failure of transmission.  This is important for determining individual risk 
following known exposure, and for modelling the potential of iatrogenic infection 




129Ola: wild type mouse line used to generate transgenic lines 
bp: base pair 
BSE: bovine spongiform encephalopathy 
CJD: Creutzfeldt-Jakob Disease 
CNS: central nervous system 
D178N/128V: D178N mutation on the V codon 129 allele (humans) 
D178N/129M: D178N mutation on the M codon 129 allele (humans) 
D178N: Aspartic acid (D) to Asparagine (N) mutation at codon 178 (humans) 
DM: dura mater 
DNA: deoxyribonucleic acid 
E200K: Glutamic acid (E) to Lysine (K) mutation at codon 200 (humans) 
EEG: electroencephalography 
ES: embryonic stem cells 
fCJD: Familial CJD 
FFI: Fatal Familial Insomnia 
FSE: Feline spongiform encephalopathy 
GPI: glycosyl-phophatidylinositol anchor 
GSS: Gerstmann Sträussler Scheinker Syndrome 
GT: gene targeting 
hGH: human growth hormone 
HLA: Human leukocyte antigen 
HuMM: NPD transgenic mouse homozygous for methionine 
HuMV: NPD transgenic mouse heterozygous for methionine / valine 
HuVV: NPD transgenic mouse homozygous for valine 
i.c.: intracerebral 
ICC: immunocytochemistry 
ICD: intercurrent death 
iCJD: iatrogenic CJD 
i.p.: intraperitoneal 
IP: incubation period 
i.v.: intravenous 
kb: kilo base pairs 
kDa: kilo Dalton 
MM: methionine homozygous at codon 129 
MM1, MM2, MV1, MV2, VV1, VV2: subgroups of sCJD 
MRI: magnetic resonance imaging 
mRNA: messenger RNA 
MV: methionine / valine heterozygous at codon 129 
NIBSC: National Institute for Biological Standards and Control 
NCJDSU: National CJD Surveillance Unit 
NFTs: neurofibrillary tangles 
NMR: nuclear magnetic resonance 
NPD: Neuropathogenesis Division, Roslin Institute 
ORF: Open Reading Frame 
P101L: Proline (P) to Leucine (L) mutation at codon 101 (mice) 
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P102L: Proline (P) to Leucine (L) mutation at codon 102 (humans) 
PCR: polymerase chain reaction 
PIPLC: phosphatidylinositol-specific phospholipase C 
PNS: peripheral nervous system 
PRND: human doppel protein gene 
Prnd: mouse doppel protein gene 
PRNP: human prion protein gene 
Prnp: mouse prion protein gene 
Prnp+/+: wild-type mouse with two copies of the PrP gene 
Prnp0/0: wild-type mouse that does not express PrP 
Prnpa: wild-type line with leucine at codon 108 and threonine at codon 189 
Prnpb: wild-type line with phenylalanine at codon 108 and valine at codon 189 
PrP: prion protein 
PrPC: normal cellular form of PrP 
PrPSc: abnormal ‘scrapie’ form of PrP 
QTL: quantitative trait loci 
RGI: random genomic insertion 
RNA: ribonucleic acid 
sCJD: sporadic CJD 
TME: transmissible mink encephalopathy 
TMER: Transfusion Medicine Epidemiology Review 
TSE: transmissible spongiform encephalopathy 
Type 1: protease resistant core of PrPSc with 21kDa electrophoretic mobility 
Type 2: protease resistant core of PrPSc with 19kDa electrophoretic mobility 
UK: United Kingdom 
vCJD (BSE): vCJD associated with BSE infection 
vCJD (transfusion): vCJD associated with blood transfusion infection 
vCJD: variant Creutzfeldt-Jakob Disease 
VV: valine homozygous at codon 129 
WHO: World Health Organisation 
 vii
 
TABLE OF CONTENTS 
 
DECLARATION........................................................................................... ii 
ACKNOWLEDGEMENTS .......................................................................... iii 
ABSTRACT................................................................................................ iv 
ABBREVIATIONS ......................................................................................vi 
TABLE OF CONTENTS ........................................................................... viii 
TABLE OF FIGURES................................................................................xx 





1.1  PHD THESIS INVESTIGATIONS........................................................ 1 
1.2  TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY (TSE)......... 3 
Figure 1.F1:  Examples of TSE Histopathology ........................... 4 
1.3  THE PRION HYPOTHESIS................................................................. 4 
1.3.1  The Prion Protein.......................................................................... 5 
Figure 1.F2:  Human PrP Structure.............................................. 8 
Table 1.T1:  Comparison of PrPC and PrPSc Properties............... 9 
Figure 1.F3:  Western Blot Analysis of PrPSc ............................. 11 
1.4  THE PRION PROTEIN GENE........................................................... 11 
Figure 1.F4:  PrP Amino Acid Comparison Between Species.... 12 
1.4.1  Prion Protein Gene DNA Variation.............................................. 13 
1.4.2  Human Codon 129 Polymorphism.............................................. 14 
Figure 1.F5:  Human PRNP Gene Variation .............................. 15 
Table 1.T2:  Codon 129 Genotype Frequencies Worldwide ...... 16 
Table 1.T3:  Codon 129 Genotype Frequency Variation in TSE 
Disease...................................................................................... 17 
1.5  NON-PRNP GENETIC FACTORS .................................................... 18 
1.5.1  Doppel ........................................................................................ 18 
 viii
 
1.5.2  Quantitative Trait Loci Analysis .................................................. 19 
1.6  HUMAN PRION DISEASES.............................................................. 20 
1.6.1  Sporadic CJD ............................................................................. 21 
Table 1.T4:  Subgroups of sCJD................................................ 24 
Table 1.T5:  PrPSc Deposition in sCJD Subgroups .................... 25 
Figure 1.F6:  Pathology Profiles for sCJD Subgroups................ 26 
1.6.2  Genetic / Inherited Prion Disease ............................................... 27 
1.6.2.1  Familial CJD (fCJD) ............................................................. 28 
1.6.2.1.1  Codon 178: Asp (D) to Asn (N)...................................... 28 
1.6.2.1.2  Codon 200: Glu (E) to Lys (K) ....................................... 29 
1.6.2.1.3  Codon 210: Val (V) to Ile (I) ........................................... 29 
1.6.2.1.4  Insertions ....................................................................... 29 
1.6.2.2  Gerstmann Sträussler Scheinker Syndrome (GSS) ............. 30 
1.6.2.2.1  Codon 102: Pro (P) to Leu (L) ....................................... 30 
1.6.2.2.2  Codon 117: Ala (A) to Val (V) ........................................ 30 
1.6.2.2.3  Codon 198: Phe (F) to Ser (S)....................................... 30 
1.6.2.2.4  Codon 217: Gln (Q) to Arg (R)....................................... 31 
1.6.2.3  Fatal Familial Insomnia (FFI)................................................ 31 
1.6.3  Acquired Prion Disease .............................................................. 31 
1.6.6.1  Iatrogenic CJD (iCJD) .......................................................... 32 
1.6.6.2  Kuru ..................................................................................... 33 
1.6.6.3  Variant CJD (vCJD).............................................................. 34 
Figure 1.F7:  vCJD Histopathology ............................................ 37 
1.7  TRANSMISSION OF TSE TO EXPERIMENTAL ANIMALS.............. 41 
1.7.1  Scrapie Transmission ................................................................. 42 
1.7.2  BSE Transmission ...................................................................... 43 
Figure 1.F8:  Lesion Profiles of Wild-type Mice with BSE and 
vCJD .......................................................................................... 44 
1.7.3  Other Non-Human TSE Transmission ........................................ 44 
1.7.4  Human TSE Transmission.......................................................... 45 
1.7.4.1  Inoculation of Non-Human Primates .................................... 45 
1.7.4.2  Sporadic CJD Transmission to Rodents .............................. 46 
 ix
 
1.7.4.3  Genetic TSE Transmission to Rodents ................................ 48 
1.7.4.4  Variant CJD Transmission to Rodents ................................. 48 
1.8  TRANSGENIC MOUSE MODELS OF TSE TRANSMISSION .......... 49 
1.8.1  Random Genomic Insertion (RGI) of Genetic Elements ............. 50 
1.8.2  Gene Targeting (GT) for Precise Insertion of Genetic Elements 51 
1.8.3  Knockout / Null Transgenic Mice and the Role of PrP ................ 52 
1.8.4  Chimeric Transgenic Mice and PrP Molecular Interaction .......... 53 
1.8.5  Transgenic Mice with Mutations Associated with Human Disease
............................................................................................................. 54 
1.9  TRANSGENIC MICE WITH FULL-LENGTH HUMAN PRION GENE 
SEQUENCE............................................................................................. 55 
Table 1.T6:  Transgenic Lines Expressing Human PrP ............. 56 
1.9.1  Random Genomic Insertion (RGI) Method ................................. 57 
1.9.1.1  Co-Expression of Human and Mouse Prion Genes.............. 57 
1.9.1.2  Expression of Human Prion Gene in the Absence of Mouse 
PrP.................................................................................................... 58 
Table 1.T7:  Tg152 (VV) Transgenic Mice with Various TSE 
Inocula ....................................................................................... 59 
1.9.1.3  Expression of Human PrP Homozygous (MM or VV) at Codon 
129.................................................................................................... 60 
Table 1.T8:  SCJD Inoculation of Various Transgenic Mouse 
Lines .......................................................................................... 61 
1.9.1.3.1  Expression Level Effects ............................................... 62 
1.9.1.3.2  Genetic Background Effects .......................................... 62 
1.9.1.3.3  Host Codon 129 Genotype Effects ................................ 63 
1.9.1.3.4  SCJD Inoculum Codon 129 Genotype Effects............... 63 
1.9.1.4  Expression of Human PrP Heterozygous (MV) at Codon 129
.......................................................................................................... 64 
Table 1.T9:  Comparison of Collinge Group Transgenic Lines .. 66 
1.9.2  Gene Targeting (GT) Method ..................................................... 67 
1.9.2.1  Sporadic CJD Transmission to the Kitamoto GT Mice ......... 67 
 x
 
1.9.2.2  Variant CJD and BSE Transmission to the Kitamoto GT Mice
.......................................................................................................... 68 
1.9.3  Possible Evidence for Strain Selection ....................................... 69 
1.9.4  Summary of Data for Human TSE Transmission to Transgenic 
Mice...................................................................................................... 71 
Table 1.T10:  Human TSE Transmission to Various Transgenic 
Mouse Lines .............................................................................. 72 





2.1  GENE TARGETED TRANSGENIC MOUSE LINE PRODUCTION ... 74 
2.1.1  Construction of Gene Targeting Vectors..................................... 74 
Figure 2.F1:  Gene Vector Flowchart ......................................... 75 
2.1.2  DNA Vector Insertion into Embryonic Stem (ES) Cells ............... 76 
2.1.3  Production of Recipient Blastocysts............................................ 76 
2.1.4  Transfer of ES Cells to Blastocysts............................................. 76 
2.1.5  Embryo Transfer to Female Mice................................................ 76 
2.1.6  Germline Transmission of Gene Targeted Vector ...................... 77 
2.1.7  PCR Genotyping of Mouse Tail DNA.......................................... 77 
2.2  DNA EXTRACTION........................................................................... 77 
2.3  GENOTYPING, SEQUENCING, AND SEQUENCE ANALYSIS ....... 78 
2.3.1  Genotyping ................................................................................. 78 
Figure 2.F2:  Codon 129 Genotyping Gel Image ....................... 80 
2.3.2  Sequencing and Sequence Analysis .......................................... 80 
2.4  RNA EXTRACTION........................................................................... 81 
2.5  NORTHERN ANALYSIS OF EXTRACTED RNA .............................. 82 
2.5.1  Agarose Gel Separation of RNA Fractions ................................. 82 
2.5.2  Northern Transfer ....................................................................... 83 
2.5.3  Northern Blot Probe Preparation ................................................ 84 
2.5.4  Radioactive Probing of Blots....................................................... 85 
 xi
 
2.6  PROTEIN EXTRACTION FROM UNINFECTED MICE..................... 86 
2.6.1  Deglycosylation of PrPC.............................................................. 86 
2.6.2  GPI Anchor Cleavage of PrPC .................................................... 87 
2.7  CLINICAL AND PATHOLOGICAL INVESTIGATION OF 
INOCULATED TRANSGENIC MICE........................................................ 88 
2.7.1  Assessment of TSE Associated Vacuolation – Lesion Profiling.. 89 
Table 2.T1:  Vacuolation Score Definition.................................. 90 
Figure 2.F3:  Lesion Profiling Scoring Regions.......................... 90 
Figure 2.F4:  Lesion Profile Examples ....................................... 91 
2.7.2  Assessment of TSE Associated PrPSc Deposition ...................... 92 
2.7.2.1  Brain Sectioning ................................................................... 92 
2.7.2.2  ICC Detection of PrP............................................................ 92 
2.8  WESTERN BLOT DETECTION OF PRPSC....................................... 95 
2.8.1  Purification of PrPSc from Frozen Brain Tissue ........................... 96 
2.8.2  Polyacrylamide Gel Electrophoresis of Protein Extracts ............. 97 
2.8.3  Western Transfer ........................................................................ 98 
2.8.4  Antibody Binding to PrP.............................................................. 99 
2.8.5  Chemiluminescence Detection of Antibody Binding.................... 99 
 
CHAPTER 3 
CONFIRMATION OF GENETIC, BIOCHEMICAL, AND PHYSIOLOGICAL 
CONFIGURATION OF TRANSGENIC MICE .............................................101 
 
3.1  AIMS ............................................................................................... 101 
3.2  INTRODUCTION............................................................................. 102 
3.3  EXPERIMENTAL RESULTS ........................................................... 102 
3.3.1  Sequence Analysis of the PRNP Transgene ............................ 102 
Figure 3.F1:  Transgene Sequence Comparison with Wild-type 
Reference ................................................................................ 104 
3.3.2  Codon 129 Genotyping of the PRNP Transgene...................... 105 
Figure 3.F2:  Codon 129 Genotype Analysis ........................... 105 
3.3.3  PRNP RNA Assessment in the Transgenic Mice...................... 106 
 xii
 
Figure 3.F3:  Northern Blot of RNA Levels Across Various 
Tissues .................................................................................... 106 
3.3.4  Transgenic Prion Protein (PrPC) Characterisation .................... 107 
Figure 3.F4:  Characterisation of PrPC by Western Blot........... 108 
3.3.5  Effect on Survival of Transgenic Modification ........................... 109 
Figure 3.F5:  Survival Curves for Aged Transgenic Mice......... 110 
3.4  DISCUSSION.................................................................................. 111 
 
CHAPTER 4 
IDENTIFYING THE UNIQUE SPECIFICITY OF VARIANT CJD STRAIN 
TRANSMISSION PROPERTIES DEFINED BY CODON 129 GENOTYPE 
IN HOSTS OTHERWISE GENETICALLY IDENTICAL...............................113 
 
4.1  AIMS ............................................................................................... 113 
4.2  INTRODUCTION............................................................................. 115 
4.2.1  The Role of Codon 129 Genotype in vCJD Disease Transmission
........................................................................................................... 115 
4.2.2  Iatrogenic Spread of vCJD Strain in the Human Population ..... 116 
4.3  EXPERIMENTAL RESULTS ........................................................... 117 
4.3.1  Intracerebral Inoculation of vCJD.............................................. 117 
Table 4.T1:  Data Table for Intracerebral Inoculation with vCJD
................................................................................................. 119 
4.3.1.2  Clinical TSE Findings ......................................................... 120 
4.3.1.3.  Survival Analysis ............................................................... 120 
Table 4.T2:  Tarone-Ware Test for Survival Analysis of 
Intracerebral Inoculation with vCJD ......................................... 121 
Figure 4.F1:  Kaplan-Meier Survival Curve of Intracerebral 
Inoculation with vCJD .............................................................. 122 
4.3.1.4  Vacuolation Scoring ........................................................... 123 
Figure 4.F2:  Lesion Profile of vCJD Inoculated HuMM Mice... 125 
Figure 4.F3:  Lesion Profile of vCJD Inoculated 129Ola Mice.. 125 
 xiii
 
Table 4.T3:  Comparison of Neuropathology in Transgenic Mice 
Inoculated with vCJD ............................................................... 127 
4.3.1.5  Detection of PrPSc by Immunocytochemistry...................... 128 
Figure 4.F4:  Histopathology of vCJD Transmission to Transgenic 
Mice ......................................................................................... 130 
4.3.1.6  Detection of PrPSc by Western Blot .................................... 131 
Figure 4.F5:  Western Blot Analysis of Transgenic Mice 
Inoculated with vCJD ............................................................... 132 
4.3.2  Secondary Inoculation of Mice with Primary Passage Material 133 
Figure 4.F6:  Immunocytochemistry of Mouse Brains Selected for 
Second Passage...................................................................... 134 
Table 4.T4:  vCJD Second Passage Data ............................... 135 
4.3.2.1  Clinical Assessment ........................................................... 136 
4.3.2.2  Vacuolation Scoring ........................................................... 137 
Figure 4.F7:  Second Passage Lesion Profile Comparisons for 
129Ola Mice............................................................................. 138 
4.3.2.3  ICC Detection of PrPSc ....................................................... 139 
4.3.3  Intraperitoneal Inoculation of vCJD........................................... 140 
Table 4.T5:  Data Table for Intraperitoneal Inoculation with vCJD
................................................................................................. 141 
4.3.3.1  Clinical TSE Findings ......................................................... 142 
4.3.3.2  Vacuolation Scoring and Detection of PrPSc by ICC........... 142 
Figure 4.F8:  Lesion Profile of 129Ola Mice Following 
Intraperitoneal Inoculation with vCJD....................................... 143 
4.4  DISCUSSION.................................................................................. 144 
4.4.1  A New Mouse Model for Human vCJD ..................................... 144 
4.4.1.1  Intracerebral Inoculation Results........................................ 144 
Table 4.T6:  Comparison with Kitamoto Group Data on vCJD 
Transmission ........................................................................... 145 
4.4.1.2  Intraperitoneal Inoculation Results ..................................... 147 
4.4.1.3  Replication of vCJD Pathological Features ........................ 148 
 xiv
 
4.4.2  Codon 129 Genotype and Transmission Properties of the vCJD 
Agent .................................................................................................. 149 
4.4.2.1  Clinical Disease Associated with Genotype ....................... 149 
4.4.2.2  Vacuolation Scoring Associated with Genotype................. 150 
4.4.2.3  PrPSc Properties Associated with Genotype....................... 150 
4.4.3  Modelling Iatrogenic Spread of vCJD ....................................... 152 
4.4.3.1  Secondary Passage to Wild-Type Mice ............................. 153 
 
CHAPTER 5 
ADAPTATION OF THE VCJD STRAIN FOLLOWING BLOOD 
TRANSFUSION ASSOCIATED VARIANT CJD INFECTION .....................155 
 
5.1  AIMS ............................................................................................... 155 
5.2  INTRODUCTION............................................................................. 156 
5.3  EXPERIMENTAL RESULTS ........................................................... 159 
5.3.1  Intracerebral Inoculation with Transfusion Associated vCJD .... 159 
Table 5.T1:  Data Table for Intracerebral Inoculation with vCJD 
(transfusion)............................................................................. 160 
5.3.2  Clinical TSE Findings................................................................ 161 
Figure 5.F1:  Incubation Period Plot for 129Ola Mice Inoculated 
with vCJD................................................................................. 162 
Figure 5.F2:  Kaplan-Meier Survival Curve for vCJD Inoculated 
129Ola Mice............................................................................. 162 
5.3.3  Survival Analysis....................................................................... 163 
Figure 5.F3:  Kaplan-Meier Curve for Inoculation with vCJD 
(transfusion)............................................................................. 164 
Table 5.T2:  Tarone-Ware Test Data for Inoculation with vCJD 
(transfusion)............................................................................. 164 
5.3.4  Vacuolation Scoring.................................................................. 165 




Figure 5.F5:  Lesion Profile for 129Ola Mice Inoculated with vCJD 
(transfusion)............................................................................. 166 
5.3.5  Detection of PrPSc by Immunocytochemistry ............................ 167 
Figure 5.F6:  ICC Comparison in HuMM Mice Inoculated with 
vCJD (BSE) and vCJD (transfusion) ........................................ 169 
Figure 5.F7:  ICC Detection of PrPSc in Hippocampus of HuMM 
Mice with vCJD ........................................................................ 170 
Figure 5.F8:  ICC Detection of PrPSc in Hippocampus of 129Ola 
Mice with vCJD ........................................................................ 170 
5.3.6  Detection of PrPSc by Western Blot........................................... 171 
Figure 5.F9:  Western Blot of HuMM Mice Inoculated with vCJD 
(BSE) and vCJD (transfusion).................................................. 172 
5.4  DISCUSSION.................................................................................. 172 
5.4.1  Evidence for Strain Adaptation from Clinical Findings and Survival 
Analysis .............................................................................................. 172 
5.4.2  Evidence for Strain Adaptation from Vacuolation Scoring ........ 175 
5.4.3  Evidence for Strain Adaptation from Detection of PrPSc ........... 177 
5.4.4  Summary .................................................................................. 178 
 
CHAPTER 6 
IDENTIFYING THE UNIQUE TRANSMISSION PROPERTIES OF 
SPORADIC CJD SUBGROUPS DEFINED BY THE PRNP CODON 129 
GENOTYPE AND PRPSC TYPE .................................................................180 P
 
6.1  AIMS ............................................................................................... 180 
6.2  INTRODUCTION............................................................................. 181 
6.2.1  Characterisation of sCJD Subgroups as Unique Transmissible 
Strains ................................................................................................ 181 
6.2.2  Role of Codon 129 Genotype and PrPSc Type in Transmission of 
sCJD................................................................................................... 182 
6.3  EXPERIMENTAL RESULTS ........................................................... 182 
6.3.1  Primary Intracerebral Inoculation of sCJD ................................ 182 
 xvi
 
6.3.1.1  Mouse Data Tables ............................................................ 183 
Table 6.T1:  Data Table for sCJD(MM1) Inoculation................ 184 
Table 6.T2:  Data Table for sCJD(MM2) Inoculation................ 185 
Table 6.T3:  Data Table for sCJD(MV1) Inoculation ................ 186 
Table 6.T4:  Data Table for sCJD(MV2) Inoculation ................ 187 
Table 6.T5:  Data Table for sCJD(VV1) Inoculation ................. 188 
Table 6.T6:  Data Table for sCJD(VV2) Inoculation ................. 189 
6.3.1.2  Survival Analysis to Investigate Clinical and Subclinical TSE
........................................................................................................ 190 
6.3.1.2.1  Effect of Inoculum Source on Survival ......................... 190 
Table 6.T7:  Tarone-Ware Analysis by sCJD Inoculum ........... 192 
Figure 6.F1:  Kaplan-Meier Survival Curves for Primary sCJD 
Inoculation ............................................................................... 193 
6.3.1.2.2  Effect of Mouse Codon 129 Genotype on Survival ...... 194 
Figure 6.F2:  Kaplan-Meier Survival Curves Grouped by Mouse 
Line .......................................................................................... 195 
Table 6.T8:  Tarone-Ware Analysis Grouped by Mouse Genotype
................................................................................................. 196 
6.3.1.3  Incubation Period Variation Determined by Codon 129 
Genotype of Inoculum and Host...................................................... 197 
Table 6.T9:  Incubation Period Data for sCJD Inoculation ....... 198 
6.3.1.4  Vacuolation Scoring ........................................................... 198 
Table 6.T10:  Vacuolation Scoring Data for sCJD Inoculation . 200 
6.3.1.5  Lesion Profile Comparison ................................................. 200 
Figure 6.F3:  Lesion Profile Data for sCJD Inoculations .......... 202 
6.3.1.6  Hierarchical Cluster Analysis of Lesion Profile Data .......... 203 
6.3.1.6.1  ‘Type 1’ cluster ............................................................ 203 
6.3.1.6.2  ‘Type 2’ cluster ............................................................ 204 
6.3.1.6.3  ‘Fast’ cluster ................................................................ 204 
Figure 6.F4:  Hierarchical Cluster Analysis Dendrogram ......... 205 
6.3.1.7  Detection of PrPSc by Immunocytochemistry...................... 206 
Table 6.T11:  ICC Scoring Data for sCJD Inoculations ............ 207 
 xvii
 
6.3.1.8  Distribution of PrPSc as Detected by ICC ........................... 208 
6.3.1.8.1  sCJD(MM1) PrPSc Deposition...................................... 208 
6.3.1.8.2  sCJD(MV2) and sCJD(VV2) PrPSc Deposition............. 209 
Figure 6.F5:  ICC Comparison for Three Common sCJD 
Subgroups ............................................................................... 210 
Figure 6.F6:  Brain Map Reference Diagrams ......................... 211 
6.3.1.9  Detection of PrPSc by Western Blot .................................... 211 
6.3.1.9  Detection of PrPSc by Western Blot .................................... 212 
Figure 6.F7:  Western Blot Images for sCJD Inoculations ....... 213 
6.3.2  Secondary Inoculation of Mice with Primary Passage Material 214 
Table 6.T12:  Data Table for Second Passage sCJD(MV2) 
Inoculation via HuVV Mouse.................................................... 215 
Table 6.T13:  Data Table for Duplicate Second Passage 
sCJD(MV2) Inoculation via HuVV Mouse ................................ 216 
6.3.2.1  Summary of Second Passage Data ................................... 217 
6.3.2.1.1  Clinical Features of Transmission................................ 217 
6.3.2.1.2  Pathological Features of Secondary Passage Mice .... 217 
Table 6.T14:  Summary of Data for Primary and Secondary 
sCJD(MV2) Inoculation ............................................................ 218 
Figure 6.F8:  Lesion Profile Similarities for Primary and 
Secondary sCJD(MV2) Inoculation .......................................... 219 
6.4  DISCUSSION.................................................................................. 220 
Table 6.T15:  Summary of sCJD Transmission Data ............... 221 
6.4.1  Characterisation of sCJD Subgroups as Unique Transmissible 
Strains ................................................................................................ 221 
6.4.1.1  SCJD(MM1) ....................................................................... 222 
6.4.1.2  SCJD(MV1) ........................................................................ 224 
6.4.1.3  SCJD(VV2) and SCJD(MV2).............................................. 225 
6.4.1.4  SCJD(VV1) ........................................................................ 227 
6.4.1.5  SCJD(MM2) ....................................................................... 228 








7.1  AIMS ............................................................................................... 232 
7.2  HYPOTHESES................................................................................ 232 
7.2.1  Codon 129 Genotype is the Key Factor in Defining Susceptibility 
to Human TSE Transmission.............................................................. 232 
7.2.2  The Agent Strain Responsible for vCJD is Transmissible to 
Humans with Codon 129 MV and VV Genotypes ............................... 236 
7.2.3  The Pathology in the Central Nervous System Following vCJD 
Infection in Individuals of Codon 129 MV and VV Genotype is Different 
from that of MM Cases ....................................................................... 238 
7.2.4  There is an Increase in Incubation Period for vCJD in Codon 129 
MV and VV Individuals ....................................................................... 239 
7.2.5  Adaptation of the vCJD Agent Following Human Passage will 
Produce a More Infectious Strain. ...................................................... 241 
7.2.6  The Risk of Iatrogenic Infection from sCJD Varies According to the 
Codon 129 Genotype of Source and Recipient .................................. 242 
7.2.7  The Currently Defined Subgroups of sCJD are Unique Strains of 
Human Disease, with Individual Transmission Properties .................. 245 
7.3  CONCLUDING REMARKS ............................................................. 249 
7.3.1  The Transgenic Mouse Model .................................................. 249 







TABLE OF FIGURES 
Figure 1.F1:  Examples of TSE Histopathology ............................................. 4 
Figure 1.F2:  Human PrP Structure ............................................................... 8 
Figure 1.F3:  Western Blot Analysis of PrPSc ............................................... 11 
Figure 1.F4:  PrP Amino Acid Comparison Between Species...................... 12 
Figure 1.F5:  Human PRNP Gene Variation ................................................ 15 
Figure 1.F6:  Pathology Profiles for sCJD Subgroups ................................. 26 
Figure 1.F7:  vCJD Histopathology .............................................................. 37 
Figure 1.F8:  Lesion Profiles of Wild-type Mice with BSE and vCJD ........... 44 
Figure 2.F1:  Gene Vector Flowchart........................................................... 75 
Figure 2.F2:  Codon 129 Genotyping Gel Image ......................................... 80 
Figure 2.F3:  Lesion Profiling Scoring Regions............................................ 90 
Figure 2.F4:  Lesion Profile Examples ......................................................... 91 
Figure 3.F1:  Transgene Sequence Comparison with Wild-type Reference ....
 ............................................................................................. 104 
Figure 3.F2:  Codon 129 Genotype Analysis ............................................. 105 
Figure 3.F3:  Northern Blot of RNA Levels Across Various Tissues .......... 106 
Figure 3.F4:  Characterisation of PrPC by Western Blot ............................ 108 
Figure 3.F5:  Survival Curves for Aged Transgenic Mice........................... 110 
Figure 4.F1:  Kaplan-Meier Survival Curve of Intracerebral Inoculation with 
 vCJD .................................................................................... 122 
Figure 4.F2:  Lesion Profile of vCJD Inoculated HuMM Mice .................... 125 
Figure 4.F3:  Lesion Profile of vCJD Inoculated 129Ola Mice ................... 125 
Figure 4.F4:  Histopathology of vCJD Transmission to Transgenic Mice... 130 
Figure 4.F5:  Western Blot Analysis of Transgenic Mice Inoculated with vCJD
 ............................................................................................. 132 
Figure 4.F6:  Immunocytochemistry of Mouse Brains Selected for Second 
 Passage ............................................................................... 134 
Figure 4.F7:  Second Passage Lesion Profile Comparisons for 129Ola Mice .
 ............................................................................................. 138 
Figure 4.F8:  Lesion Profile of 129Ola Mice Following Intraperitoneal 
 Inoculation with vCJD........................................................... 143 
 xx
 
Figure 5.F1:  Incubation Period Plot for 129Ola Mice Inoculated with vCJD....
 ............................................................................................. 162 
Figure 5.F2:  Kaplan-Meier Survival Curve for vCJD Inoculated 129Ola Mice
 ............................................................................................. 162 
Figure 5.F3:  Kaplan-Meier Curve for Inoculation with vCJD (transfusion) 164 
Figure 5.F4:  Lesion Profile for HuMM Mice Inoculated with vCJD 
 (transfusion) ......................................................................... 166 
Figure 5.F5:  Lesion Profile for 129Ola Mice Inoculated with vCJD 
 (transfusion) ......................................................................... 166 
Figure 5.F6:  ICC Comparison in HuMM Mice Inoculated with vCJD (BSE) 
 and vCJD (transfusion)......................................................... 169 
Figure 5.F7:  ICC Detection of PrPSc in Hippocampus of HuMM Mice with 
 vCJD .................................................................................... 170 
Figure 5.F8:  ICC Detection of PrPSc in Hippocampus of 129Ola Mice with 
 vCJD .................................................................................... 170 
Figure 5.F9:  Western Blot of HuMM Mice Inoculated with vCJD (BSE) and...
  vCJD (transfusion)............................................................... 172 
Figure 6.F1:  Kaplan-Meier Survival Curves for Primary sCJD Inoculation 193 
Figure 6.F2:  Kaplan-Meier Survival Curves Grouped by Mouse Line ....... 195 
Figure 6.F3:  Lesion Profile Data for sCJD Inoculations ............................ 202 
Figure 6.F4:  Hierarchical Cluster Analysis Dendrogram ........................... 205 
Figure 6.F5:  ICC Comparison for Three Common sCJD Subgroups ........ 210 
Figure 6.F6:  Brain Map Reference Diagrams ........................................... 211 
Figure 6.F7:  Western Blot Images for sCJD Inoculations ......................... 213 
Figure 6.F8:  Lesion Profile Similarities for Primary and Secondary 







TABLE OF TABLES 
Table 1.T1:  Comparison of PrPC and PrPSc Properties................................. 9 
Table 1.T2:  Codon 129 Genotype Frequencies Worldwide ........................ 16 
Table 1.T3:  Codon 129 Genotype Frequency Variation in TSE Disease .... 17 
Table 1.T4:  Subgroups of sCJD.................................................................. 24 
Table 1.T5:  PrPSc Deposition in sCJD Subgroups ...................................... 25 
Table 1.T6:  Transgenic Lines Expressing Human PrP ............................... 56 
Table 1.T7:  Tg152 (VV) Transgenic Mice with Various TSE Inocula .......... 59 
Table 1.T8:  SCJD Inoculation of Various Transgenic Mouse Lines ............ 61 
Table 1.T9:  Comparison of Collinge Group Transgenic Lines .................... 66 
Table 1.T10:  Human TSE Transmission to Various Transgenic Mouse Lines
 ............................................................................................... 72 
Table 2.T1:  Vacuolation Score Definition.................................................... 90 
Table 4.T1:  Data Table for Intracerebral Inoculation with vCJD................ 119 
Table 4.T2:  Tarone-Ware Test for Survival Analysis of Intracerebral 
 Inoculation with vCJD........................................................... 121 
Table 4.T3:  Comparison of Neuropathology in Transgenic Mice Inoculated 
 with vCJD ............................................................................. 127 
Table 4.T4:  vCJD Second Passage Data ................................................. 135 
Table 4.T5:  Data Table for Intraperitoneal Inoculation with vCJD............. 141 
Table 4.T6:  Comparison with Kitamoto Group Data on vCJD Transmission ..
 ............................................................................................. 145 
Table 5.T1:  Data Table for Intracerebral Inoculation with vCJD (transfusion).
 ............................................................................................. 160 
Table 5.T2:  Tarone-Ware Test Data for Inoculation with vCJD (transfusion)..
 ............................................................................................. 164 
Table 6.T1:  Data Table for sCJD(MM1) Inoculation.................................. 184 
Table 6.T2:  Data Table for sCJD(MM2) Inoculation.................................. 185 
Table 6.T3:  Data Table for sCJD(MV1) Inoculation .................................. 186 
Table 6.T4:  Data Table for sCJD(MV2) Inoculation .................................. 187 
Table 6.T5:  Data Table for sCJD(VV1) Inoculation................................... 188 
Table 6.T6:  Data Table for sCJD(VV2) Inoculation................................... 189 
 xxii
 
Table 6.T7:  Tarone-Ware Analysis by sCJD Inoculum ............................. 192 
Table 6.T8:  Tarone-Ware Analysis Grouped by Mouse Genotype ........... 196 
Table 6.T9:  Incubation Period Data for sCJD Inoculation ......................... 198 
Table 6.T10:  Vacuolation Scoring Data for sCJD Inoculation ................... 200 
Table 6.T11:  ICC Scoring Data for sCJD Inoculations.............................. 207 
Table 6.T12:  Data Table for Second Passage sCJD(MV2) Inoculation via 
 HuVV Mouse ........................................................................ 215 
Table 6.T13:  Data Table for Duplicate Second Passage sCJD(MV2) 
 Inoculation via HuVV Mouse ................................................ 216 
Table 6.T14:  Summary of Data for Primary and Secondary sCJD(MV2) 
 Inoculation............................................................................ 218 






1.1  PHD THESIS INVESTIGATIONS 
 These PhD investigations will provide model data upon which the following 
hypotheses about human disease can be tested: 
• Codon 129 genotype is the key factor in defining susceptibility to human 
transmissible spongiform encephalopathy (TSE) transmission. 
• The agent strain responsible for variant Creutzfeldt-Jakob Disease (vCJD), is 
transmissible to humans with codon 129 MV and VV genotypes. 
• The pathology in the central nervous system following vCJD infection in 
individuals of codon 129 MV and VV genotype is different from that of MM 
cases. 
• There is an increase in incubation period for vCJD in codon 129 MV and VV 
individuals. 
• Adaptation of the vCJD agent following human passage will produce a more 
infectious strain. 
• The risk of iatrogenic infection from sporadic CJD (sCJD) varies according 
to the codon 129 genotype of source and recipient. 
• The currently defined subgroups of sCJD are unique strains of human 




Model data will be generated by the experimental transmission of a number 
of different forms of human transmissible spongiform encephalopathy (TSE), that 
vary in clinical features, pathology, codon 129 genotype, and prion protein 
configuration.  The recipient transgenic mice are unique to the field of prion disease 
transmission research and have been produced by gene targeting so that they express 
physiological levels of the human prion protein (PrP) as a direct replacement for the 
original mouse PrP.  The inserted full-length human prion gene sequence of these 
novel lines has been modified at codon 129 to produce mice that are MM, MV, or 
VV genotype.  It will also be possible to examine other biochemical (Western blot 
type) and histological (plaque development and PrP deposition) phenotypes of 
human disease that could be mirrored in these mice.   
 The initial stages of this study will be to assess the transgenic mice to ensure 
that the replacement human PRNP gene is functioning correctly and producing intact 
prion protein at the correct approximate physiological concentrations and of the 
normal configuration.  Following this the mice will be tested for susceptibility to 
infection by human TSE agents.  Groups of mice will be inoculated with brain 
material from typical cases of vCJD and sCJD via the intracerebral (i.c.) or 
intraperitoneal (i.p.) routes, and positive transmissions subsequently subpassaged.  
This will provide an initial analysis of the susceptibility of these mice to material 
whose infectivity is well characterised in wild-type mice.  This study is important as 
it will be the first time that it has be possible to study the specific effect of codon 129 
genotype on human TSE transmission in a mouse model.   
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1.2  TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY 
(TSE) 
 TSEs are fatal neurodegenerative disorders that occur in many species of 
mammal including man.  They include the cattle disease bovine spongiform 
encephalopathy (BSE) (Bradley and Wilesmith, 1993), the human disease 
Creutzfeldt-Jakob Disease (CJD) (Goldfarb and Brown, 1995), scrapie in sheep and 
goats (Hunter et al., 2000), and Chronic Wasting Disease (CWD) in deer and elk 
(Williams, 2005).  For a review of animal TSE see reference (Sigurdson and Miller, 
2003).  Following active surveillance for BSE and scrapie, atypical forms of these 
diseases have recently been identified with unknown cross-species transmissibility 
(Benestad et al., 2003, Buschmann et al., 2006, Capobianco et al., 2007, Jacobs et 
al., 2007, Luhken et al., 2007).  There are also experimental TSE diseases where 
repeated subpassage of disease within one laboratory animal species has lead to 
characteristic, adapted forms of TSE.  Examples of such are mouse-scrapie ‘ME7’, 
hamster-scrapie ‘236K’, and mouse-BSE ‘301V’ (Bruce, 1993, Bruce, 2003). 
 The name TSE is used because these diseases are generally transmissible, 
within and sometimes between species, and are pathologically defined by appearance 
of sponge-like vacuolation in the grey matter (location of neuronal cell bodies) of the 
brain.  Pathology of these diseases is also characterised by astrogliosis (proliferation 
of the neuroglial cells that form a protective scaffold for neurons), neuronal loss, and 
the deposition of an abnormal form of the host encoded prion protein (PrP) (Rezaie 
and Lantos, 2001) (Figure 1.F1).   
 Transmission to a variety of laboratory animal species has shown the 
presence of distinct strains of TSE, the unique properties which can be maintained on 
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passage through multiple hosts (Brown et al., 1994b, Bruce et al., 2002, Nonno et 
al., 2006).  Transmission studies in primates and rodents have been performed using 
brain material from cattle diagnosed with BSE (Lasmezas et al., 2001, Brown et al., 
2003, Lasmezas et al., 2005).  This has provided significant proof that the acquired 
form of TSE in humans, variant Creutzfeldt-Jakob disease (vCJD), and in cats (feline 
spongiform encephalopathy) are attributable to infection by the BSE strain (Will et 
al., 1996b, Bruce et al., 1997, Hill et al., 1997).   
Figure 1.F1:  Examples of TSE Histopathology 
Example of vacuolation in frontal cortex (A: haematoxylin and eosin stain) and 
astrocytosis in the pulvinar region (B: staining for glial fibrillary acidic protein – 
brown colour) in variant CJD, from reference (Ironside et al., 2002b). 
 
1.3  THE PRION HYPOTHESIS 
 TSE strain properties may be coded for in the mechanism of propagation or 
structure of the infectious agent.  Typical components of this nature that occur in 
infectious agents such as bacteria or viruses are DNA or RNA molecules in which 
nucleic acid sequence variation can lead to a characteristic strain appearance.  An 
example of this is the configuration of virus coat proteins that determine how virus 
molecules are recognised by antibodies in a strain specific immune response.  The 
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coding information for determining a strain must also be propagated by the agent as 
it multiplies within the host so that the characteristics are replicated in subsequent 
hosts.   
 Theories that TSE was a result of virus activity (Diringer, 1991) were tested 
by attempting to isolate non-host nucleic acid components from fractions of material 
such as brain tissue known to transmit disease.  These fractions were also treated 
with chemicals known to disrupt nucleic acid.  Neither of these methods identified a 
mechanism of strain identification linked to recognised nucleic acid molecules and it 
was subsequently proposed that strain identification and infectivity was via a novel 
disease mechanism involving a protein component only, the prion protein (Prusiner, 
1982).  This protein component found in TSE diseases has lead to a more common 
terminology for TSEs, the ‘prion diseases’.   
 The search for additional disease vectors is continuing as it is likely that the 
prion protein alone does not define all the disease attributes, and the proposal that its 
involvement is secondary to other truly disease causing factors is still considered by 
some researchers (Brown, 2001).  ‘Slow-viruses’ were considered during the earlier 
years of TSE research and have recently been proposed again following the 
description of 25nm spherical particles in experimental rodent TSE models 
(Manuelidis, 2007).  There is still the possibility that an as yet undescribed 
mechanism involving a nucleic acid component that is protected from current 
methods of identification is the true disease agent.   
1.3.1  The Prion Protein 
 Prion protein (PrP) occurs in mammals, birds, and reptiles, as a membrane-
bound, glycosyl-phophatidylinositol (GPI) anchored glyco-protein of approximately 
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20-30 kDa, with possible roles in synaptic transmission and signal transduction in the 
central nervous system (CNS) (Collinge et al., 1994, Lee et al., 1998, Wopfner et al., 
1999, Harris, 2003).  It is produced in a wide range of tissues, including lymphoid, 
heart, lungs, skeletal muscle, salivary gland, and at the highest levels in neurons of 
the central nervous system (Brown et al., 1990, McLennan et al., 2001).  Ablating 
expression of the protein does not appear to be detrimental to the organism (Bueler et 
al., 1992, Manson et al., 1994a) although some physiological processes are believed 
to be affected (Collinge et al., 1994, Sakaguchi et al., 1996, Tobler et al., 1996, 
Wong et al., 2001).   
 PrP tertiary structure has been determined through computational analysis of 
circular dichroism and infrared spectroscopy data (Bazan et al., 1987, Huang et al., 
1994) and more recently by crystal structure analysis (Haire et al., 2004).  It contains 
three alpha-helices, two beta-sheets, a single disulphide bridge between helix two 
and three, and two sites of asparagine (N)-linked glycosylation (Figure 1.F2).   
 The glycans / sugar molecules attached to the two glycosylation sites confer 
a considerable degree of variation to this protein (Rudd et al., 2002).  Either, both, or 
neither site can be occupied with sugar chains.  The variation in type and overall 
structure of these chains is an example of one possible mechanism for protein 
encoded strain variation (Vorberg and Priola, 2002, Lawson et al., 2005, Cancellotti 
et al., 2006).  Strain properties may also be defined by the flexible, unstructured, N-
terminal region, as assessed by nuclear magnetic resonance (NMR) imaging of 
recombinant PrP (Prusiner, 1998).  Between the flexible N-terminal and beta-sheet-1 
lies the octapeptide repeat sequence that has a copper binding role, and may 




 In most types of tissue targeted by TSE disease pathology an over-
abundance of the protease resistant form of PrP is found with a modified tertiary 
structure, one of a predominantly beta-sheet formation (Pan et al., 1993, Prusiner, 
1998).  The disease associated form of the prion protein is designated PrPSc 
(Sc=Scrapie form) to differentiate it from the normal form, designated PrPC 
(C=Cellular).  PrPSc has remarkable physical properties including an ability to 
withstand routine autoclave disinfection and incineration procedures up to 600°C 
(Brown et al., 2000b).  Isolation of the two forms has been used to confirm the 
different structural components, however the true structure of PrPSc cannot currently 
be determined because it cannot be crystallized, as it is insoluble in detergents.  
Other intermediary forms of PrP have been postulated (Review: (Weissmann, 
1999)).  The differences between the two major prion protein isoforms are 
summarised in Table 1.T1. 
DNA repeat of 24bp coding for the same eight amino-acids, with five repeats present 
in the human sequence.  Genetic expansion of up to an additional ten extra repeats 
has been linked to familial, inherited forms of human TSE, which will be discussed 





Human prion protein secondary structure components. 








Table 1.T1:  Comparison of PrPC and PrPSc Properties 




Disease Associated Form 
Mainly alpha-helical structure Mainly beta-sheet structure 
 
Monomeric Forms aggregates (amyloid) 
 
Soluble under non-denaturing conditions Insoluble in detergents 
 
Protease sensitive Partially protease resistant 
 
Rapidly metabolised (T½=5h in vitro) Stable (T½=15h in vitro) 
(Borchelt et al., 1990) 
Present in normal tissue Presence associated with the pathology of 
prion disease * 
 
* Recent evidence has shown the presence of PrP with attributes of PrPSc in healthy 
brain tissue, suggesting that we all may harbour quantities of disease-associated PrP 
that are routinely maintained at a non-pathological level (Yuan et al., 2006). 
 
 
 In vitro evidence shows that in the presence of PrPSc, PrPC undergoes 
structural conversion to PrPSc (Raymond et al., 1997, Saborio et al., 2001).  In 
disease this conversion results in an abundance of PrPSc in the CNS although the 
precise cellular location and mechanism of conversion is unclear (Harris, 1999).  
Some TSE such as scrapie, and others acquired via specific infection routes (vCJD), 
also have an accumulation of PrPSc in tissues of the peripheral nervous system (PNS) 
such as the spleen, appendix, and lymph nodes (Brown et al., 1999a, Head et al., 
2004b). 
 Electrophoretic gel analysis of protease treated PrPSc in human disease has 
shown the presence of three major conformations commonly designated types 1, 2, 
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and 2B (Parchi et al., 1996, Parchi et al., 1999, Head et al., 2004a).  The difference 
between type 1 and 2 is a decrease in size of the protease resistant core of PrP due to 
differential protease action that results from changes in folding properties of the 
protein.  Type 2B shows an increase in the level of PrP present with both 
glycosylation sites occupied (Figure 1.F3).  The type 2B ‘glycoform signature’ is a 
common strain characteristic of BSE in cattle and other animal species (Collinge et 
al., 1996).  Humans infected with vCJD have the same glycoform signature (Ironside 
et al., 2000).  An alternative typing nomenclature has been proposed by Prof John 
Collinge’s group but there has been difficulties in replicating this in other 
laboratories (Collinge et al., 1996). 
 Examination of sCJD cases in more detail has shown that potentially a 
significant proportion (36% in one study (Puoti et al., 1999)) have co-occurrence of 
both PrPSc types (Parchi et al., 1999, Head et al., 2001, Head et al., 2004a, Puoti et 
al., 2005).  There is also a direct association between type and pathology as shown in 
remarkable detail by Puoti et al where adjacent regions of the cerebral cortex from 
one brain showed either diffuse or plaque-like PrPSc deposits which when micro-
dissected gave type 1 or type 2 respectively by Western blot (Puoti et al., 1999).  In 
transition fields showing both forms of pathology, mixed PrPSc type results were 
found by Western blot.  Further to this study the same authors determined that strong 
microglial activation was associated with the type 1 brain region compared to mild 
microglial reaction found in those regions with type 2 PrPSc (Puoti et al., 2005).   
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Figure 1.F3:  Western Blot Analysis of PrPSc
Western blot analysis of proteinase K treated PrPSc showing types 1 and 2 (here 
labelled as 2A) from sporadic Creutzfeldt-Jakob disease, and type 2B from variant 
Creutzfeldt-Jakob disease associated with BSE infection. (Image from reference 










1.4  THE PRION PROTEIN GENE 
 The human prion protein gene region is located on the short arm of 
chromosome 20 (Band: 20p12-pter).  The exon two contains the Open Reading 
Frame (ORF), the complete DNA sequence required for producing the prion protein, 
which is 762bp long and translates to a protein of 253 amino acids.  The human 
gene, PRNP, was first described in 1986 (Liao et al., 1986) and its DNA sequence is 
available through the Internet bioinformatics sites (GenBank accession number 
AL133396), together with bovine PRNP (GenBank: AB001468), ovine PRNP 
(GenBank: AJ223072), and murine Prnp (GenBank: NM_011170) data.  The PrP 
gene is highly conserved across many different species suggesting an important role 
for the protein (Lee et al., 1998, Wopfner et al., 1999, Van Rheede et al., 2003, 
Premzl and Gamulin, 2007).  Figure 1.F4 shows a comparison of the PrP amino acid 
sequence from human beings, chimpanzee, mouse, sheep, goat, elk, cat, bovine.  
Complete homology across the eight species is widespread (~80% of amino acids) 
and is shown by the red colour key.   
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Figure 1.F4:  PrP Amino Acid Comparison Between Species 
Prion protein amino acid sequence comparison between selected species. 




1.4.1  Prion Protein Gene DNA Variation 
 Polymorphisms fall into two categories those that are directly associated 
with a disease phenotype (generally producing changes in the amino acid sequence – 
non-synonymous), and those that may influence clinical features or susceptibility.  
(For the sake of simplicity in this thesis the former will be referred to as ‘mutations’ 
and the latter as ‘polymorphisms’.)  Twenty-nine mutations, and twenty-one 
polymorphisms have been found throughout the human gene (Figure 1.F5).  There 
are also polymorphic sites outside of the gene region where variations may 
determine changes such as gene expression levels (Funke-Kaiser et al., 2001, Mahal 
et al., 2001, McCormack et al., 2002). 
 The sheep prion gene has a number of polymorphic sites.  Codons 136, 154, 
and 171 in particular have been associated with varying degrees of susceptibility/ 
resistance to scrapie infection across many breeds of sheep, however the 
136A/154R/171R allele is particularly noted for providing most breeds with a level 
of resistance to scrapie (Hunter et al., 1994a, Bossers et al., 1996).  The UK National 
Scrapie Plan was instigated to increase the level of resistant genotypes in the 
National Flock, but the bias towards these genotypes has been brought into question 
following recent evidence suggesting that new atypical forms of scrapie affect more 
frequently those ‘resistant’ genotype sheep (Saunders et al., 2006).   
 The domestic cattle prion gene is much less variable compared with the 
sheep gene with no evidence to suggest associations to a disease state (Hunter et al., 
1994b, Horiuchi et al., 1998, Hills et al., 2001).  There are rare alleles with only five 




effect (Hunter et al., 1994b), and four (Seabury et al., 2004) and seven (Schlapfer et 
al., 1999) repeats that have been found only in healthy Brown Swiss cattle.   
 The level of genetic variation in the laboratory mouse is limited to amino 
acids 108 and 189, which are linked to changes in incubation period following 
experimental inoculation with TSE (Westaway et al., 1994a, Moore et al., 1998, 
Barron et al., 2005, Cancellotti et al., 2006).   
1.4.2  Human Codon 129 Polymorphism 
 An extensively studied polymorphism of the human prion gene is the 
methionine to valine change at codon 129.  (DNA sequence change ATG (coding M) 
to GTG (coding V))  The normal population frequencies for the three genotypes are 
shown in Table 1.T2, showing wide variability in different geographical areas 
(Soldevila et al., 2003).  The frequencies have also been found to vary region-to-
region within a country (Plaitakis et al., 2001, Lucotte and Mercier, 2005).   
 It has been proposed that codon 129 genotype may play a role in or have an 
effect on the following characteristics of human prion disease: 
1. Susceptibility to disease (Collinge et al., 1991, Deslys et al., 1994, Zeidler 
et al., 1997, Deslys et al., 1998, Lee et al., 2001, Brandel et al., 2003) 
2. Survival (Alperovitch et al., 1999, Pocchiari et al., 2004) 
3. Phenotype of familial forms of CJD (Goldfarb et al., 1992) 
4. Neuropathology of sCJD (Parchi et al., 1999, Hauw et al., 2000, Kovacs et 
al., 2000) 
5. Protease cleavage of PrPSc (Parchi et al., 2000) 
6. Oligomerisation of PrP PSc (Tahiri-Alaoui et al., 2004, Lewis et al., 2006) 
7. PrPSc amyloid formation (Baskakov et al., 2005) 
 
 
Human prion gene variation showing positions of non-pathogenic polymorphisms, and pathogenic mutations. (The codon numbers are 
shown.) 




Table 1.T2:  Codon 129 Genotype Frequencies Worldwide 
Codon 129 genotype frequency variation in human populations worldwide (ordered 
geographically East to West).   
 
Population Number Tested MM MV VV 
Japan  
(Doh-ura et al., 1991) 179 165 (92%) 14 (8%) 0 (0%) 
Taiwan  
(Tsai et al., 2001) 100 97 (97%) 3 (3%) 0 (0%) 
Turkey  
(Erginel-Unaltuna et al., 2001) 100 57 (57%) 34 (34%) 9 (9%) 
Greece (Crete) 
(Plaitakis et al., 2001) 205 117 (57%) 77 (38%) 11 (5%) 
Greece (mainland) 
(Saetta et al., 2006) 348 174 (50%) 136 (39%) 38 (11%) 
Finland  
(Nurmi et al., 2003) 1957 969 (49%) 818 (42%) 170 (9%) 
Denmark  
(Dyrbye et al., 2007) 352 131 (37%) 168 (48%) 53 (15%) 
Poland  
(Bratosiewicz et al., 1999) 109 49 (45%) 43 (39%) 17 (16%) 
Austria 
(Zimmermann et al., 1999) 300 129 (43%) 146 (49%) 25 (8%) 
Slovenia 
(Galvani et al., 2005) 97 43 (43%) 46 (46%) 11 (11%) 
Germany 
(Windl et al., 1999) 74 31 (42%) 33 (45%) 10 (13%) 
Italy (Medori and Tritschler, 
1993, Salvatore et al., 1994) 206 93 (45%) 83 (40%) 30 (15%) 
France (Deslys et al., 1994, 
Laplanche et al., 1994) 161 63 (39%) 82 (51%) 16 (10%) 
UK (Collinge et al., 1991, 
Nurmi et al., 2003) 406 164 (40%) 196 (48%) 46 (11%) 
Spain  
(Combarros et al., 2000) 546 231 (42%) 239 (44%) 76 (14%) 
Ireland  
(Nurmi et al., 2003) 203 69 (34%) 114 (56%) 20 (10%) 
Iceland  
(Georgsson et al., 2006) 208 97 (46%) 93 (45%) 18 (9%) 
Brazil  
(de Paula et al., 2005) 191 87 (46%) 92 (48%) 12 (6%) 
USA  
(Brown et al., 1994a) 86 33 (38%) 44 (51%) 9 (10%) 
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An association of codon 129 genotype and disease can be seen in the 
genotype frequencies of the sporadic form of CJD (sCJD) and vCJD cases.  In sCJD 
there is an increase in the homozygote (MM and VV) frequencies with the level of 
MM at over 70% (Alperovitch et al., 1999, Parchi et al., 1999, Pocchiari et al., 
2004), and in vCJD all cases so far analysed have been MM (n=146 of 163) (Zeidler 
et al., 1997) (See Table 1.T3).  This observation indicates a level of susceptibility 
conferred by homozygosity or a degree of protection by the heterozygote genotype 
(Prusiner et al., 1990, Cervenakova et al., 1998, Mead et al., 2003).  Codon 129 is in 
the second position of four amino acids that make up beta-sheet-1 (see Figure 1.F2) 
and therefore could affect elements of the tertiary structure which may be important 
during conversion of PrPC to PrPSc, see points 5, 6, and 7 above (Petchanikow et al., 
2001).   
Table 1.T3:  Codon 129 Genotype Frequency Variation in TSE Disease 
Codon 129 genotype frequency data from various forms of human TSE disease.  (EU 
data from (Pocchiari et al., 2004), UK control data from (Nurmi et al., 2003), UK 
data from National CJD Surveillance Unit.  (DM: dura mater; hGH: human growth 
hormone) 
 
 MM (%) MV (%) VV (%) Sample Size 
UK Healthy Controls 42 47 11 300 
sCJD (UK) 63 19 18 614 
sCJD (EU) 68 16 16 1453 
vCJD (UK) 100 0 0 146 
fCJD-E200K (EU) 78 20 2 113 
iCJD-DM (EU) 75 17 8 12 






1.5  NON-PRNP GENETIC FACTORS 
 Multi-genic influences are likely to determine the prion disease phenotype.  
At the present time there are only candidate regions found from murine studies 
together with analysis of chromosome 20 in the vicinity of the prion gene, as detailed 
below.   
1.5.1  Doppel 
 Downstream of the prion gene lies the coding sequence for the prion-like 
doppel protein (Human gene: PRND, Genbank: AF106918.  Mouse gene: Prnd, 
GenBank: NM_023043).  This has a high homology (24% of the coding sequence) to 
the prion gene with the octapeptide repeat region missing (Makrinou et al., 2002, 
Premzl and Gamulin, 2007).  Generation of PrP knockout mice accidentally 
generated an overexpression of doppel due to reconfiguration of splicing sites, and 
this lead to detrimental neurodegenerative consequences (Sakaguchi et al., 1996, 
Moore et al., 1999, Mastrangelo and Westaway, 2001, Moore et al., 2001a, Rossi et 
al., 2001).  Association studies of doppel polymorphisms and human disease 
(specifically sCJD) have shown both positive (Schroder et al., 2001, Croes et al., 
2004, Jeong et al., 2005) and negative relationships (Mead et al., 2000, Peoc'h et al., 
2000).  This disparity in results appeared to be dependent on the control population 
genotype frequencies.  A more recent study using larger numbers of samples and 
controls showed no association between doppel polymorphisms and risk of 
developing sCJD (Vollmert et al., 2006).  Murine studies have added further 
evidence to dissociate doppel and TSE disease, showing that expression of doppel in 
the CNS does not affect experimentally induced TSE (Tuzi et al., 2002).   
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1.5.2  Quantitative Trait Loci Analysis 
 The most recent technical advances in genetic analysis allow rapid scanning 
of the whole genome for variations associated with observable phenotypes, 
quantitative trait loci (QTL), that are linked to a disease state.  Such analysis has 
been carried out to observe differences between lines of mice with short and long 
incubation periods, those with Prnpa (leucine at codon 108; threonine at codon 189) 
and Prnpb (phenylalanine at codon 108; valine at codon 189) genotypes respectively, 
when infected with a mouse-adapted form of sheep scrapie (Westaway et al., 1987, 
Moore et al., 1998, Lloyd et al., 2001).  This work identified three highly 
significantly linked regions on chromosomes 2, 11, and 12 (with the possibility of 
multiple QTL at each site), and suggestive evidence for linkage on chromosomes 6 
and 7.  The Prnp locus was within the 95% confidence interval for the region on 
chromosome 2 and is therefore likely to be the candidate for that QTL.  A 
continuation of this work with mouse-adapted BSE incubation time analysis in 
various lines of mice showed highly significant linkage to regions on chromosomes 2 
and 11 (Lloyd et al., 2002). 
 A further QTL analysis was carried out on two lines of mice (C57BL and 
RIII) that showed significant difference in incubation periods when challenged with 
a BSE inoculum but had the same prion gene sequence (Prnpa) (Manolakou et al., 
2001).  Four QTL were identified on regions of chromosomes 2, 4, 8, and 15.  In this 
case the Prnp locus was outside the 95% confidence interval for the region on 
chromosome 2.  These studies now require more detailed analysis of the candidate 
regions to try and pin-point the genetic components that are affecting incubation 
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time.  This type of analysis has been made easier since the publication of the mouse 
genome in 2002.   
 Finding QTL in human TSE cases is difficult due to the small numbers of 
case samples available; two of the studies detailed above used over 1000 mice each.  
This is however under investigation and direct comparisons can be made between 
homologous regions of the published mouse and human genome (Mead et al., 2001).   
 
1.6  HUMAN PRION DISEASES 
 Hans Gerhard Creutzfeldt and Alfons Maria Jakob first described prion 
disease in humans in the 1920s.  Since that time the specific clinico-pathological 
features of Creutzfeldt-Jakob disease (CJD) have been defined in great detail from 
cases world-wide (Parchi et al., 1999, Zeidler and Ironside, 2000, Van Everbroeck et 
al., 2001b, Pocchiari et al., 2004).  The commonest form of prion disease, sporadic 
CJD (sCJD), occurs at an incidence rate of approximately one to two cases per 
million population per year (Will et al., 1996a).  Prion disease cases linked to a prion 
gene mutation contribute 5 – 15% of the total (Windl et al., 1996, Kovacs et al., 
2005).  The first prion gene mutation associated with a human prion disease was a 
proline to leucine change at codon 102 (P102L) in a case of Gerstmann Sträussler 
Scheinker Syndrome (GSS) (Hsiao et al., 1989).  (See below for phenotype 
description.)  Since then over 20 mutations have been identified in families with GSS 
and other inherited forms of human prion disease (Goldfarb and Brown, 1995, 
Prusiner and Scott, 1997).  The high degree of familial association of these mutations 
with disease, over many generations in some cases, indicate that the mutations are of 
key pathogenic significance in familial prion disease.   
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  The following list shows the types of human prion disease: 
• Sporadic CJD (sCJD) 
• Genetic/ inherited prion disease 
o Familial CJD (fCJD) 
o Gerstmann Sträussler Scheinker Syndrome (GSS) 
o Fatal Familial Insomnia (FFI) 
• Acquired prion disease 
o Iatrogenic CJD (iCJD) (via medical treatment) 
o Kuru (endo-cannibalism in Papua New Guinea) 
o Variant CJD (vCJD) 
1.6.1  Sporadic CJD 
 Sporadic CJD predominantly occurs in elderly individuals (average age 60 
to 70 years) with a rapid duration of illness usually less than 12 months and 
presenting as a progressive deterioration of intellectual faculties (dementia).  There is 
currently no known cause, or trigger, for the onset of this disease.  The onset of sCJD 
may be controlled by direct genetic influences, such as prion gene promoter regions 
(Funke-Kaiser et al., 2001, Mahal et al., 2001, Mead et al., 2001, McCormack et al., 
2002, Vollmert et al., 2006), or indirect influences such as genes coding for proteins 
involved in similar cellular processes (Van Everbroeck et al., 2001a, Croes et al., 
2004).  Spontaneous conformational change from PrPC to PrPSc due to a chance 
collection of factors in the biochemical environment, such as a change in pH, could 
also be a trigger (Zanusso et al., 2001).  With increasing age cells become more 
susceptible to deleterious DNA damage which may cause somatic mutations, a 
potential explanation for the elderly age of onset for sCJD.  It is also possible that an 
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infection could be passed between individuals, however as sCJD is not seen clustered 
in families or in healthcare workers this may be unlikely.  A link between surgery 
and sCJD has been suggested but the level of risk is small and the data may be biased 
because of the way these case/control studies are designed (van Duijn et al., 1998, 
Ward et al., 2002, Doerr et al., 2003).   
 Sporadic CJD is a transmissible disease and has been proposed as the likely 
strain responsible for known cases of iatrogenic (medical transmission) CJD such as 
those linked to growth hormone therapy, dura mater grafts (replacement of the 
protective covering of the brain), and neurosurgery (Brown et al., 2000a).  It may 
also have been the initial seed for the kuru disease epidemic in the Fore linguistic 
group of Papua New Guinea (Gajdusek and Zigas, 1959, Collinge et al., 2006).  (See 
later sections on iatrogenic CJD and kuru in this Introduction.)  Monitoring the 
clinical and pathological transmission characteristics in human iatrogenic cases can 
only provide a small data-set and the details of the initial contaminating material are 
likely to be unknown due to pooling of material, and difficulties with traceability.  
Therefore, experimental animals have been widely used as models for examining the 
transmission properties of TSE strains (Brown et al., 1994b, Bruce, 2003).  (See 
section 1.7.4 on ‘Human TSE Transmission’.)   
 Statistical analysis of the relationship between codon 129 genotype and the 
sCJD phenotype, compared with normal, healthy individuals, shows a high level of 
significance (P value < 0.001) (Parchi et al., 1999, Pocchiari et al., 2004).  The 
increased frequency of codon 129 MM cases in relation to the other genotypes 
suggests that it is a significant susceptibility factor (Palmer et al., 1991, Alperovitch 




 Detailed analysis of clinical and pathological features of 300 sCJD cases has 
led to classification of the disease according to six different subgroups, differentiated 
by the PrPSc type (Figure 1.F3) and the codon 129 genotype (Parchi et al., 1999) 
(Table 1.T4).  This classification has been added to by other groups (Hill et al., 
2003) and updated by the original authors (Cali et al., 2006) but the first publication 
is used by many to define sCJD.   
 Further subgroup definition provided by the Parchi et al paper concerned the 
detailed pathological analysis of the cases.  Table 1.T5 shows the similarities and 
differences in PrPSc deposition across the subgroups and Figure 1.F6 compiles data 
for CNS grey matter pathology profiles, a combined assessment of the severity and 
location of TSE associated pathological changes (vacuolation, astrogliosis, and 
neuronal loss).   
 Data generated for this thesis on transmission of each subgroup of sCJD, to 
transgenic mice, will provide additional evidence for the classification of this 
disease.   
 
 
Table 1.T4:  Subgroups of sCJD 
sCJD disease subgroups as defined by analysis of 300 cases. (Parchi et al., 1999)  





































Rapidly progressive dementia, early 
and prominent myoclonus, typical 
EEG, visual impairment or unilateral 
signs at onset in 40% of cases  
‘Classic CJD’ distribution of pathology; often prominent 
involvement of occipital cortex; ‘synaptic type’ PrP staining; one 
third of cases shows confluent vacuoles and perivacuolar PrP 
staining 
VV2 Ataxic variant 16% 61.3 6.5 
Ataxia at onset, late dementia, no 
typical EEG in most cases 
Prominent involvement of subcortical, including brain stem nuclei; 
in neocortex, spongiosis  limited to deep layers; PrP staining shows 





9% 59.4 17.1 
Ataxia in addition to progressive 
dementia, no typical EEG, long 
duration (>2 yr) in some cases 
Similar to VV2 but with presence of amyloid-kuru plaques in the 
cerebellum, and more consistent plaque-like, focal deposits 
MM2 Thalamic variant 2%  52.3 15.6 
Insomnia and psychomotor 
hyperactivity in most cases, in 
addition to ataxia and cognitive 
impairment, no typical EEG 
Prominent atrophy of the thalamus and inferior olive (no 
spongiosis) with little pathology in other areas; spongiosis may be 
absent or focal, and PrPSc is detected in lower amounts than in the 
other variants 
MM2 Cortical variant 2%  64.3 15.7 
Progressive dementia, no typical 
EEG 
Large confluent vacuoles with perivacuolar PrP staining in all 
cortical layers; cerebellum is relatively spared 
VV1 Rare 1% 39.3 15.3 
Progressive dementia, no typical 
EEG 
Severe pathology in the cerebral cortex and striatum with sparing 
of brain stem nuclei and cerebellum; no large confluent vacuoles, 





Table 1.T5:  PrPSc Deposition in sCJD Subgroups 
Differences in location and pattern of PrPPSc deposition for subgroups of sCJD.  Data 
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Comparison of grey matter pathology profiles for sCJD cases grouped by codon 129 and PrPSc type.   
Regions of brain analysed: frontal (FC), temporal (TC), parietal (PC), and occipital (OC) neocortices, hippocampus (HI – CA1 region), parasubiculum and entorhinal 
cortex (EC), neostriatum (ST – nuclei caudatus and putamen), thalamus (TH – mediodorsal nucleus), substantia nigra (SN), midbrain periventricular grey (PG), locus 
ceruleus (LC), medulla (ME – periventricular grey and inferior olive), and cerebellum (CE). (Mean + SD for three scores – spongiosis, astrogliosis, and neuronal loss. 
For number of cases analysed see Table 1.T5.)  Data from reference: (Parchi et al., 1999) 






1.6.2  Genetic / Inherited Prion Disease 
 Genetic prion disease, diagnosed through the presence of a mutation in the 
prion gene (shown in the lower half of Figure 1.F5), is thought to occur because the 
mutant prion protein may more readily convert to the disease associated form, or 
may alter the fine balance of turn-over for production and degradation of the protein.  
This may be due to destabilisation of the tertiary structure following changes in the 
protein amino acid sequence.  Supportive evidence for this comes from that fact that 
PrPSc is formed from the mutant allele PrPC in all of the limited number of cases 
studied.  Whether the wild-type PrPC is converted also (most genetic prion disease 
cases are heterozygous for the mutation), is dependent on which mutation is present 
(Chen et al., 1997, Silvestrini et al., 1997).   
 According to the non-prion hypothesis instability of the mutated protein 
may lead to increased susceptibility to infection by an alternative disease agent or 
pathway; a proposal given further backing by the fact that some carriers of some 
PRNP mutations can live long healthy lives (low penetrance) (Pocchiari et al., 1993, 
Spudich et al., 1995, Mitrova and Belay, 2002). 
 Some of the more common mutations are associated with diseases which 
show near complete penetrance with increasing age (all carriers of the mutation 
develop disease), however only a minority of genetic prion disease cases have a 
family history of neurological disease, suggestive of a prion disease.  Mutations at 
codons 178 and 200 and a six octapeptide repeat insertion have been traced back 
through the generations to where and when the original mutation events are thought 
to have occurred (Nicholl et al., 1995, Harder et al., 1999, Lee et al., 1999).  Due to 
the relatively late onset age in these diseases the mutation phenotype may not show 
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for a number of generations as asymptomatic carriers of the mutation may die of 
other causes.  (For reviews see references: (Prusiner and Scott, 1997, Kovacs et al., 
2002, Kovacs et al., 2005))  
 Some specific mutations are associated with particular clinical and 
pathological phenotypes and have thus been classified under alternative names 
including Gerstmann Sträussler Scheinker (GSS) and fatal familial insomnia (FFI) 
(see below).  The following sections describe in more detail of some of the PRNP 
mutations linked to genetic forms of human TSE, grouped by phenotype. 
1.6.2.1  Familial CJD (fCJD) 
 Familial CJD (fCJD) is a common term given to forms of human TSE, 
associated with PRNP mutations, that frequently have a phenotype similar to that of 
sCJD, and are unlike GSS or FFI.  This group is difficult to recognise through 
clinical features alone as the phenotypes are too varied both within and between 
family groups.  The following describes details of the common mutations associated 
with fCJD cases. 
1.6.2.1.1  Codon 178: Asp (D) to Asn (N) 
 With valine at codon 129 on the same allele this mutation has been found 
throughout the world including a large pedigree in Finland (Haltia et al., 1991, 
Goldfarb et al., 1992).  The phenotype differs from that of sCJD in that it affects 
younger people, has a longer duration, and does not show periodic sharp wave 
activity by electroencephalography (EEG).   
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1.6.2.1.2  Codon 200: Glu (E) to Lys (K) 
 This is the most common fCJD mutation with clinical features and 
pathology very similar to sCJD.  It has been found in clusters in Italy, Slovakia, 
Chile, and Sephardic Jews.  In Jews of Libyan origin the incidence of fCJD is 100 
times that of sCJD and accounts for the majority of Israeli CJD cases (Meiner et al., 
1997, D'Alessandro et al., 1998, Lee et al., 1999, Colombo, 2000, Mitrova and 
Belay, 2002). 
1.6.2.1.3  Codon 210: Val (V) to Ile (I) 
 Identified initially in Italian and French families, and now found around the 
world, the codon 210 mutation presents a phenotype very similar to sCJD (Pocchiari 
et al., 1993, Ripoll et al., 1993). 
1.6.2.1.4  Insertions 
 Insertion mutations are variable numbers of additional octapeptide repeats 
(two to ten copies of a 24bp sequence) in the repeat region of the prion gene.  Some 
insertions occur more frequently than others, such as cases with six extra repeats that 
have been found in UK families (Nicholl et al., 1995, Mead et al., 2006).  This type 
of mutation causes a wide spectrum of phenotypes dependent on the number of 
additional repeats causing difficulties with diagnosis (Vital et al., 1998, Moore et al., 
2001b).  The disease duration can be between two months and 18 years, with 
phenotypes similar to CJD or GSS (Kovacs et al., 2005).  As a general rule the CJD-
like phenotype occurs with up to six extra repeat elements and a duration of less than 
one year.  The GSS-like phenotype occurs with a larger number of repeats and a 
longer duration (Parchi et al., 1998b). 
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1.6.2.2  Gerstmann Sträussler Scheinker Syndrome (GSS) 
 The original GSS study involved an Austrian family that now encompasses 
221 members in nine generations.  The clinical features that specifically differentiate 
GSS from sCJD are earlier age at onset (30-40 years old) and longer duration (~5 
years) (Hainfellner et al., 1995).  Pathologically GSS is characterised by the presence 
of multicentric amyloid plaques and a truncated form of PrPSc by Western blot 
(Ghetti et al., 1996, Parchi et al., 1998a).  This disease phenotype can occur 
associated with a number of different mutations (Piccardo et al., 1998). 
1.6.2.2.1  Codon 102: Pro (P) to Leu (L) 
 This is the commonest GSS phenotype mutation and is recognised as the 
ataxic variant of GSS (due to early movement disorders) with age at onset 
approximately ten years earlier than sCJD (Hainfellner et al., 1995, Young et al., 
1997). 
1.6.2.2.2  Codon 117: Ala (A) to Val (V) 
 This mutation has been studied in families from Italy, Hungary, France, and 
the UK.  It is described as the dementia variant of GSS with occurrence of presenile 
dementia at onset (Mallucci et al., 1999, Kovacs et al., 2001, Tagliavini et al., 2001). 
1.6.2.2.3  Codon 198: Phe (F) to Ser (S) 
 With valine at codon 129, this mutation has been studied in detail for one 
pedigree referred to as the Indiana kindred.  This mutation is recognised by the slow 
progression of disease, and pathologically by the presence of neurofibrillary tangles 




1.6.2.2.4  Codon 217: Gln (Q) to Arg (R) 
 With valine at codon 129, found in a Swedish family, this mutation shows 
similar clinical features and pathology to codon 198 cases including the presence of 
NFTs (Hsiao et al., 1992). 
1.6.2.3  Fatal Familial Insomnia (FFI) 
 This phenotype is clinically characterised by inattention, sleep loss, and 
dysautonomia (abnormal functioning of the autonomic nervous system), and 
pathologically characterised by a preferential degeneration of the thalamus (the 
organ that organizes peripheral sensory information (Reder et al., 1995, Cortelli et 
al., 1999).  It is associated with a single mutation, D178N, as shown above for fCJD 
but with methionine at codon 129.  This disease is clearly distinct from the fCJD 
phenotype where the mutation occurs with valine at codon 129 (Goldfarb et al., 
1992).  This mutation has been found in over 20 individual families and has been 
recognised since 1986 (Lugaresi et al., 1986, Medori and Tritschler, 1993).  
Variation in this phenotype has been reported in an Australian FFI cohort where 
individuals were characterised with typical CJD, FFI, and cerebellar ataxia (McLean 
et al., 1997).   
1.6.3  Acquired Prion Disease 
 This group of TSE diseases arise due to the passage of infectious material 
from one individual to the next and has so far been limited to the three following 
causes in humans: 
1. Iatrogenic CJD (iCJD): disease acquired from infected human tissues by 
medical or surgical procedures 
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2. Kuru: ritualistic cannibalism of infected human tissues 
3. Variant CJD (vCJD): disease primarily acquired via diet from infected 
bovine tissues, and secondarily via blood donated by individuals who 
went on to develop vCJD 
1.6.6.1  Iatrogenic CJD (iCJD) 
 ICJD has been shown to be transmitted through a variety of means and was 
first reported in 1974 in the recipient of a corneal graft from a donor who died of 
unsuspected CJD (Duffy et al., 1974).  The current world-wide total for all identified 
iCJD cases is 405 (Brown et al., 2006).  Now that the risk of TSE transmission is 
known precautions are in place to attempt to avoid further cases in the future.  In the 
mid-1980s the major risk factors for this acquired disease were identified as 
contaminated human dura mater grafts (the outermost protective membrane of the 
brain) and human growth hormone (hGH) derived from cadaver pituitaries.  The 
highest incidence of iCJD is in growth hormone patients in France, USA and the UK; 
and contaminated dura mater graft recipients in Japan. 
 The pathology and clinical features of iCJD show similarities to vCJD, 
which might be predicted, as both are prion diseases acquired through an exogenous 
infectious source.  Differences seen may be a result of the alternative routes of 
infection, oral for vCJD and intravenous or intracerebral for iCJD. 
 It is of interest to examine the codon 129 genotype of iCJD cases because 
vCJD case genotypes might follow the same temporal patterns, e.g. incubation time 
and the appearance of different codon 129 genotypes at different periods from the 
point of infection.  This is of specific relevance to peripherally acquired iCJD such as 
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for the growth hormone cases, as BSE infection of humans was via the periphery 
(although the routes are different: intravenous versus oral respectively).  As seen in 
sCJD, homozygosity (MM or VV) is more frequent in iCJD cases and the UK hGH 
cases show a marked increase in VV genotypes indicating possible contamination by 
VV genotype infectious material (Collinge et al., 1991, Brown et al., 2000a).  It is 
possible that for this TSE infection the MV genotype individual may be relatively 
protected to some degree.  There is a statistically significant increase in the 
incubation time for heterozygotes, as found in French growth hormone cases 
(d'Aignaux et al., 1999).  A study of donor/ recipient pairs where material was 
available for codon 129 analysis showed all donors were MM and the recipients were 
both MM and MV.  As MV individuals were affected, complete genetic homology 
was not required for disease transmission (Brown et al., 1998).   
1.6.6.2  Kuru 
 Identified in the Fore linguistic group in the Eastern Highlands of Papua 
New Guinea, kuru was first reported in 1959 (Gajdusek and Zigas, 1959).  It has 
been classified as a form of acquired prion disease as it is proposed that this prion 
disease spread through ritualistic cannibalistic practices involving exposure to, and 
probably consumption of, CNS material.  The numbers of kuru cases currently stands 
at approximately 3000 (Goldfarb, 2002).  The last cases (mostly MV genotype) 
appeared over 40 years after cessation of cannibalism, suggesting incubation periods 
of over 50 years (Collinge et al., 2006).  This is of significant relevance to other 
acquired human prion diseases, such as vCJD, which may have similarly long 
incubation periods in certain individuals.  
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 A codon 129 study in the Fore group showed the variation in genotype 
frequencies of the population over the course of the kuru epidemic.  The kuru 
survivor population sampled in the late 1950s was found to have a significantly 
lower level of MM genotypes, indicating that these individuals were the first to die 
from kuru.  The last group of kuru cases, who would have been infected at a similar 
time, was subsequently found to have a high frequency of MV.  This genotype may 
have been subject to balancing selection over many generations because of the 
occurrence of acquired TSE diseases such as kuru that appear because of 
cannibalism (Hedrick, 2003, Mead et al., 2003).  These data suggest variation in 
incubation time between the genotypes with MM being the most susceptible, and 
having the shorter incubation period (Cervenakova et al., 1998, Lee et al., 2001, 
Collinge et al., 2006). 
1.6.6.3  Variant CJD (vCJD) 
 Variant CJD (vCJD) is an acquired form of human prion disease caused by a 
cross-species transmission of the BSE infectious agent from cattle to humans (Bruce 
et al., 1997, Hill et al., 1997).  Following the identification of vCJD in 1996, (Will 
et al., 1996b) there have been many attempts to estimate the extent of the UK 
epidemic for public health reasons (Ghani et al., 2000, Valleron et al., 2001, Ghani 
et al., 2003).  It has been estimated that over 500,000 BSE infected cattle entered the 
human food chain (Anderson et al., 1996) and therefore a significant number of 
people may have been exposed to infection through their diet.  However, as of July 
2008, there have been only 167 cases of the disease in the UK, and a further 43 
cases in other countries worldwide. (www.cjd.ed.ac.uk)  Annual mortality rates 
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indicate that the vCJD outbreak is now in decline in the UK following a peak in 
1999/2000 (Andrews et al., 2003).   
 One explanation for the current low number of cases is that there may be 
genetic determinants, or influences, on susceptibility to infection.  DNA sequence 
analysis of the prion protein gene in vCJD cases has shown that 100% of tested 
cases are homozygous for methionine (MM) at the codon 129 polymorphism, 
compared with about 40% of the UK population (Nurmi et al., 2003) and about 
70% of sporadic CJD cases (Pocchiari et al., 2004) suggesting that this may be the 
only susceptible genotype.   
 Human leukocyte antigen (HLA) typing in vCJD cases (n=50) indicated that 
there was a reduction in frequency for the class-II type DQ7 compared with sporadic 
CJD cases (Jackson et al., 2001) however this association was not maintained on 
testing a larger sample size (Pepys et al., 2003).  Detailed analysis of a 35kb 
sequence flanking the prion gene locus identified 56 single nucleotide 
polymorphisms (SNPs) and one of these showed strong association with sCJD but 
not vCJD or iatrogenic CJD (Mead et al., 2001).  At this stage no genetic factor has 
been found to link the few vCJD cases other than MM at codon 129.  Identification 
of such factors may shed light on the reasons why these specific individuals 
developed vCJD at this time, and thus may allow for treatments to be developed 
based on correcting the genetic changes that have occurred.  Testing for these genetic 
factors could also be used to determine someone’s risk of developing vCJD 
following a known point of infection.   
 The clinical and pathological features of vCJD are clearly distinct from 
those of sCJD.  The younger age of affected individuals (median age at death 28 
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years) and the longer disease duration (median time 13 months) are quite different 
when compared with sCJD (65 years, and <12 months) (Will et al., 2000).  The 
presenting clinical signs are generally psychiatric, such as depression, followed by 
ataxia after about six months, then involuntary movements and cognitive 
impairment.  World Health Organisation approved criteria are available to assist with 
diagnosis (www.cjd.ed.ac.uk/criteria.htm).   
 There are pathological changes unique to vCJD that assist with confirmation 
of the cause of death at autopsy.  As with most prion diseases, vCJD, has 
vacuolation, gliosis, and neuronal loss, although the targeting and intensity are not 
the same as other human TSEs.  Some of the unique features of vCJD are listed 
below: 
• Presence of ‘florid’ plaques in the brain (as shown in Figure 1.F7) 
• Non-CNS tissue deposition of PrPSc (Figure 1.F7) 
• Type 2B pattern of protease treated PrPSc by Western blot (Figure 1.F3) 
• Hyperintensity of the pulvinar of the thalamus region of the brain by 
magnetic resonance imaging (MRI) 
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Figure 1.F7:  vCJD Histopathology 
Characteristic pathological features of vCJD (images from reference: (Ironside et al., 
2002a)) 
Panel A: typical florid plaque in the cerebral cortex (centre) comprises an 
eosinophilic core with a pale radial periphery, surrounded by spongiform change 
(haematoxylin and eosin stain) 
Panel B: follicular dendritic cells and tangible body macrophages within the 





 In 2003 the first case of human-to-human transmission of vCJD via blood 
transfusion was identified through a collaborative study between the UK National 
Blood Services, the National CJD Surveillance Unit, and the Office of National 
Statistics (Transfusion Medicine Epidemiology Review, TMER) (Llewelyn et al., 
2004, Hewitt et al., 2006).  This patient (MM at codon 129) had received a 
transfusion of non-leucodepleted red cells that had originated from a donor who 
three years and four months later developed clinical vCJD, this therefore was the 
likely source of infection.  Statistical analysis indicated that the probability of 
recording a case of BSE derived vCJD amongst those who received blood products 
from ‘infectious’ donors, in the absence of transfusion transmitted infection, was 
between 1 in 15,000 and 1 in 30,000 (Llewelyn et al., 2004).  The blood donor must 
have been in a pre-clinical phase during which PrPSc levels were increasing in the 
periphery.  Peripheral tissue amplification of PrPSc during the preclinical phase of 
TSE infection is a common finding for mouse TSE strains that target the peripheral 
nervous system (Mabbott and Bruce, 2001). 
 Two further cases of vCJD linked to blood transfusion, in MM genotype 
individuals, have subsequently been identified (Wroe et al., 2006, HPA, 2007).  
These cases instigated policy changes in relation to blood donation in the UK and 
elsewhere.  The UK Blood Service deferred transfusion recipients from acting as 
blood donors and began out-sourcing blood products from other countries, including 
the USA, for specific uses such as treating children. 
 A fourth case, of asymptomatic infection following blood transfusion, was 
described in 2004, in a patient that died of a ruptured abdominal aortic aneurysm.  As 
they were on the ‘at risk’ list held by the TMER study group, autopsy tissues were 
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examined.  These were confirmed as having signs of vCJD infection, including the 
presence of type 2 PrPSc in spleen and deposition of PrPSc in germinal centres within 
spleen and cervical lymph nodes  This individual was heterozygous (MV) at codon 
129 (Peden et al., 2004).  This was the first indication that non-MM individuals 
might be susceptible.   
 All three codon 129 genotypes are now thought to be susceptible to vCJD 
infection following analysis of two of the three positive appendix tissues discovered 
in a retrospective immunocytochemical study that aimed to detect disease 
associated prion protein (PrPSc) in appendix and tonsil specimens from the UK 
(Hilton et al., 2004a).  These two tissues were homozygous for valine (VV) at codon 
129 (Ironside et al., 2006).   
 Further confirmation has come from successful transmission of vCJD to 
‘humanised’ transgenic mice of each codon 129 genotype (this thesis) (Bishop et al., 
2006).  The implications of these findings are that a significant number of the UK 
population, of all codon 129 genotypes, may be carriers of vCJD infectivity, that 
some of the individuals may be donating blood, and that not only those with an MM 
genotype may be susceptible to infection from this source.  Results from second 
passage of vCJD in human transgenic mice, will help to model the extent to which 
non-MM individuals infected with vCJD agent, could efficiently transmit infection 
(See Chapter 4, section 4.3.2).  
 For the four known cases of blood transfusion transmission of infectivity the 
time periods between the donation of blood and development of vCJD in the donors 
were: 40 months (Llewelyn et al., 2004); 18 months (Peden et al., 2004); 20 months 
(Wroe et al., 2006); and 17 months (HPA, 2007).  This confirms the hypothesis that 
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the vCJD preclinical phase is lengthy and that during this time host tissues or fluids 
are able to transmit disease.  It is known that the kuru incubation time from infection 
to clinical onset may be up to 50 years but there is no evidence indicating when 
during the incubation period levels of infectivity / PrPSc reach a point at which 
tissues or fluids would be transmissible.   
 Evidence that PrPSc is present during the pre-clinical phase in TSEs has 
come from studies of vCJD (positive appendix eight months prior to onset of clinical 
vCJD) (Hilton et al., 1998), BSE (PrPSc detection six months prior to onset) (Schaller 
et al., 1999, Schulz-Schaeffer et al., 2000), and scrapie (PrPSc detection 
approximately 50% through the incubation period) (Schreuder et al., 1998).   
 The identification of four instances of secondary transmission of vCJD 
infection from a group of 66 individuals known to have received blood products 
from vCJD donors, including only 28 who survived at least five years post 
transfusion indicates that blood transfusion is a significant risk factor for vCJD.  It is 
unknown whether this is because the route of infection is more efficient, or because 
the agent involved is more infectious than the original BSE strain.  A sheep blood 
transfusion model used intravenous (i.v.) transfusion of whole blood and blood 
fractions from clinical and preclinical sheep infected with BSE or scrapie.  
Preliminary data showed that the i.v. route gave relatively short and consistent 
incubation periods suggesting an efficient transmission route, with success rates of 
60% (n=3 of 5 transfused) for sheep infected with BSE and 40-45% for natural 
scrapie (Houston et al., 2000, Hunter et al., 2002, McCutcheon et al., 2007).  
Contrary to this is a publication that indicated the i.v. route was less efficient than the 
intracerebral (i.c.) route in a cross-species transmission of a human TSE strain to a 
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mouse (Brown et al., 1999b).  However, a less artificial transmission model of BSE 
to macaques by the i.v. route has been shown i.v. to be more efficient than the oral 
route (Herzog et al., 2004).   
 
1.7  TRANSMISSION OF TSE TO EXPERIMENTAL ANIMALS 
 Transmission studies in TSE research have been undertaken for many 
decades, particularly on scrapie as this was the first TSE disease to be characterised.  
Sheep and goats were used for such studies, as these were the original host species, 
and are still used today but the use of mice, hamsters, and other small rodents is 
more practical.  Using experimental rodent lines is more practical as they are easier 
and more cost effective to house and maintain, and they have relatively short 
gestation times, incubation periods, and life-spans.  Genetic manipulation of mice 
has been used to model many human diseases.  Mouse genes that have homology to 
human genes can be manipulated to observe the phenotypic effect on the host and 
therefore allow better understanding of the human response to similar genetic 
changes.  An example of such a model is the mutation of the mouse prion gene at 
codon 101, modelling the human GSS mutation at codon 102 (proline to leucine 
change).  These mice, when over-expressing the gene, developed a spontaneous 
disease phenotype with similarities to human GSS.  (See section 1.8.5 Transgenic 
Mice With Mutations Associated With Human Disease)   
 Non-human primates, such as Squirrel Monkeys (Williams et al., 2007) and 
Cynomolgus Macaques (Lasmezas et al., 2005), have been extensively used as they 
are evolutionarily closer organisms to humans and therefore physiologically and 
neuropathologically may model human disease more accurately.   
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1.7.1  Scrapie Transmission 
 The use of mouse lines for assaying scrapie has been underway since the 
1960s and has provided some of the core descriptions of TSE transmission, leading 
to the detailed classification of different scrapie strains (Bruce et al., 1991).  One of 
the uses for mice in investigating scrapie is as a bioassay, an in vivo diagnostic test 
system.  Confirmation that a Dorset Down ram had died from scrapie (an 
unidentified disease in that breed) was determined by inoculation of a panel of mice 
with brain material (Zlotnik and Stamp, 1965).   
 Many natural strains of scrapie exist, with the possibility of mixed 
infections.  Many more have been isolated from serial passage of scrapie in different 
mice and hamster lines, generating a number of experimental TSEs that have now 
become extremely well characterised. These are used as model TSE systems due to 
the predictable nature of the disease pathogenesis produced.  Examples of such are 
263K from Syrian hamsters (Kimberlin and Walker, 1977), and RML scrapie and 
Chandler (Chandler, 1961), and ME7 and 79A (Bruce et al., 1991) in mice.  
 To determine a possible scrapie origin for BSE, brain material from a 
number of affected animals was passaged through mouse lines for strain typing 
(Fraser et al., 1992, Bruce et al., 1994, Bruce et al., 2002).  The results of this work 
showed that from UK sources of BSE only one strain was detected and this was 
different from any of the many strains of sheep scrapie.  It was important to know 
whether the BSE agent could infect sheep as this could be an alternative route to the 
human food chain.  This was shown to be experimentally possible by intracerebral 
injection or oral dosing of sheep and goats (Foster et al., 1993).   
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 Alternatively, it may be that during feed production, the sheep carcass 
rendering process biased selection of a rare scrapie strain that was infectious to 
cattle.  Scrapie transmission to transgenic mice expressing the bovine prion gene has 
been successful indicating that the scrapie origin of BSE is a possibility, however 
there are some clear distinctions between the results for BSE and scrapie inocula.  
One study showed clear differences in the pathology (Scott et al., 1999) and a second 
showed an increase in incubation period for scrapie transmission compared with BSE 
(Castilla et al., 2003).  Both these studies used mice that over-express bovine PrP 
and therefore inocula may more readily transmit than with wild-type PrP expression.  
This does however, add further weight to the hypothesis that BSE may have been 
due to a spontaneous disease in cattle.  (See section 1.7.2 below.) 
 Scrapie has been successfully transmitted from sheep-to-sheep by blood 
transfusion, a result published before the identification of human-to-human 
transmission of vCJD by the same route (Houston et al., 2000, Hunter et al., 2002, 
McCutcheon et al., 2007).  This model is now being examined further to find 
evidence as to which blood components carry the highest infectivity levels, in order 
to assist with determining the risk to humans from contaminated blood.   
1.7.2  BSE Transmission 
 When bovine spongiform encephalopathy (BSE), or ‘mad-cow’ disease, was 
identified in the late 1980s it was important to ascertain the origins of the infection.  
The two main theories put forward were that either scrapie had crossed species to 
become a cattle disease, or it was a spontaneous disease in cattle initiated perhaps by 
a single mutation event in one animal.  Due to the continual recycling of infected 
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material in cattle feed the disease spread rapidly throughout the UK cattle population 
(Bradley and Wilesmith, 1993). 
 An important proof of the hypothesis that BSE had infected humans to 
produce vCJD was the transmission characteristics of infected brain material from 
these two diseases to indicative lines of mice (Bruce et al., 1997, Hill et al., 1997).  
Both sources were characterised as being the same ‘strain’ due to similar lesion 
profiles (Figure 1.F8) and incubation periods.  Further evidence that BSE could 
infect humans has also been provided from the successful oral inoculation of 
nonhuman primates (Bons et al., 1999).   
 
Figure 1.F8:  Lesion Profiles of Wild-type Mice with BSE and vCJD 
Lesion profiles of BSE and vCJD from inoculation of RIII wild-type mice. 
Panel ‘b’ from reference (Bruce et al., 1997) shows the pooled grey matter data from 
four cattle with BSE. 
Panel ‘d’ from reference (Bruce et al., 1997) shows the grey matter data from three 
cases of vCJD (dashed line is pooled BSE data). 
 
 
1.7.3  Other Non-Human TSE Transmission 
 Feline spongiform encephalopathy (FSE) has also been transmitted to 
rodents (Fraser et al., 1994).  The comparison of FSE to BSE was important as the 
disease was only identified in 1990 after the BSE outbreak in the UK.  Inoculation of 
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a mouse typing panel with brain material from three cats provided data on incubation 
periods, clinical phenotype and neuropathology, that were comparable to BSE data, 
indicating that these two diseases were likely to have the same source of infectivity 
(Fraser et al., 1994).  Further evidence for BSE infection of other species came from 
mouse transmissions of Greater Kudu and Nyala (antelopes) suspected of showing 
signs of TSE (Bruce et al., 1994). 
1.7.4  Human TSE Transmission 
1.7.4.1  Inoculation of Non-Human Primates 
 Following the appearance of kuru in the 1950s human material was used to 
inoculate nonhuman primates (Gajdusek et al., 1966).  The clinical disease 
phenotype seen in these chimpanzees showed similarities to those of kuru and 
spongiform change was seen on pathological analysis (Beck et al., 1966).  One of the 
largest human TSE transmission data sets available was reported by the United 
States National Institutes of Health with three hundred experimentally transmitted 
cases of human prion disease to nonhuman primates: 234 sCJD, 36 fCJD, 8 iCJD, 18 
kuru, and 4 with GSS (Brown et al., 1994b).  Successful transmission was highest 
for iCJD (100%), kuru (95%), and sCJD (90%), and lowest for fCJD (68%).  
Whether the differences were attributable to variation in the codon 129 genotype or 
PrP type cannot be assessed as these investigations were not in place at that time.   
 There was some variation found amongst the fCJD group dependent on the 
specific mutation present in the case material.  The E200K cases produced the most 
efficient transmission rates (85%), similar to sCJD, with which it shares significant 
similarities in clinico-pathological features.  Comparatively less successful were the 
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P102L GSS cases (39%).  None of the three D178N/129M fatal familial insomnia 
(FFI) cases transmitted disease which was of interest as the fCJD form carrying this 
mutation (D178N/128V) produced a high transmission rate of 70%.  FFI was 
subsequently been found to be transmissible to wild-type mice (Tateishi et al., 1995).   
 Even though the familial TSE cases showed variation in transmission rates, 
as a group, the incubation periods were statistically significantly shorter (in squirrel 
monkeys) than for sCJD (p<0.001; Student’s t-test) (Brown et al., 1994b).  As 
familial TSE patients will have expressed the mutated form of PrPC from birth, end-
stage disease tissues may have a higher titre of infectivity leading to shorter 
incubation periods.  In contrast, the period from clinical disease onset to death in 
sCJD in significantly shorter, possibly resulting in tissues with a lower titre of 
infectivity.  Alternatively there may be other characteristics of these TSE strains, 
such as the PrPSc conformation, that may effect the transmission incubation period.   
 Variant CJD and BSE serial passage in non-human primates (macaques) 
confirmed the BSE origin of vCJD in the UK, Republic of Ireland, and France, that 
passage of BSE in humans may produce a more human infectious agent 
transmissible via a peripheral route such as blood transfusion, and that if such a 
human-to-human infection occurred the clinical and pathological features would be 
readily recognised by current vCJD diagnostic criteria (Lasmezas et al., 2001).  This 
evidence in an experimental host that is significantly closer to humans than mice, on 
the evolutionary scale, must remove any doubt that BSE is the origin of vCJD.   
1.7.4.2  Sporadic CJD Transmission to Rodents 
 Sporadic CJD transmissions have been performed on wild-type mice (Bruce 
et al., 1997), bank voles (Nonno et al., 2006), and an array of transgenic mice 
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(Telling et al., 1994, Asante et al., 2002, Kitamoto et al., 2002, Korth et al., 2003, 
Taguchi et al., 2003, Asante et al., 2006, Kobayashi et al., 2007, Beringue et al., 
2008).  The transgenic mice studies became more frequent following the 
development of methods to alter the genetic components of the prion protein gene 
locus; by replacing it with multiple copies, with mutated / chimeric copies, or copies 
from different species such as humans.  Many types of sCJD were found to transmit 
inefficiently to wild-type mice, without clinical symptoms, (Bruce et al., 1997) and 
therefore these new mouse models provided the first opportunity to observe more 
extensive transmission characteristics.   
 Most of these studies used random genomic insertion to produce over-
expressing models, however those from Professor T Kitamoto’s group, and the mice 
used for this study, are based on gene targeting methodology giving physiological 
(single copy) expression of an introduced ‘human’ gene.  The genetic differences 
between published transgenic lines will be discussed in a later section of this 
Introduction.   
 Sporadic CJD transmission to bank voles has provided some interesting data 
(Nonno et al., 2006).  The classical form of sCJD (subgroups MM1 and MV1) 
transmits with high efficiency and short incubation times compared to an equally 
high efficiency but longer incubation times in the less common MM2 subgroup.  In 
contrast, subgroups MV2 and VV2 show no evidence of transmission.  As the vole 
prion gene codes for methionine at the equivalent position to human codon 129, this 
data may suggests a PrP methionine allele dominance for successful transmission.   
 47
 
1.7.4.3  Genetic TSE Transmission to Rodents 
 There are variable transmission rates for genetic TSE inocula in wild-type 
mice which depend on the specific mutation present and the tissue selected for the 
inoculum, as detailed above in primate studies.  An extensive Japanese study of 
genetic TSE involved inoculation of wild-type mice with a wide variety of source 
material, although usually only single cases (Tateishi and Kitamoto, 1995).  The 
majority of fCJD cases did not show evidence of transmission.  The results for sCJD 
versus P102L (GSS), where multiple case data are available with successful 
transmission, show the latter to have a much lower transmission frequency (82% vs. 
33% respectively).  This is similar to the primate transmission study data discussed 
above (sCJD 90% vs. P102L 38%) (Brown et al., 1994b).  
1.7.4.4  Variant CJD Transmission to Rodents 
 Variant CJD has been inoculated into both wild-type mice, and a number of 
different transgenic lines expressing various forms of  human and bovine PrP.  The 
results of vCJD transmission to human transgenic mice will be discussed in detail in 
a later section of this Introduction.  Many of these studies were performed to link 
BSE infection with clinical cases of vCJD.  The first of these studies appeared in the 
subsequent years after the 1996 discovery of vCJD.  Wild-type mouse data from 
NPD (Bruce et al., 1997), wild-type and transgenic mice expressing human PRNP 
(VV at codon 129) data from the Collinge group (Hill et al., 1997), and bovine 
transgenic mice from the Prusiner group (Scott et al., 1999) all produced compelling 
evidence for the link between transmission properties of BSE and vCJD suggesting 
that the human disease was caused by the bovine sourced infectious agent.   
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 Further work on wild-type mice demonstrated that vCJD peripheral tissues 
(spleen and tonsil) known to contain PrPSc (unlike sCJD) but not blood fractions, 
were infectious to mice (Bruce et al., 2001).  Also, that detailed neuropathological 
analysis of mice infected with vCJD and BSE showed close similarities (Brown et 
al., 2003).  An extension of this work was in the use of material from wild-type 
mouse passaged vCJD.  Blood fractions including buffy coat and plasma were found 
to be infectious using this method (Cervenakova et al., 2003).   
 The majority of transmission work carried out since these initial studies has 
involved the use of transgenic mice.  VCJD inoculation was to assess new mouse 
models of human disease (Barron et al., 2001), and in transmission to human 
transgenic mice to further understand human susceptibility to the bovine origin 
agent, and the effect of codon 129 genotype on this (Asante et al., 2002, Wadsworth 
et al., 2004, Asano et al., 2006, Asante et al., 2006, Beringue et al., 2008).  All of 
this work is described in detail in other sections of this Introduction.   
 
1.8  TRANSGENIC MOUSE MODELS OF TSE TRANSMISSION 
 To investigate species barrier effects on transmission, mouse lines were 
developed that expressed prion gene sequences from other species.  As it is known 
that transmission is more efficient within species than between species (Bruce et al., 
1994), these models have been used to examine this relationship within a controlled 
host environment.  Laboratory methods for the production of transgenic mice have 
developed significantly over the last two decades, using two distinct methods: 
random genomic insertion (RGI) and gene targeting (GT) (Manson and Tuzi, 2001).   
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1.8.1  Random Genomic Insertion (RGI) of Genetic Elements 
 A section of DNA can be microinjected into a fertilised mouse oocyte.  This 
genetic material integrates randomly into the host’s genome, and through genetic 
screening of the offspring, those mice with the additional gene can be identified.  
There is no control of the insertion point or how many copies of the transgene have 
been integrated.  The transgene copy number is rarely mentioned in publications. 
Three lines that express human PrP have this information.  One, called Tg110, has 2-
4 copies of the gene giving equivalent normal expression levels (Telling et al., 
1994), a second, called Tg152, has 30-50 copies giving 4-8x expression levels 
(Telling et al., 1994), and a third called tg650 has 5 copies giving 6x expression 
levels (Beringue et al., 2008) (Table 1.T6).   
 The number of copies present is therefore not directly proportional to 
expression level, highlighting the effects that insertion point can have on transgene 
expression.  No detailed investigation of the specific location of genomic insertion 
has been published and therefore any deleterious effects on the surrounding genes 
are unknown.  In addition, regulatory elements such as promoter sequences of host 
genes in the vicinity of the transgene may determine the location and expression 
level of PrP.  The confirmation that a new over-expressing transgenic line is suitable 
generally relies on two points: that PrP is expressed in the brain, and that the mice 
live to normal life-span without any obvious harmful phenotype.  This confirmation 
may be too limited for mice that could have up to 50 lengths of non-murine DNA 
sequence inserted in the genome, possibly disrupting other genetic elements.  Over-
expression of even wild-type PrP can have detrimental effects leading to a TSE-like 
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clinical phenotype and so this method can give data that may be difficult to interpret 
(Westaway et al., 1994b).   
 These mice have been used to investigate the relationship between PrP 
expression levels and susceptibility to disease, and as a result there are mice lines 
available that develop signs of TSE in less than 100 days post inoculation.  In 
addition, this has made the mouse bioassay system more affordable and with a faster 
reporting time (Kitamoto et al., 2002).  The ‘natural’ pathogenesis of TSE, and 
comparisons between mouse lines, however cannot be modelled in such mice, and 
these are two of the reasons why the gene targeting method was developed for 
producing mice used in this thesis.   
1.8.2  Gene Targeting (GT) for Precise Insertion of Genetic Elements 
 Predetermined genomic positioning of a transgene allows replacement of 
murine genes with those of other species.  The genetic material to be inserted has 
flanking DNA homologous to the recipient mouse.  This is introduced into 
embryonic stem (ES) cells where homology between the transgene flanking DNA 
and the murine DNA ensures precise insertion by homologous replication.  The ES 
cells are then microinjected into mouse blastocysts.  Once offspring have been 
identified as carrying the transgene they are used in the breeding of germline 
transgenic mice.  Continued breeding generates mice homozygous for the transgene.  
It is this method that has been used successfully in generating the human transgenic 
mice lines used in this thesis.  The benefits of using these gene targeted mice lines 
are that the inserted human PRNP gene is under the direct control of the normal 
expression modifiers for the equivalent mouse Prnp gene, and that following 
inoculation with human prions there will be homologous human PrPSc / PrPc 
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interaction.  In addition to this the NPD lines have been generated in an inbred wild-
type line (129Ola) therefore the only genetic variation is that of the codon 129 
genotype in the inserted human prion gene.  The effect of this codon 129 
polymorphism can therefore be studied in isolation.   
1.8.3  Knockout / Null Transgenic Mice and the Role of PrP 
 Stopping expression of the prion protein gene in transgenic mice allows 
analysis of the phenotype attributable to lack of PrP.  PrP knockout or null mice 
(designated Prnp0/0) have been produced by a few laboratories: NPD (Manson et al., 
1994a), Edinburgh (Moore et al., 1999), Zurich (Bueler et al., 1992, Rossi et al., 
2001), Nagasaki (Sakaguchi et al., 1996).  The usual method is to disrupt the ORF by 
either insertion or deletion of DNA fragments, however, deletion of the start of the 
ORF has been found to result in up-regulation of expression of the doppel protein, 
due to alternative splicing events, producing a deleterious phenotype (Sakaguchi et 
al., 1996, Moore et al., 1999).  The NPD and ‘Zurich1’ null mice show no adverse 
symptoms and develop and reproduce normally. However, null mice may show 
changes to circadian rhythms and sleep patterns (Tobler et al., 1996), 
electrophysiological defects (Collinge et al., 1994) and alterations in copper binding 
and superoxide dismutase activity in the CNS (Brown et al., 1997).   
 Heterozygous null mice (designated Prnp+/0) with only one active gene have 
been used to assess the effect of PrP expression levels on TSE pathogenesis.  
Heterozygous and homozygous null mice were used in mouse scrapie transmission 
studies to define the requirement for PrP in disease (Bueler et al., 1993, Prusiner et 
al., 1993, Manson et al., 1994b).  Using either mouse inoculum, RML or ME7, the 
published data-sets show TSE disease occurring in heterozygous null mice at 
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approximately double the number of days as seen with the Prnp+/+ wild-type mice.  
No clinical or pathological signs of disease transmission were seen in homozygous 
null mice.  The heterozygous null mice data suggest that the gene copy number can 
influence disease onset and pathogenesis, and provides strong evidence to support 
the central role of PrP.   
1.8.4  Chimeric Transgenic Mice and PrP Molecular Interaction 
 To identify critical components of the prion protein structure, and those 
required for molecular interaction such as when PrPSc converts PrPC, chimeric 
transgenes can be used.  Studies using chronically infected mouse neuroblastoma 
cells (an ex vivo method using cells that continually produce mouse derived PrPSc) 
were carried out using mouse/hamster PrP chimeras (Scott et al., 1992).  The mouse 
and hamster prion genes were segmented according to restriction enzyme digestion 
and recombined into a variety of chimeric sequences.  Only one of the chimeras 
tested was found to form PrPSc in the presence of mouse scrapie prions, indicating 
that the specific mouse amino acid sequences of that chimera were important for 
susceptibility to mouse prions. 
 An in-vivo methodology produced a chimeric human/mouse PrP line that 
expressed normal levels of PrPC, from 2-4 copies of the transgene, with nine 
different amino acids when compared with mouse PrP (Telling et al., 1994).  After 
inoculation with human TSE material these mice developed signs of neurological 
disease and deposited PrPSc formed from the chimeric protein.  This indicated that 
the human component of the chimeric PrP molecule was acting as a recognition site 
for the infecting agent.  This mouse line also expressed mouse PrPC but when this 
was ablated the incubation periods decreased (Telling et al., 1995b).  It was 
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hypothesized that mouse specific PrP chaperone molecules were preferentially 
binding mouse PrPC and so when this was removed they were free to bind to the 
chimeric protein.  This lead to the hypothetical scenario of a ‘protein X’ chaperone 
molecule playing an important role in TSE (Telling et al., 1995b). 
1.8.5  Transgenic Mice with Mutations Associated with Human Disease 
 Converting proline to leucine at codon 101 (equivalent to the human P102L 
GSS mutation – see section 1.6.2.2.1 above) in a transgenic mice line that expressed 
PrP at levels eight-fold higher than control mice was the first example of a human 
mutation mouse model (Scott et al., 1989, Telling et al., 1995a).  These mice 
appeared healthy until spontaneous symptoms of muscular incoordination, lethargy, 
and rigidity occurred at a mean time of ~170 days, a similar ataxic clinical phenotype 
to that of human GSS (Hsiao et al., 1990).  Serial transmission confirmed this 
disease could be transmitted to hamsters and transgenic mice, but not to wild-type 
mice (Hsiao et al., 1994). 
 Mice with single copy P101L transgenes were developed to more closely 
model the effect of this mutation as it is found in humans (Manson et al., 1999).  
These mice did not develop a spontaneous TSE, however, the mutation was 
associated with a dramatic alteration in incubation periods and susceptibility.  
Inoculation with human GSS material (at 1% concentration) produced clinical 
disease in only one wild-type mouse (from a group of eight) at 456 days, whereas in 
transgenic mice homozygous for the mutation 100% (n=15) showed clinical signs at 
288 days.  Inoculation with mouse passaged scrapie strain ME7 showed 100% 
transmission for both transgenic and wild-type mice but the incubation period was 




 To further investigate this difference in strain transmission for these 
transgenic mice they were inoculated with TSE material from four different species: 
human (vCJD), hamster (passaged scrapie), sheep (scrapie), and mouse (passaged 
scrapie) (Barron et al., 2001).  In transgenic mice the human and mouse derived TSE 
showed an increase in the incubation period, whereas TSE from hamster and sheep 
decreased the incubation period, all compared with wild-type mice.   
 These results indicate a significant role for the protein structure of PrP 
around amino acid position 101, with effects seen across three species barriers, and 
support the theory that humans carrying the P102L mutation may have altered 
susceptibility to TSE infection (Manson et al., 1999, Barron et al., 2001). 
 
1.9  TRANSGENIC MICE WITH FULL-LENGTH HUMAN PRION 
GENE SEQUENCE 
 There are five research groups that have published data on transgenic mice 
expressing full-length human PrP with either MM, MV, or VV genotype at codon 
129, and an additional group that have published only MM mice.  The lines are listed 
in Table 1.T6 together with the methodology used to create them; either random 
genomic insertion (RGI) (multiple copy / over-expressing) or gene targeting (GT) 
(single copy / physiological expression).  The data obtained using each method will 
be discussed below.  Much of the data from the other research groups, comparing 
codon 129 genotype between lines, including the heterozygote genotype, was 
published since the beginning of this thesis.   
 
 
Table 1.T6:  Transgenic Lines Expressing Human PrP 








Expression Level Use References 






Definition of strain and role 
of codon 129 genotype in 
susceptibility 
(Bishop et al., 2006, 
Cancellotti et al., 2006, 




















Development of bioassay 
and role of codon 129 
(Kitamoto et al., 1996, 
Kitamoto et al., 2002, 
Taguchi et al., 2003, Asano et 
al., 2006) 






Characterisation of PrP 
structural properties and 
association with infectivity 
(Telling et al., 1994, Telling 
et al., 1995b, Korth et al., 
2003) 








Definition of strains and 
human susceptibility 
(Collinge et al., 1995, Hill et 
al., 1997, Asante et al., 2002, 
Asante et al., 2006) 
Laude RGI Tg650 (MM) 6x Definition of strains and 
human susceptibility 




1.9.1  Random Genomic Insertion (RGI) Method 
1.9.1.1  Co-Expression of Human and Mouse Prion Genes 
 The first transgenic mouse lines with the complete human gene sequence 
were developed in the mid 1990s as a novel experimental tool for investigating 
transmission of human strains of TSE (Telling et al., 1994, Telling et al., 1995b).  
Two such lines were used to study the effect of PrP expression levels on disease 
transmissibility; Tg110 had between two and four copies of the transgene 
representing an approximation of normal expression levels, and Tg152 had 30-50 
copies and gave a four to eight-fold increase in expression (Telling et al., 1994) 
(Table 1.T6).  The inserted gene coded for valine at codon 129 as this was thought to 
be the most susceptible genotype in iCJD (Collinge et al., 1991), and the mice still 
expressed mouse PrP.   
 Only approximately 10% of these mice were found to be susceptible to 
infectivity from GSS, sCJD, iCJD, and fCJD cases which was unexpected as 
transgenic mice expressing chimeric human / mouse PrP were readily infected.  
HuPrPSc was however found in the brains of two Tg110 mice that showed clinical 
signs nearly 600 days after inoculation with a case of iCJD.  This suggested that the 
incubation period was probably greater than the usual life-span.   
 When six mice of the higher-expressing Tg152 line were inoculated with the 
same case of iCJD an incubation period ~280 days in three mice.  The difference in 
susceptibility between the Tg110 and Tg152 lines was thought to be due to the level 
of transgene expression, although it was also stated that the Tg152 mice “may be 
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homozygous [for the transgene] since both parents carried the transgenes” whereas 
the Tg110 line was hemizygous (one copy) (Telling et al., 1994).  
 Compared with the other case material, this iCJD case possibly had a higher 
titre of infectivity or, as it is likely to have had a VV genotype (from details in a 
contemporary paper known to be the source of the inocula (Collinge et al., 1991)), it 
may therefore have transmitted more efficiently to the VV mice (Telling et al., 
1995b).   
1.9.1.2  Expression of Human Prion Gene in the Absence of Mouse PrP 
 Valine homozygous Tg152 mice were crossed with PrP null mice to 
generate a line expressing only human PrP.  When these Tg152 / Prnp0/0 mice were 
challenged with sCJD or iCJD infectivity there was 100% transmission and short 
incubation periods (~250 days) (Telling et al., 1995b).  This indicated that the 
presence of mouse PrPC had to some degree inhibited development of a TSE 
infection from the human inoculum.  The mechanism behind this remains unclear but 
it may be due to host factors, such as chaperones, that had higher specificity for host 
PrPC during TSE infection, which on removal of host PrPC were then able to interact 
with the transgenic PrPC.   
 To predict human response to BSE infection these Tg152 / Prnp0/0 
transgenic mice were inoculated with vCJD and BSE (Hill et al., 1997).  These data 
supported results from wild-type mouse (Bruce et al., 1997) proposing that vCJD 
cases harboured the same agent strain as BSE.  These Tg152 / Prnp0/0 mice were also 
inoculated with iCJD and sCJD of different codon 129 genotypes (Table 1.T7). 
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Table 1.T7:  Tg152 (VV) Transgenic Mice with Various TSE Inocula 
Inoculation of valine homozygous Tg152 / Prnp0/0 mice with bovine and human TSE 











MM 25/56 (45%) 228±15 
BSE 
(n=5) 
‘MM’ 10/26 (39%) 602±50  
sCJD 
(n=9) 
MM 66/67 (99%) 210±4  
sCJD 
(n=2) 
MV 15/15 (100%) 218±2  
sCJD 
(n=1) 
VV 5/5 (100%) 337±11  
iCJD(hGH) 
(n=1) 
MM 7/7 (100%) 211±5  
iCJD(hGH) 
(n=1) 
MV 4/4 (100%) 195±9  
iCJD(hGH) 
(n=1) 
VV 5/5 (100%) 193±4  
iCJD(DM) 
(n=1) 
MM 4/4 (100%) 204±6  
iCJD(G) 
(n=1) 





The Hill et al 1997 publication identified similar, success rates for 
transmission, and pathological changes after inoculation with both vCJD and BSE 
(although the incubation period was longer for BSE inoculation) and differences 
between these and sCJD and iCJD inocula.  This was suggestive of a similar origin 
for vCJD and BSE.  The longer incubation period with BSE may be due to a species 
barrier effect as the vCJD inoculum is human passaged bovine infectivity 
compounded by the difference in codon 129 of the host mouse (VV) and the inocula 
(MM).  For sCJD and iCJD, variation in inocula codon 129 genotype did not appear 
to show a preference for homology to the host, possibly due to the over-expression of 
PrP.   
1.9.1.3  Expression of Human PrP Homozygous (MM or VV) at Codon 129 
 As the host codon 129 genotype is of importance when considering 
susceptibility of an individual human being, the next stage in transgenic development 
was to compare further the VV and MM transgenic lines.   
 The comparison of host codon 129 homozygous genotypes in HuPrP / 
Prnp0/0 transgenic mice has been the subject of five publications (Telling et al., 
1995b, Asante et al., 2002, Kitamoto et al., 2002, Korth et al., 2003, Wadsworth et 
al., 2004).  The results from sCJD inoculation, where data are comparable across 
publications, are summarized in Table 1.T8.  The differences in genetic background, 
expression level, host and inoculum genotype, and the lack of consistency in the 




Summary of sCJD transmission data from, random genomic insertion, transgenic lines expressing homozygous human PrP.  (Data shown 
as incubation period ±SEM, and percentage affected.) (Asante et al., 2002, Kitamoto et al., 2002, Korth et al., 2003) 















































































Mixed: FVB/N x 






437±31 (100%) 354 (30%) 
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1.9.1.3.1  Expression Level Effects 
 To be able to determine the effect of expression level on transmission a 
comparison can only be made using mice with the same genetic background and 
codon 129 genotype, and using the same inocula.  Therefore, only the data from the 
Kitamoto group can be used, comparing the two VV genotype lines, Tg-ChV#12 and 
Tg-ChV#21, that express PrPC at 2x and 4x respectively.  For two sources of sCJD 
inoculum, of either MM or MV genotype,  the 4x expressing line has longer 
incubation periods contrary to expectations.  This underlines the potential problems 
that can be encountered with this method of transgenic mouse production, as the 
reasons for the 4x expressing mice having longer incubation period are unclear, and 
the benefits of gene targeted transgenic production as used for this thesis.  
1.9.1.3.2  Genetic Background Effects 
 To see the effects of the genetic background on transmission, mice are 
needed to express PrP at the same level, of the same genotype, and be inoculated 
with the same type of material.  In this case a comparison can be made between the 
MM genotype lines from each research group that express PrP at approximately 1-
2x, inoculated with sCJD(MM1).  The Kitamoto line Tg-ChM#30 and the Prusiner 
line Tg440 have similar incubation periods suggesting that the 129Sv and FVB 
mouse genetics are similar.  The Collinge line is of mixed genetics (FVB/N x 129Sv 
x C57BL/6) and gives incubation periods approximately 70 days longer.  This may 
indicate that the C57BL/6 input into the genetics is lengthening the incubation 
period.  However, there was a near seven-fold increase in the amount of brain 
homogenate inoculated into the Kitamoto line which could have caused the decrease 
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in incubation period.  (Kitamoto: 20μl of 10% brain homogenate (Taguchi et al., 
2003).  Collinge: 30μl of 1% brain homogenate (Asante et al., 2002))  From wild-
type mouse inoculations performed alongside this thesis, sCJD(MM1) inoculum did 
not transmit to C57BL/6 mice.  This thesis describes the use of gene targeted 
transgenic lines produced from an in-bred line which removes any effect of 
background genetics.   
1.9.1.3.3  Host Codon 129 Genotype Effects 
 To see the effect of codon 129 genotype on transmission mice need to 
express PrP at the same level, have the same genetic background and receive the 
same inoculum.  Due to the random nature of the RGI method of transgenic 
production only rarely do two lines express the protein at the same level.  Only the 
Kitamoto group data can be used comparing the 0.7x expressing Tg-ChM#30 (MM) 
line and the 2x expressing Tg-ChV#12 (VV) line.  With both sCJD(MM1) and 
sCJD(MV2) inocula there is a lengthening of the incubation period for the VV mice 
indicating that this response is due to the host genotype.  Gene targeted transgenic 
mice as used in this thesis are ideal for determining the effect of host codon 129 as 
the expression level and genetic background are identical.   
1.9.1.3.4  SCJD Inoculum Codon 129 Genotype Effects 
 The Prusiner group data can be used to see the effect of inoculum codon 129 
genotype as they have data for sCJD(MM), sCJD(MV),and sCJD(VV) transmission 
to both MM and VV lines.  The data shown in Table 1.T8 show that genotype 
compatibility will increase the number of clinically affected mice and shorten the 
incubation period.  With either MM or VV mouse lines the sCJD(MV) inoculum 
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transmits with intermediate efficiency compared with sCJD(MM) and sCJD(VV).  
Similarities between mouse lines however can only be investigated in detail if they 
are otherwise identical such as when produced by gene targeting.   
 
1.9.1.4  Expression of Human PrP Heterozygous (MV) at Codon 129 
 Production of transgenic mice heterozygous (MV) at codon 129 of PRNP by 
the RGI method is problematic as there are difficulties in expressing both alleles at 
the same level.  Only the Collinge group has attempted this by crossing the over-
expressing Tg45 (MM) and Tg152 (VV) lines (Asante et al., 2006).  These, 
Tg45/152 (MV), mice express PrP at 4-6x and the levels of the M and V alleles are 
at a ratio ~1:1.5, due to the effect of the higher expressing VV parent line.  
Heterozygous MV mice generated for this thesis were generated by cross-breeding 
the gene targeted homozygous lines, a method that gives equal allele expression at 
physiological levels and a true representation of human MV individuals.   
 The Collinge group MV line data covers inoculation with sCJD, vCJD, and 
BSE and is summarised, together with the group’s MM line data for comparison, in 
Table 1.T9.  The sCJD data show that the MV line is equally susceptible as the MM 
line to all inocula, but develops clinical disease at an earlier time, a difference more 
pronounced for the valine carrier sCJD(MV1) and sCJD(VV1) inocula.  The latter 
may be due to the greater expression of the valine allele in this line (M:V expression 
ratio is ~1:1.5) (Asante et al., 2006).   
 Inoculation of vCJD and BSE show similar properties for both MM and MV 
lines, with rare occurrence of clinical disease and limited levels of mice affected 
(defined by positive pathological markers).  This suggests that humans with the MV 
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genotype are likely to be susceptible to this agent.  However, pathological signs, e.g. 
levels and type of PrPSc deposition, that indicated a less ‘aggressive’ infection.  For 
instance, the MV mice had only moderate spongiform change, and rarely developed 
the florid plaque structures seen in the MM mice (one such plaque in one mouse) 
(Asante et al., 2006).  This would indicate subclinical BSE infection in MV genotype 
humans longer than that in MM individuals.   
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Table 1.T9:  Comparison of Collinge Group Transgenic Lines 
Comparison of the Tg35 (MM) and Tg45/152 (MV) transgenic mice transmission 
data from the Collinge group (Asante et al., 2002, Asante et al., 2006).  Case number 
shown as some inoculations are the same between the two lines. 
 
 Tg 35 MM Line 
1-2x expression 









































I024 241±1 4/4 I024 216±9 8/9 
sCJD(VV1) 
 
I022 700,708 4/6 I022 439±20 7/7 
sCJD(MV2) 
 
I020 437±31 7/7  n/d n/d 
sCJD(VV2) 
 























































1.9.2  Gene Targeting (GT) Method 
 The Kitamoto group are the only research group, in addition to NPD, to 
have published human TSE transmission data for gene targeted transgenic mice 
expressing human PRNP with all codon 129 genotypes represented (Table 1.T6) 
(Kitamoto et al., 2002).  The differences between the NPD lines and the Kitamoto 
lines are that following post-translational modification the former produce a 
complete human amino acid sequence protein whereas the latter produce a chimeric 
human protein with six amino acids at the C-terminal end that are derived from the 
mouse sequence (V215, Q219, K220, D227, G228, and R230).  In their most recent 
publication, this group have described a development of their mouse model system 
into a rapid bioassay where all mice are culled at 75 days post injection and the 
spleens examined for PrPSc deposition in the follicular dendritic cells, by 
immunocytochemistry (Asano et al., 2006).  For these transmissions there is 
therefore no incubation period data, however a previous publication describing only 
the MM genotype line does have life-span data (Taguchi et al., 2003).   
1.9.2.1  Sporadic CJD Transmission to the Kitamoto GT Mice 
 Data for sCJD transmission to the Kitamoto group mice are only available 
for the MM line of mice.  This showed short incubation periods for sCJD(MM1) and 
sCJD(MV1) subgroups at ~150 days, longer incubation times and inefficient 
transmission for sCJD(MM2-thalamic type) at >500 days. and no evidence of 
transmission for the sCJD(VV2) type inoculum.  The sCJD(MM1) and sCJD(MV1) 
types are classified together as the ‘classical’ form of sCJD and so these data are 
suggesting that they also share similar transmission properties too.  The relative 
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inefficiency of the PrP type 2 inocula compared to those already mentioned with type 
1 suggests that the protein type of the inoculum may have a determining role in the 
success of transmission.  There is also genotype incompatibility between the 
sCJD(VV2) inoculum and the MM genotype mice which may also impact on the 
success of transmission for that experiment.  Without transmission of these inocula 
to the MV and VV genotype mouse lines the effect of the host genotype cannot be 
investigated.   
1.9.2.2  Variant CJD and BSE Transmission to the Kitamoto GT Mice 
 Variant CJD inoculation of the MM genotype Kitamoto line showed rare 
development of clinical signs at >700 days however there was evidence of TSE 
pathology in the majority of mice (Taguchi et al., 2003).  This suggested a lengthy 
subclinical phase.  No data on incubation times and life-span experiments is 
available for vCJD inoculation of MV or VV genotype mice, or BSE inoculation.   
Data for both vCJD and BSE inoculation in all three codon 129 genotype 
mouse lines are only available for the bioassay model where all mice were culled at 
75 days post inoculation (Asano et al., 2006).  This data can only provide 
comparisons of the relative transmission efficiencies between the three genotype 
hosts and not data on susceptibility.  Some mice may be negative for spleen PrPSc at 
75 days but may go on to develop signs of TSE disease at a later time.   
 BSE inoculation produced only a single MM genotype mouse that was 
positive for PrPSc, and all mice of the MV and VV genotypes were negative.  This 
suggests a significant transmission barrier for BSE to humans.  VCJD transmission 
however was more successful, and showed similar high numbers (mostly >50%) of 
positive scored mice for both MM and MV lines.  The VV line failed to show 
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evidence of PrPSc in the spleen.  The levels of PrPSc in spleens of MV mice was 
lower than that seen for the MM mice.  These data suggest that human passage of 
BSE has removed part of the transmission barrier and yet there is an M allele 
dominance for infection efficiency.  This implies that humans with the MV genotype 
may be susceptible to BSE or vCJD infection but the progressive spread of TSE 
pathology is slower than for MM individuals, and may therefore have longer 
incubation periods.  The evidence for lack of transmission to VV mice comes from 
only three mice.  This may not have been a large enough group inoculated to have 
seen a positive result.   
1.9.3  Possible Evidence for Strain Selection 
 In addition to the complexities in comparing data between multiple lines of 
mice, of alternative genotypes, and expressing PrP at different levels there is also 
evidence for a form of strain selection (Asante et al., 2002, Wadsworth et al., 2004, 
Beringue et al., 2008).  The appearance of transmission differences attributable to 
selection of different strains has been reported previously in hamster inoculation 
experiments with scrapie (Kimberlin and Walker, 1978) and transmissible mink 
encephalopathy (TME) (Bartz et al., 2000).  The former publication centres on 
incubation period and susceptibility differences, however the latter also includes 
PrPSc typing differences linked to each strain as described below.   
 The Collinge group compared BSE transmission data between their two 
MM genotype lines, Tg35 (1-2x expression) and Tg45 (4x) that were independently 
generated.  Tg45 mice gave a long incubation period, no clinical disease but high 
levels (75%) of sub-clinical disease, with the PrPSc Western blot type consistent with 
the BSE strain (type 2B).  Tg35 mice however gave very different data: 12% showed 
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clinical disease, 16% were sub-clinical, and the PrPSc typing showed that 90% were 
type 1 (10% type 2B), see Figure 1.F3.  Type 1 is the common sCJD type leading to 
the conclusion that BSE infectivity could also give rise to a sCJD-like molecular 
strain classification, albeit based solely on PrP typing (Asante et al., 2002).  This has 
significant implications for human disease surveillance as some vCJD cases may be 
misdiagnosed as sCJD.   
 The genetic background of these transgenic mice is a mixture of wild-type 
lines (FVB/N, C57BL/6, and 129Sv) and when these lines were inoculated with BSE 
or vCJD some produced the sCJD PrP type.  Therefore the suggestion that these mice 
are selecting for an alternate BSE strain could be explained more simply by an 
alternative host PrP response.   
 The Laude group have also proposed this theory of strain selection in 
transgenic mice expressing M allele PrP at 6-fold normal levels (tg650) inoculated 
with vCJD and sCJD (Beringue et al., 2008).  Three French vCJD cases transmitted 
efficiently with incubation periods near to 500 days and showed the typical vCJD 
Western blot type in spleen and brain material.  This is the first example of 
transgenic mice expressing human PrP that develop clinical TSE in 100% of mice 
injected with vCJD.  These are the most highly over-expressing MM line of mice 
published which may be the cause for the 100% transmission rate.   
 Evidence for strain selection was seen following inoculation with a UK 
vCJD case (WHO reference case as used for this thesis).  With this inoculum only, 
they found two distinct incubation periods described as ‘early’ (~300 days) and ‘late’ 
(~500 days) which occurred in mice at an equal frequency.  The ‘late’ mice had type 




and sCJD-like type 1 PrPSc in the brain.  This PrPPSc type difference was transmissible 
on second passage of either brain or spleen material suggesting strain differences.   
 In the preparation of the WHO reference vCJD material a large amount of 
tissue was homogenised (100g) compared with the 1-2g that is commonly prepared 
for an inoculum.  It is therefore possible that inoculum prepared from a larger area of 
vCJD brain may contain more type 1 PrPSc that could be selected for by this 
particular over-expressing mouse line.  Type 1 PrPSc has been found at low levels in 
vCJD brain material through the use of type 1 specific antibodies (Yull et al., 2006).  
Alternatively these highly over-expressing mice may be causing an adaptation of the 
properties of the inoculum strain due to the abundance of PrP in the brain.   
1.9.4  Summary of Data for Human TSE Transmission to Transgenic 
Mice 
 The following table (Table 1.T10) summarises the overall findings from 
transmission of human TSE material to transgenic mice expressing full-length 
human PrP, produced by gene targeting or random genomic integration methods.   
 
Summary of sCJD and vCJD transmission data to transgenic lines expressing human PrP.  (GT: Gene Targeted; RGI: Random Genomic 
Integration; * <100% transmission;  ** Positive / Negative for PrPSc in spleen at 75 days;‘-’: no data; mean incubation time ± SEM; n/t: no 
transmission) 
 
Table 1.T10:  Human TSE Transmission to Various Transgenic Mouse Lines 
 















































































































































1.10  OUTLINE OF THESIS 
 The contents of this thesis are subsequently divided into six chapters.  The 
next (Chapter 2) details the Methods used and this is followed by a discussion of 
how the transgenic mice were assessed to ensure that expression of the transgene 
produced human PrPC as expected (Chapter 3).  Chapters 4 and 5 interpret the 
findings from transmission of vCJD and blood transfusion associated vCJD 
respectively, in an attempt to define the role of codon 129 genotype in the host on 
susceptibility to this BSE-associated strain, and to observe any strain changes 
following human-to-human passage.   
 Chapter 6 contains a large data set of results from inoculation of the 
transgenic mice with material from six typical cases of sCJD, performed to 
investigate the role of codon genotype in both host and inoculum and the strain-like 
transmission behaviour of the individual subgroups of sCJD.  Following this there is 
a summary (Chapter 7) of how the data generated during this study has been used to 





2.1  GENE TARGETED TRANSGENIC MOUSE LINE 
PRODUCTION 
NPD have developed unique lines of transgenic mice using a methodology 
called gene targeting.  This method allows direct replacement of the mouse prion 
protein open reading frame for an exogenous version, in this case the human PRNP 
sequence.  The non-murine sequence is therefore under the expression control of the 
host and specific for the prion protein.  It will therefore be expressed temporally and 
spatially as per the host’s original prion protein.  The methodology of gene targeting 
used to produce the human transgenic lines is as follows.  This work was carried out 
by the staff at NPD (Dr H Baybutt, Dr N Tuzi, Mrs L Blackford) and not by the 
author of this thesis.  A brief summary of this method is included here to aid 
understanding of the uniqueness of this specific model system. 
2.1.1  Construction of Gene Targeting Vectors  
Prion protein amino acids 40 to 254 of the open reading frame (ORF) were 
changed from mouse to the human.  An amplicon spanning codon 37 to six 
nucleotides downstream of the stop codon was prepared by polymerase chain 
reaction (PCR) amplification of DNA from codon 129 methionine and codon 129 
valine human samples.  PCR products were digested with the restriction enzymes 
and ligated into a gene targeting vector constructed using 129Ola wild-type DNA so 
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that the flanking DNA sequence of the human gene was homologous to that of the 
recipient mice.  For an overview see Figure 2.F1. 
 
Figure 2.F1:  Gene Vector Flowchart 





2.1.2  DNA Vector Insertion into Embryonic Stem (ES) Cells 
The plasmid vector containing the human gene sequence was inserted into 
embryonic stem cells by the electroporation method.  Successful insertion was 
confirmed by both antibiotic resistance selection and subsequently by PCR screening 
of colonies.  The ES cells were derived from 129Ola wild-type mice that have an 
agouti coat colour (light brown) so that if the genetic material is taken up by the 
recipient black-coated C57BL6 mouse embryo the offspring will be identifiable by a 
mixed coat colour.   
2.1.3  Production of Recipient Blastocysts 
Blastocysts are harvested from sacrificed, pseudopregnant, C57BL6 (black 
coated) mice at day 3.5 following mating with vasectomised males.  The blastocysts 
have to be fully mature so that the blastocoel cavity is clearly visible for ES cell 
transfer.   
2.1.4  Transfer of ES Cells to Blastocysts 
Microinjection is used to insert 12-15 gene targeted ES cells into the 
blastocoel cavity.  Only those ES cells that remain intact with an expanded 
blastocoel can then be used for the following stage.   
2.1.5  Embryo Transfer to Female Mice 
Pseudopregnant females that were mated with vasectomised males 2.5 days 
previously are used as host mothers.  Unilateral uterine horn transfer of 10-15 
microinjected ES cells is carried out on the anaesthetised mice, and then after two 
weeks it would be clear whether the implantation was successful. 
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2.1.6  Germline Transmission of Gene Targeted Vector 
A chimeric coat colour in the resultant pups indicates an inclusion of the ES 
cells genetic material into the hosts.  Male chimeras are mated to 129Ola females and 
germline transmission is confirmed by offspring with red eyes and agouti coat 
colour.  These mice will be heterozygous for the transgene and so are then crossed 
with further such mice to generate a homozygous transgenic line.  These are checked 
by PCR amplification of the gene targeted human prion gene sequence.   
 
2.1.7  PCR Genotyping of Mouse Tail DNA 
Mouse tail DNA was extracted using DNeasy Tissue DNA extraction kit 
(Qiagen, UK) and amplified using a combination of human and mouse specific 
oligos.  The human PCR product is 371bp and the murine 206bp.  Codon 129 
genotype of the human sequence was determined by digestion with NspI (NEB, UK) 
(Figure 2.F2). 
 
2.2  DNA EXTRACTION 
For confirmation of the codon 129 genotype of transgenic mice that are to 
be used in breeding programs or experiments, tailsnips are taken and the DNA 
extracted using the DNeasy DNA extraction protocol for rodent tails (Qiagen, UK).  





1. Add 180μl of Qiagen Buffer ATL to tailsnip tissue (~5 mm in length), and 20μl 
of Qiagen Proteinase K solution.  This will breakdown and lyse the cell and 
nuclear membranes to release the DNA. 
2. Mix thoroughly by vortexing, and digest overnight shaking at 55˚C. 
3. Vortex for 15 seconds. Add 400μl of 50:50 Qiagen Buffer AL-ethanol mixture 
and vortex to mix.  This will precipitate the DNA allowing it to be captured on 
the spin column in the next step. 
4. Transfer mixture to a labelled spin column. Centrifuge for 1 minute at 7500g. 
5. Replace collection tube and add 500µl Qiagen Buffer AW1 to wash off soluble 
contaminants from the column matrix.  Centrifuge for 1 minute at 7500g. 
6. Replace collection tube and add 500μl of Qiagen Buffer AW2. Centrifuge for 3 
minutes at 12000g. 
7. Replace collection tube with 1.5ml tube and add 200μl of Qiagen Buffer AE, 
incubate at room temperature for 1 minute.  This will bring the DNA back into 
solution allowing it to be eluted from the column matrix. Centrifuge for 1 minute 
at 7500g. Store DNA at +4˚C. 
 
2.3  GENOTYPING, SEQUENCING, AND SEQUENCE 
ANALYSIS 
2.3.1  Genotyping 
To determine the codon genotype of DNA extracted from mouse tissue a 
part of the open reading frame (approximately from codon 48 to 172) was amplified 
by PCR then digested with restriction endonuclease NspI (New England Biolabs, 
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UK).  This enzyme cleaves the PCR product at codon 129 when there is a 
methionine coding sequence (-ATG-) and also at codon 154 (this acts as a digest 
control). 
PCR mix recipe: 
       per 50µl reaction 
dH20       36.1 µl 
10x PCR buffer (Invitrogen) (final 1x)   5.0 µl 
50mM MgCl2  (Invitrogen) (final 1.5mM)   1.5 µl 
10mM dNTPs (Invitrogen) (final 0.2mM)   1.0 µl 
100 pmol/μl Primer Mix     1.0 µl 
[Hum5’>144: CTACCCACCTCAGGGCGGTGGTGG 
Hum3’<515: TGGTTGCTGTACTCATCCATG] 
5U/μl Taq polymerase(Invitrogen)   0.4 µl 
Template DNA   5.0 µl (0.1-0.5μg) 
 
The PCR program was: 
• 94°C / 5mins 
• 94°C / 30secs ; 62°C / 30secs ; 72°C / 1min ; 30 cycles 
• 72°C / 10mins 
 
Nsp1 Digest mix: Per 20μl reaction 
NEBuffer 2    2.0 µl 
BSA     0.2 µl 
dH20     7.4 µl 
Nsp1 (5U/μl)    0.4 µl 
PCR Product  10.0 µl 
 
The digest reaction was incubated at 37°C overnight, then the digest products were 
run on a 1.5% agarose gel and visualised with ethidium bromide under UV light. 
(Figure 2.F2)  The band sizes expected were as follows. 
PCR product undigested: 371 bp 
MM genotype: 244 bp, 74 bp, 53 bp 
MV genotype: 318 bp, 244 bp, 74 bp, 53 bp 
VV genotype: 318 bp, 53 bp 
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Figure 2.F2:  Codon 129 Genotyping Gel Image 
Agarose gel of genotyping results for mouse tail DNA, showing the respective 









2.3.2  Sequencing and Sequence Analysis 
The PCR products generated above were purified using the Qiagen 
QIAquick PCR Purification Kit.  This removes remaining primers, dNTPs and Taq, 
leaving the amplified product ready for sequencing.  The kit used for this was the 
Thermo Sequenase fluorescent labelled primer cycle sequencing kit (GE Healthcare).  
Two fluorescently labelled primers (Cy5) were used that sequenced the PCR product 
in both 5’ and 3’ directions (4L: AGG TGG CAC CCA CAG TCA GT,  6R: CGA 
TAG TAA CGG TCC TCA TA). 
The sequencing program was: 
• 95°C / 5mins 
• 95°C / 20secs ; 60°C / 10secs ; 68°C / 1min ; 15 cycles 
• 95°C / 10secs ; 60°C / 1min 30secs ; 20 cycles 
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Sequencing products were electrophoresed on an ALFexpress automated 
sequencer using ReproGel Long Read gel mix (GE Healthcare), and the data checked 
by comparison to wild-type human and mouse sequence data, using the ALFwin 
Sequence Analyzer 2.00 software. 
2.4  RNA EXTRACTION 
RNA from transgenic and wild-type mouse tissues was isolated to 
characterise the expression of the transgene throughout the mouse.   
1. Add 400μl of RNAzol Bee (Tel-Test, USA) to a 1.5ml tube and 1.5ml to a 
15ml tube. Keep on ice. 
2. Add ~100mg of frozen tissue to the 1.5ml tube and homogenize carefully 
with a sterile pestle. 
3. Immediately transfer the homogenate to the 15ml tube.  Mix by vortexing 
briefly and aliquot the homogenate into two 1.5ml tubes. 
4. Add 100μl of chloroform to each tube.  Shake vigorously for 15 seconds.  
(Do not vortex.) 
5. Incubate at 4°C for 5 minutes then centrifuge at 12000g for 15 minutes at 
4°C. 
6. Transfer aqueous phase to a fresh tube.  Add equal volume of isopropanol 
(500μl).  Mix by inversion. 
7. Incubate at 4°C for 15 minutes then centrifuge at 12000g for 15 minutes at 
4°C. 
8. Discard supernatant and wash pellet with 1ml of 70% ethanol. 
9. Centrifuge at 7500g for 8 minutes at 4°C. 
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10. Discard supernatant. 
11. Tissue-dry with care, and air-dry for 15 minutes at room temperature. 
12. Resuspend pellet in 10μl of distilled water and stand at room temperature for 
1 hour, then 20 minutes at 4°C. 
13. Combine the two aliquots. 
14. Measure the OD (optical density) of 1μl of RNA added to 199μl distilled 
water at 260/280 nm. 
15. Calculate the concentration (where 1OD=40μg/ml RNA): 260nm reading x 
40(as left) x 200(dilution factor). 
16. Calculate purity (260/280 ratio should be >=1.9). 
17. Store RNA at -70°C. 
 
2.5  NORTHERN ANALYSIS OF EXTRACTED RNA 
 This method was used to identify PrP mRNA in various mouse tissues by 
using a radio-labelled PrP mRNA probe to bind to the separated RNA which had 
been transferred and fixed to a membrane.   
2.5.1  Agarose Gel Separation of RNA Fractions 
1. Aliquot required volume of RNA stock to give 20μg for loading. 
2. Add 10% of aqueous volume of 3M Sodium oxaloacetate (NaOAc) (pH 5.0). 
3. Centrifuge at 12000g for 5 minutes at 4°C. 
4. Pour off supernatant with care. 
5. Wash pellet in 1ml of 85% ethanol. 
6. Centrifuge at 7500g for 8 minutes at 4°C. 
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7. Pour off supernatant and tissue-dry with care. 
8. Allow to dry on ice for 10-15 minutes. 
9. Resuspend pellet in 20μl RNA sample buffer (50% deionised formamide, 
18% formaldehyde, 1x MOPS) 
10. Heat samples to 65°C for 10 minutes, then store on ice. 
11. Add 5μl 6x Loading Dye and 1μl ethidium bromide. 
12. Prepare a 1% agarose / formaldehyde gel as follows: 
1g Agarose 
10ml 10xMOPS (0.2M 3-Morpholinopropanesulfonic acid, 0.05M 
sodium acetate, 0.01M EDTA) 
73ml dH2O 
Melt agarose, cool, then add 17ml formaldehyde and pour gel. 
13. Load samples and electrophorese in 1x MOPS buffer. 
14. Under ultraviolet light the 18S and 28S RNA bands should be clear. 
2.5.2  Northern Transfer 
1. Rinse gel in 10x SSC (1.5M sodium chloride / 0.15M sodium citrate) for 2 x 
30 minutes to remove the formaldehyde. 
2. Cut Hybond-N (GE Healthcare, UK) transfer membrane and 6 x filter papers 
to size of gel. 
3. Clean glass plate with RNAZap (Ambion, UK) and water, and place over tray 
containing 5x SSC. 
4. Soak wick in 10x SSC and lay across plate into 5x SSC. 
5. Place gel upside-down on the wick removing bubbles and cover surrounding 
wick with saran wrap. 
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6. Wet membrane and 6x filter papers in 10x SSC and place on gel. 
7. Add paper towels to top and weigh down. 
8. Allow to transfer overnight. 
9. View membrane under UV and mark the 18S and 28S bands. 
10. Bake membrane in filter paper at 80°C for 2 hours, store at 4°C. 
2.5.3  Northern Blot Probe Preparation 
1. Dr Herbert Baybutt provided a plasmid containing a 350bp DNA sequence 
homologous to the 3’ UTR of PRNP that can be excised using BamHI and 
EcoRI restriction endonucleases (NEB, UK). 
2. Double-digest using the two enzymes above was carried out for 3 hours at 
37°C, as follows: 
dH20    20.8μl 
Buffer E (10x) (in enzyme kit)   3.0μl 
BSA (10μg/μl)    0.2μl 
Plasmid (0.675 μg/μl)    5.0μl 
BamHI (10U/μl)    0.5μl 
EcoRI (12U/μl)    0.5μl 
   Total: 30.0μl 
3. Digest products were separated on a 1.5% agarose gel and the 350bp bands 
excised and purified using the Qiagen Gel Extraction Kit, as follows. 
4. Calculate the weight of the gel slices and add 300μl of Buffer QG per 100μg 
of gel slice. 
5. Incubate at 50°C for 10 minutes until the gel has dissolved. 
6. Add 100μl of isopropanol for each 100μg of original gel slice, mix and add to 
a spin-column. 
7. Centrifuge at 12000g for 1 minute and discard eluate. 
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8. Add 0.5ml Buffer QG and centrifuge at 12000g for 1 minute, discard eluate. 
9. Add 0.75ml Buffer PE and centrifuge at 12000g for 1 minute, discard eluate, 
spin again at 12000g for 1 minute. 
10. Place column in 1.5ml tube, add 50μl of Buffer EB, stand for 2-5 minutes, 
centrifuge at 12000g for 1 minute, and store eluate at 4°C. 
11. Spectrophotometer analysis was used to calculate the probe concentration. 
2.5.4  Radioactive Probing of Blots 
1. Membranes were soaked in prehybridisation solution (ULTRAHYB, 
Ambion, UK) for 1-2 hours at 42°C, 
2. The probe was radiolabelled with 32P using the Amersham Rediprime II kit. 
1. Denature 25ng of probe at 100°C for 5 minutes. 
2. Snap-cool on ice, and pulse down. 
3. Add probe to Rediprime tube. 
4. Add 5μl of 32P d-CTP and mix. 
5. Incubate at 37°C for 30 minutes then stop reaction with 5μl of 0.2M 
EDTA. 
3. The labelled probe was purified using a ProbeQuant G-50 Micro-column 
(Amersham). 
4. The probe was denatured at 100°C for 5 minutes, snap-cooled, then added to 
membrane for overnight hybridization. 
5. In the morning the membranes were washed once in 2x SSC / 0.1% SDS and 




2.6  PROTEIN EXTRACTION FROM UNINFECTED MICE 
A 10% tissue homogenate can be prepared by homogenising 100mg of 
tissue, on ice, in 1ml NP40 lysis buffer. 
NP40 Lysis Buffer: 
1% NP40 
0.5% Sodium deoxycholate 
150mM NaCl 
50mM Tris/HCl pH 7.5 
1. Add 100mg of tissue to 200μl of NP40 lysis buffer. 
2. Homogenise until uniform and tissue macerated. 
3. Transfer 100μl to 1.5ml tube containing 900μl NP40 lysis buffer. 
4. Add 900μl NP40 lysis buffer to remaining sample, and mix. 
5. Centrifuge at 12000g for 3 minutes, at 4°C. 
6. Transfer supernatant to -80°C storage tubes. 
 
2.6.1  Deglycosylation of PrPC
To clarify that the triplet of bands seen on a Western blot are the alternate 
glycoforms of PrP the glycans can be removed with PNGaseF (peptide N-
glycosidase F, NEB, UK), leaving one unglycosylated band. 
 
1. Add 20μl of 5% tissue homogenate to 3μl of Denaturation Solution (provided 
in PNGaseF kit). 
2. Incubate at 100°C for 10 minutes. 
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3. Add 8μl dH2O, 4μl 10x G7 buffer, 4μl 10% NP40, and 500U PNGaseF. 
4. Incubate overnight at 37°C, then add 60μl dH2O to leave 100μl of 1% 
homogenate ready for gel loading. 
 
2.6.2  GPI Anchor Cleavage of PrPC
To confirm that the transgenic form of PrP is correctly bound to the plasma 
membrane by a glycophosphatidylinositol anchor, the GPI anchor can be cleaved by 
PIPLC (phosphatidylinositol-specific phospholipase C).  The resultant two fractions 
at the end of this method are labelled ‘supernatant’ and ‘pellet’.  If the PrPPC seen in 
the supernatant fraction has an apparent decrease in electrophoretic mobility 
following Western blot detection then it is concluded that this form of the protein has 
been released from the membrane anchor.   
1. Prepare a 10% tissue homogenate.  Half-brain is homogenised in 400μl of 
cold phosphate buffered saline (PBS) then transferred into 1.6ml of PBS with 
20μl each of 100mM phenylmethylsulphonyl fluoride (PMSF) and N-ethyl-
maleamide (NEM) (protease inhibitors). 
2. Split the homogenate into two 2ml tubes and centrifuge at 900g for 5 minutes 
at 4°C. 
3. Transfer the supernatant to ultracentrifuge tubes. 
4. Resuspend and pool the pellets in 1ml of cold PBS (this fraction is the ‘cell 
debris’). 
5. Top up the ultracentrifuge tube with cold PBS to balance and centrifuge at 
16,000g for 12 minutes at 4°C. 
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6. Discard the supernatant and resuspend the pellet in 500μl of cold PBS.  Split 
this sample into two equal aliquots. 
7. To one tube add 0.5U of PIPLC.  Mix well and incubate at 4°C overnight or 
on ice for 4 hours. 
8. Centrifuge both treated and non-treated samples at 12000g for 15 minutes at 
4°C. 
9. Transfer the supernatant to a 1.5ml tube labelled ‘S’. 
10. Resuspend the pellet in 600μl of cold PBS, labelled ‘P’. 
11. Store samples at -20°C. 
 
2.7  CLINICAL AND PATHOLOGICAL INVESTIGATION OF 
INOCULATED TRANSGENIC MICE 
Mice were anaesthetised with halothane and then injected either via the 
intracerebral (20μl volume) or intraperitoneal (100μl volume) routes with an 
inoculum (at 1% dilution) made from homogenised tissue in sterile saline.  
Inoculated mice were assessed weekly, from 100 days posts injection until the end of 
their natural life-span for clinical signs of TSE disease, such as kyphosis (hunching 
of the back) and movement disorders (ataxia).  The time at which mice were culled 
due to the appearance of a clinical TSE phenotype was recorded as the incubation 
period.  The mean incubation period from the group of mice inoculated gives an 
indication as to the relative efficiency of disease transmission in different mouse 
lines, and is one of the transmission characteristics that help to define TSE strains.  
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Following culling of the mice due to TSE or for animal health reasons (intercurrent 
deaths) the brains were removed for biochemical and histological analysis.   
Histological analysis of brain material is a key component for confirmation 
of successful transmission, as the detection of TSE associated vacuolation and 
deposition of PrPSc, are sensitive markers signifying that TSE disease is present.   
2.7.1  Assessment of TSE Associated Vacuolation – Lesion Profiling 
One of the standard methods of TSE strain identification in wild-type mice 
is the use of lesion profiling matched with recording the incubation period. (Fraser 
and Dickinson, 1967, Dickinson et al., 1968, Fraser and Dickinson, 1968)  Lesion 
profiling is the categorisation of the degree of vacuolation, scored from one to five 
(Table 2.T1), seen in nine grey matter areas of the brain and three areas of white 
matter. (Fraser and Dickinson, 1968, Bruce et al., 2004) (Figure 2.F3)  The scoring is 
shown by graphical representation to enable quick, visual comparison of different 
experiments.  Figure 2.F4 shows examples of these lesion profiles for mouse-
passaged BSE and scrapie.  This method has been developed for use in analysis of 
pathological material from wild-type mice and was used without alteration to assess 









Table 2.T1:  Vacuolation Score Definition 
Definition of vacuolation scores. (From reference: (Bruce et al., 2004)) 
Vacuolation Score Description 
0 No vacuoles  
1 A few vacuoles widely and unevenly scattered, not convincingly TSE specific pathology 
2 A few vacuoles evenly scattered, more than for score 1 and convincingly diagnostic for TSE 
3 Moderate numbers of vacuoles, evenly scattered  
4 Many vacuoles with some confluence  
5 Dense vacuolation with most of microscopic field confluent, lace-like appearance 
 
Figure 2.F3:  Lesion Profiling Scoring Regions 
Scoring regions are coloured blue and labelled as below. (Image: W-G Lui, NPD) 
Grey matter: 1: dorsal medulla, 2: cerebellar cortex, 3: superior colliculus, 4: 
hypothalamus, 5: thalamus, 6: hippocampus, 7: septum, 8: retrosplenial and adjacent 
motor cortex, 9: cingulate and adjacent motor cortex.  White matter: WM1: 





Figure 2.F4:  Lesion Profile Examples 
Examples of grey matter lesion profiles from the NPD strain typing mice panel 
(R111, C57BL, VM, and C57BL/VM cross) inoculated with BSE and sheep scrapie 
that have been sub-passaged in the VM wild-type mouse line.  (Reproduced from 




2.7.2  Assessment of TSE Associated PrPSc Deposition 
Key strain differences may be seen by comparing the type and spread of 
PrPSc deposits throughout the brain.  Assessment of PrPSc by immunocytochemistry 
in mice inoculated for this thesis will hopefully provide evidence for relationships 
between the different inocula and codon 129 genotype of the inoculated mice.   
2.7.2.1  Brain Sectioning 
Half-brains that were required for immunocytochemical analysis were 
primarily fixed in 10% formal saline. Then they were treated for 1.5 hours in 98% 
formic acid (to reduce the titre of infectivity for safety reasons) and cut in the coronal 
plane into four sections using a cutting guide to reproducibly section all of the brains 
for comparative analysis. These brain sections were then embedded in paraffin 
blocks, cut into 6 μm slices, and dried onto microscope slides for further analysis. 
All of this work was carried out by staff at NPD and the CJDSU as cutting and 
slicing mouse brains requires significant training.   
2.7.2.2  ICC Detection of PrP 
PrP detection used the Vectastain Elite ABC Kit (Vector Labs, UK) with 
overnight primary antibody incubation, 6H4 at 1:2000 dilution (Prionics, 
Switzerland; Product number 01-010; 0.5-2mg/ml).  Detection of antibody binding 
was through deposition of DAB (3,3'-diaminobenzidine) chromogen via a 
horseradish peroxidase reaction. 
1. Incubate slides at 60ºC overnight to ensure sections are fixed securely to slides. 
2. Remove the paraffin and hydrate the sections as follows: 
Xylene for 5 minutes 
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Absolute alcohol for 5 minutes 
74OP (IMS) for 5 minutes 
70% alcohol for 5 minutes 
Rinse well in tap water 
3. Autoclave under water for 10 minutes at 121ºC.  This will open-up more of the 
antibody epitopes on PrP to improve the signal. Rinse in tap water. 
4. Submerse slides in formic acid (98%) for 5 minutes.  This will also release more 
of the PrP antibody epitopes. Rinse carefully in tap water. 
5. Submerse slides in block (9ml Hydrogen Peroxide in 300ml Methanol) for 10 
minutes. This will inhibit the endogenous peroxidases leaving a clearer 
background which will allow better detection of the true PrP antibody binding.  
Rinse carefully in tap water. 
6. Wash slides in 1xTBS/BSA for 3 x 5 minutes. 
Tris Buffer Saline (TBS):  
10x stock of Tris pH 7.6 
500ml of 0.5M Tris (30.25g / 500ml) 
Add N HCl until pH 7.6 (150ml) 
Make up to 2 litres with dH2O 
Saline: 
0.85% stock (8.5g NaCl in 1 litre) 
1xTBS/BSA: 
1 litre 1xTBS (900ml TBS + 100ml Saline) 




7. Add four drops of Normal Rabbit Serum (NRS) to cover sections and incubate 
for 20 minutes. 
NRS:  1:5 dilution of stock in TBS/BSA (2 ml NRS + 8 ml TBS/BSA) 
8. Tip off NRS. 
9. Make up primary antibody. 
6H4 – 4µl in 8ml of TBS/BSA equals a 1:2000 dilution of stock solution. 
10. Add 6H4 (3 drops) to cover the sections and incubate overnight at room 
temperature.  Add NRS to negative control. 
11. Wash slides three times in TBS/BSA for 5 minutes each.  
12. Drain slides then add secondary antibody (Stratech, UK; Product number 315-
067-003; 1.1mg/ml) biotinylated rabbit anti-mouse at 1:400 (15μl in 6 ml 
TBS/BSA)) to cover the sections.  Incubate for 1 hour. 
13. Make up ‘ABC’ reagent (at least 30 minutes prior to use) from Vectastain Elite 
PK6100 kit.  
ABC: 10 ml TBS/BSA + 100μl A + 100μl B (mix and store at 4°C) 
14. Wash slides three times in TBS/BSA for 5 minutes each. 
15. Add ABC to cover the sections and incubate for 30 minutes. 
16. Prepare the DAB chromogen. 
DAB: Add 10 drops of Substrate Buffer Concentrate (Tris-HCl) to 10 ml of 
dH2O, then add a Substrate Tablet (10 mg 3,3’-diaminobenzidine 
tetrahydrochloride (DAB)). Mix. 
17. Wash slides three times in TBS/BSA for 5 minutes each.  
18. Add 1 drop of hydrogen peroxide (0.8%) per 2ml of DAB (5 drops in 10 ml), 
then add to slides (4 drops). 
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19. Leave for 2 minutes or until signal is clear in positive control slide. Rinse in tap 
water. 
20. Counterstain the nuclei in the sections with haematoxylin as follows. 
Submerse in haematoxylin for 12-15 seconds. 
Rinse well in tap water. 
Dip into Acid Alcohol (1%) bath. (99ml 70% alcohol + 1ml conc. HCl) 
Rinse well in tap water. 
Dip into lithium carbonate (1% w/v) six times. 
Rinse well in tap water. 
 
21. The sections are then dehydrated back to Xylene for automated coverslipping. 





22. Bath in formic acid (98%) for 5 minutes. This allows for handling the slides 
outside of the laboratory. 
 
2.8  WESTERN BLOT DETECTION OF PRPSC
The same Western blot method was also used for detection of PrPC in 
uninfected mice following an alternative protein preparation method (see section 
2.6).   
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2.8.1  Purification of PrPSc from Frozen Brain Tissue 
1. All tissue manipulation was carried out in a Class 1 Microbiological Safety 
Cabinet in the CJDSU High Risk Lab as human derived material and material 
from these human transgenic mice is Hazard Group 3 classification. Sealed rotors 
were used for all pulses and longer centrifugations. 
2. The following tubes were labelled as shown: 
 2ml safelock labelled ‘I’ for ‘inoculum’ 
 1.5ml safelock ‘P’ for ‘pellet’ 
 1.5ml safelock ‘S’ for ‘supernatant’ 
 1.5ml screwtop ‘PK’ for ‘PK digested’ 
3. Weigh the ‘I’ tube and note the weight. 
4. Transfer the tissue sample to the ‘I’ tube and reweigh. Note the weight and 
calculate the amount of saline to add which will give a 10-1 inoculum. All 
samples were made up as inoculum so that transmission experiments can be 
performed if necessary. 
5. Add a maximum of 500μl of saline (0.9%, sterile) to the tissue and homogenise 
using a disposable plastic micropestle. Add the remainder of the saline and 
vortex to mix. 
6. Add 25μl of 10x Extraction Buffer to the ‘P’ tube and add 225μl of the 
homogenate. Vortex to mix then centrifuge at 2000 rpm for 5 minutes at 4°C. 




7. Transfer 100μl of the supernatant to the ‘PK’ tube and the remainder to the ‘S’ 
tube. The remaining tissue in the pellet tube can be used for determining the 
genotype at codon 129. 
8. Add 2.5μl of 2mg/ml Proteinase K to ‘PK’ tube and vortex to mix. (Final PK 
concentration 50μg/ml.) 
9. Incubate at 37ºC for 60 minutes. 
10. Add 1µl of Pefabloc SC (Roche, UK) (final concentration 1mM, stored at -20°C) 
to halt further action of the proteases. Vortex and store at -20°C. 
11. For centrifugation concentration of prion protein: 
11.1. Centrifuge the ‘PK’ tube at 14,000 rpm for 60 minutes at 4°C. 
11.2. Decant and dispose of supernatant. 
11.3. Resuspend pellet in 20μl of 2x Sample Buffer (Invitrogen). 
11.4. Vortex and boil at 100°C for 10 minutes before storing at –20°C. 
2.8.2  Polyacrylamide Gel Electrophoresis of Protein Extracts 
1. Type 1 and Type 2B human tissue standards are loaded alongside mouse samples 
for comparison of the mobility and glycoform ratio.  
2. Ensure that the stocks are vortexed thoroughly before taking an aliquot. The 
usual sample and marker mixes for loading are: 
2.1. 5μl sample + 10μl Extraction Buffer + 5μl Sample Buffer (4x) 
2.2. 5μl Benchmark (Prestained Protein Ladder, Invitrogen) + 1μl Magic Marker 
(Western Protein Standard, Invitrogen) (+ 9μl of Extraction Buffer + 5μl of 
Sample Buffer (4x) 
3. Vortex the samples to mix. Boil at 100ºC for 10 minutes, then pulse down. 
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4. Clamp 2 gels (or 1 gel and a blank cassette) into the holding cassette. Gels used 
are 10 or 12% Bis/Tris NuPAGE (Invitrogen). 
5. Fill the inner compartment with 1x MES (2-(N-morpholino) ethanesulfonic acid) 
running buffer (50ml 20x MES (Invitrogen), 950ml dH2O). 
6. Load the samples, fill the outer compartment with running buffer (until 3/4 full) 
and replace gel tank lid. 
7. Run the gel for 50-60 minutes at 200V, then proceed with the Western transfer.   
 
2.8.3  Western Transfer 
Once the proteins have been separated by the electrophoretic mobility they 
are then transferred and fixed onto a membrane so that they can then be detected 
with an anti-PrP antibody.   
1. Make up 1x transfer buffer. (Per gel: 375ml dH20, 100ml of methanol, 25ml of 
20x NuPAGE Transfer Buffer (Invitrogen)) 
2. Soak the PVDF (polyvinylidene fluoride) membrane (9cm x 6cm) in methanol, 
rinse thoroughly with dH20 and soak in transfer buffer.  Soak the blotting paper 
and the sponges in transfer buffer. 
3. When the electrophoresis is complete place the gel into a transfer cassette 
sandwiched thus: 3 sponges / blotting paper / gel / PVDF membrane / blotting 
paper / 3 sponges (from back of cassette to front). 
4. Completely fill the transfer cassette with transfer buffer, and the tank 3/4 full 
with tap water.  Run at 30V for 60 minutes, then proceed to antibody detection of 




2.8.4  Antibody Binding to PrP 
1. Make up the following reagents: 
1.1. TBST / Milk blocking solution (2.5g milk powder in 50ml TBST) 
1.2. Primary antibody (6H4 1μl in 40ml TBST – 1:40000) 
1.3. Secondary antibody (GE Healthcare; Product number NA9310; Anti-mouse 
IgG peroxidase-linked 1μl in 40ml TBST – 1:40000) 
2. After the Western transfer stage perform the following incubations and washes. 
2.1. 3 x 3 min washes in TBST 
2.2. 45 min-1 hr in Milk / TBST or overnight shaking at 4°C 
2.3. 3 x 3 min washes in TBST 
2.4. 45 min-1 hr in 1o Ab / TBST 
2.5. 3 x 3 min washes in TBST 
2.6. 45 min-1 hr in 2o Ab / TBST 
2.7. 4 x 3 min washes in TBST 
2.8.5  Chemiluminescence Detection of Antibody Binding 
ECL+ (GE Healthcare, UK) kit was used for the chemiluminescence 
detection of the secondary antibody.  
 
1. Remove two ECL+ reagents from the fridge to allow to come to room 
temperature (large brown bottle and small brown bottle). 
2. Aliquot 2ml (per gel) of the large brown ECL+ bottle into a 15ml universal tube. 
3. Lay out a piece of cling film onto a piece of tissue and cut relevant sized acetate 
sheet for the size or number of membranes (A4 sheet cut in half per 2 gels). 
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4. Once the TBST washes are complete, place the membrane onto the cling film 
(protein side up). 
5. Add 50μl (per gel) of the small bottle to the 15ml universal and mix. 
6. Distribute 2ml of the solution evenly over each membrane, rocking the 
membrane to ensure there are no dry areas. 
7. Leave to develop for 5 minutes, occasionally rocking the membrane. 
8. Using tweezers, lift the membrane from the top and drain the solution against the 
tissue. 
9. Place the membrane onto the acetate sheet and cover with a same sized piece. 
10. Rub the acetate firmly with a piece of tissue from the middle outwards to remove 
all excess solution from the membrane, squeezing the excess to the edges.  This 
will reduce the background noise.   
11. Place the membrane into an x-ray cassette and expose the membrane to film for 






CONFIRMATION OF GENETIC, BIOCHEMICAL, 
AND PHYSIOLOGICAL CONFIGURATION OF 
TRANSGENIC MICE 
3.1  AIMS 
This chapter describes the assessment of the novel lines of transgenic mice 
used in this study, confirming that they are a suitable model system.   
The first assessment carried out was to confirm that the transgene introduced 
into the mice had the correct DNA sequence.  This had already been done by Dr H 
Baybutt during the production stage of the mice, however was repeated for a HuVV 
mouse as part of this thesis.   
The next check was that the transgene was expressed in the correct tissues of 
the mice, most importantly the brain, and that the levels were comparable with the 
wild-type 129Ola line which was used to generate the transgenic lines.   
Analysis of the mature PrPC was then required to confirm that it was attached 
to the cell membrane by a glycophosphatidylinositol (GPI) anchor and that it existed 
in the three glycosylation states, at relative levels to that found in wild-type mice.   
The final check was that the lifespan of the transgenic mice had not been 
affected by the genetic manipulation, and that there was no evidence of spontaneous 




3.2  INTRODUCTION 
The key component of this new mouse model of human TSE transmission is 
the ability to compare data within and between mouse lines, and to identify the 
specific role of codon 129 genotype in disease transmission.  To this end the three 
transgenic mice lines used in this study were: inbred, with an identical genetic 
background, were produced by the gene targeting method involving direct 
replacement of the mouse PRNP gene with the human equivalent, and could be cross 
bred between the HuMM and HuVV lines to generate the true MV heterozygote line 
(HuMV).   
There have been many transgenic mouse lines produced by other research 
groups but only one other (Kitamoto Group) has produced the three codon 129 
genotype lines by gene targeting. (See Introduction section 1.9)  The Kitamoto group 
culls all their mice at 75 days post injection, and so this thesis is the first description 
of experimental data for susceptibility to human TSE over the entire mouse lifespan.   
 
3.3  EXPERIMENTAL RESULTS 
The following sections describe the data showing confirmation that the 
transgene, gene expression, and mature PrPC production, are as expected for these 
novel lines of transgenic mice, and that the genetic manipulation has not affected 
the lifespan survival. 
3.3.1  Sequence Analysis of the PRNP Transgene 
One HuVV mouse was positive for transmission of the vCJD agent as 
described in Chapter 4, and therefore to ensure that there was nothing peculiar about 
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the genetics of this mouse, PRNP sequence analysis was carried out to check the 
transgene.  Previous work by Dr H Baybutt at NPD had confirmed the transgenic 
lines had been produced correctly, but in case the genotype of this HuVV mouse had 
been labelled incorrectly it was checked again as part of this thesis.   
Figure 3.F1 shows the alignment of amino acid sequence data from this 
mouse alongside the published human and mouse sequences.  These data confirm 
that the N-terminal signal sequence (up to amino acid 20) was like that of mouse and 
the remaining sequence was human.  The genotype at codon 129 was also confirmed 
as valine homozygous.   
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Figure 3.F1:  Transgene Sequence Comparison with Wild-type Reference 
PRNP amino acid sequence alignment of HuVV mouse (ID # 115, experiment 553A-
1A) with published mouse and human sequences. (Top: human, Middle: mouse, 
Bottom: HuVV mouse.  Red shows differences.)  
 
MANLGCWMLV LFVATWSDLG LCKKRPKPGG WNTGGSRYPG QGSPGGNRYP PQGGGGWGQP 60 
-----Y-L-A ---TM-T-V- ---------- ---------- ---------- ----T*---- 59 
-----Y-L-A ---TM-T-V- ---------- ---------- ---------- ---------- 60 
 
HGGGWGQPHG GGWGQPHGGG WGQPHGGGWG QGGGTHSQWN KPSKPKTNMK HMAGAAAAGA 120 
---------- -S-------S ---------- ------N--- --------L- -V-------- 119 
---------- ---------- ---------- ---------- ---------- ---------- 120 
 
VVGGLGGYML GSAMSRPIIH FGSDYEDRYY RENMHRYPNQ VYYRPMDEYS NQNNFVHDCV 180 
---------- -------M-- --N-W----- ----Y----- -----V-Q-- ---------- 179 
--------V- ---------- ---------- ---------- ---------- ---------- 180 
 
NITIKQHTVT TTTKGENFTE TDVKMMERVV EQMCITQYER ESQAYYQ--R GSSMVLFSSP 238 
---------- ---------- ---------- ----V---QK ------DGR- S--T------ 241 
---------- ---------- ---------- ---------- ---------- ---------- 240 
 
PVILLISFLI FLIVG   253 
---------- -----   256 
---------- -----   255 
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3.3.2  Codon 129 Genotyping of the PRNP Transgene 
Producing sequence data for the full length of the transgene for a number of 
transgenic mice is costly and time consuming, and so a more rapid genotyping 
method was used to check that the human PRNP gene was present, and the codon 
129 genotype.  This PCR / restriction enzyme digest method was used to check the 
genotype of breeding stocks and also the mice that were selected for use in the 
experiments. (See Methods, section 2.3, Genotyping, Sequencing, and Sequence 
Analysis)  Figure 3.F2 shows a representative agarose gel of genotyping results. 
 
Figure 3.F2:  Codon 129 Genotype Analysis 
Agarose gel of codon 129 genotyping tests showing the banding pattern obtained for 
wild-type mice, wild-type / transgenic cross (WT/Tg), and transgenic mice of each of 
the three genotypes.  (+Nsp1: PCR product digested with restriction enzyme. All 












3.3.3  PRNP RNA Assessment in the Transgenic Mice 
It was proposed to assess the mRNA levels of the transgene in a number of 
tissues to compare with data from the 129Ola wild-type.  The tissues selected were: 
brain, heart, kidney, liver, lung, and muscle.  Due to the difficulties in obtaining 
reproducible quantity and quality or RNA from these samples only a limited analysis 
was undertaken of the HuMM and wild-type mice.  It was deemed more critical that 
the mature prion protein was present in the correct configuration in the brain than 
whether the levels of mRNA were equivalent.   
Figure 3.F3 shows the Northern blots obtained from these mice.  PRNP 
transgene mRNA was seen at equivalent levels in both transgenic and wild-type mice 
in all tissues studied.   
Figure 3.F3:  Northern Blot of RNA Levels Across Various Tissues 
Northern blots of HuMM and 129Ola wild-type mice showing similar levels of 





3.3.4  Transgenic Prion Protein (PrPC) Characterisation 
Four properties of the PrPC produced by the transgenic mice were checked 
to ensure that the introduced transgene was being expressed by the host mice as if it 
was the endogenous copy of the murine gene.   
1. Similar expression levels were indicated by the relative amounts of PrPC detected 
on the Western blots for both the wild-type mice and the transgenics.  
2. Glycosylation profiles were correct for the transgenic mice as shown by the 
presence of the three bands, and confirmation that the bands were attributable to 
glycans was shown by specific cleavage of these structures by the PNGaseF 
enzyme (peptide N-glycosidase F) leaving only the unglycosylated fragment. 
3. The PrPC produced was of the protease sensitive form as shown by the 
disappearance of the blot signal following digestion of the sample with 
proteinase K.  This is important as abnormal forms of PrP tend to be more PK 
resistant.   
4. The PrPC produced was attached to the surface of the cell membrane by a 
glycophosphatidylinositol (GPI) anchor, confirmed by the apparent increase in 
size of the protein bands in the supernatant fraction following GPI cleavage by 
PIPLC (phosphatidylinositol-specific phospholipase C). 
Figure 3.F4 shows the confirmation of all four properties for the transgene 
expressed human amino acid sequence PrPC.  
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Figure 3.F4:  Characterisation of PrPC by Western Blot 
Confirmation, for both transgenic and wild-type 129Ola mice, of equivalent PrPPC 
expression level and glycosylation (A), that the PrPC is protease sensitive (B), and 









3.3.5  Effect on Survival of Transgenic Modification 
Twenty-four mice of each homozygous genotype line (HuMM and HuVV) 
were left to age naturally without inoculation or any other experimentation.  Six were 
culled at one year of age and a further six at 500 days old.  The remaining twelve 
were left to live to the end of their natural life.   
The mice were scored routinely as per the experimental animals for signs of 
TSE disease, and when culled they were scored blind for TSE vacuolation.  A few of 
the mice that lived to their natural lifespan were also tested by immunocytochemistry 
for abnormal PrP deposition in the brain.  No evidence was seen of any of these 
observations, indicating that these mice did not develop spontaneous TSE disease 
due to the inserted transgene.   
Figure 3.F5 shows the survival curve of those mice that were left to live to 
their natural lifespan.  There was no evidence of an adverse effect on survival 
between either HuMM or HuVV mice and no evidence of a difference compared 
with the survival curves of 129Ola wild-type mice.  The latter had been inoculated 
with the six sCJD subgroups where only sCJD(MM1) showed high level of 
transmission (although without clinical disease).  As the majority of these mice did 
not develop clinical or pathological TSE disease their survival curves should be 
similar to uninfected mice.   
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Figure 3.F5:  Survival Curves for Aged Transgenic Mice 
Kaplan-Meier survival curves for aged mice, showing no difference between the two 
transgenic lines nor between the transgenic lines and 129Ola mice infected with 
sCJD. (HuMM: blue solid squares, HuVV: red solid triangles, sCJD(MM1): blue 
solid, sCJD(MM2): blue dashed, sCJD(MV1): green solid, sCJD(MV2): green 



















3.4  DISCUSSION 
The novel nature of the mouse model used in this thesis centred around 
generation of three lines of mice that expressed human amino acid sequence PrPC 
with variation at the polymorphic codon 129 residue.  The three lines would be 
methionine homozygous (HuMM), valine homozygous (HuVV), and methionine / 
valine heterozygous (HuMV).  Not only would the mice express these three genotype 
versions of PrPC but due to the gene targeting method used, the transgenic protein 
would be expressed in direct replacement of the mouse version.  This would mean 
that in accordance with the original mouse PrPC, the transgenic human protein would 
be expressed in the exact temporal and spatial patterns (with variation over the 
mouse lifespan and in different tissues around the body, respectively).  The inbred 
nature of the mice, on the 129Ola background, also meant that the three codon 129 
genotype lines would be genetically identical except for just this specific 
polymorphism.  Together these factors mean that experimental transmission of TSE 
disease to these mice should follow a more natural physiological course, and the 
differences between the three lines would be attributable to the variation in codon 
129 genotype.   
DNA sequence analysis has confirmed the specific genetic changes in the 
mice.  The N-terminal signal sequence is mouse derived to ensure that the immature 
protein is correctly transported through the endoplasmic reticulum, for post-
translational modification, to the cell surface.  The C-terminal sequence that codes 
for the recognition sequence for the GPI anchor is human derived, however as the 
human amino acid sequence is identical to that of the mouse, there should not be any 
problems with membrane attachment.   
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Confirmation that the transgenic PrPC was membrane bound and glycosylated 
correctly signified that the human PRNP transgene was being transcribed and 
translated into a mature protein, with post-translational modification and trafficking 
according the original pathway of the murine prion protein.  This means that the 
resultant TSE disease transmission pathogenesis would not be affected by unusual 
location or biochemistry of the transgenic prion protein.   
The expression level of the transgenic protein was shown to be similar to that 
of wild-type PrPC by assessment of mRNA levels in a few tissues, and the amount of 
protein in the brain by Western blot.   
Finally, the survival curve data show that expression of human PrPC has not 
lead to spontaneous TSE disease, by clinical and pathological analysis, or a reduction 
in the usual lifespan of the mice.  These mice therefore show no evidence of a 
detrimental effect due to the genetic manipulation and express human PrPC as if it 




IDENTIFYING THE UNIQUE SPECIFICITY OF 
VARIANT CJD STRAIN TRANSMISSION 
PROPERTIES DEFINED BY CODON 129 
GENOTYPE IN HOSTS OTHERWISE 
GENETICALLY IDENTICAL 
4.1  AIMS 
 This chapter aims to address two important areas of research concerning the 
transmission properties of vCJD. 
• The role of codon 129 genotype in susceptibility to disease. 
• The potential for iatrogenic spread of vCJD in the human population. 
 The goal of much of the research into vCJD centres around the reasons why 
only approximately 200 individuals worldwide have so far shown susceptibility to 
the disease, as understanding this may eventually lead to finding ways to halt or 
reverse the clinical and pathological symptoms.  Presentation of clinical vCJD has so 
far been confined to only MM genotype individuals at codon 129 of the PRNP gene, 
and therefore being able to predict the presence of disease in non-MM people would 
enable better estimation of the number of future vCJD cases.  Also, the valine allele 
in non-MM people may have a protective effect and therefore PrPC with valine at 
codon 129 could be used as part of a potential treatment program. 
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 Before the NPD transgenic mouse lines were generated there were no mouse 
models of codon 129 genotype effect, where true comparisons could be made 
between the three genotypes (MM, MV, and VV).  Most transgenic lines expressing 
human PrP had multiple copies of the gene inserted randomly into the genome and 
therefore between line comparisons were problematic.  There was too much genomic 
variation, and difference in expression levels of PrP, to be able to directly link 
changes in transmission characteristics to codon 129 genotype alone.  Wild-type 
mice, although susceptible to the vCJD agent, could not be used to directly model 
human PrP interaction, and the effects of codon 129.   
 A more detailed understanding of the strain transmission properties of 
vCJD, through this study, may allow predictions to be made about whether human-
to-human iatrogenic spread of this disease may be more of a public health problem 
than the original BSE associated infection.  Serial passage of vCJD in humans may 
lead to a more infectious ‘humanized’ strain of the original bovine disease.  The 
discovery of vCJD infection via blood transfusion has raised the possibility of an 
additional epidemic of vCJD cases acquired by human-to-human passage of the 
agent.   
 Data from this study were published in 2006 in Lancet Neurology (See 




4.2  INTRODUCTION 
4.2.1  The Role of Codon 129 Genotype in vCJD Disease Transmission 
 All tested patients with clinical vCJD (147/167 in the UK) have been found 
to be homozygous for methionine (MM) at codon 129, including three cases of vCJD 
infection via contaminated blood products (Hewitt et al., 2006).  One case of 
subclinical infection via blood transfusion was heterozygous (MV) (Peden et al., 
2004).  Two of three anonymous appendix samples that were positive for PrPSc 
deposition (from a screen of 12,674 samples), which is highly specific for vCJD 
infection (Hilton et al., 2004b), were valine homozygous at codon 129 (Ironside et 
al., 2006).  It is however unknown whether these individuals would go on to develop 
vCJD.  Clinical and pathological evidence from an extensive surveillance 
programme over nearly 20 years in the UK clearly shows that the codon 129 
genotype plays a significant role in determining susceptibility of individuals to BSE 
and vCJD infection.   
Transgenic mice expressing the human PRNP gene sequence have provided 
laboratory data on the role of codon 129 genotype and its effect on experimental 
transmission of vCJD (See Introduction).  The MM genotype appears to be the most 
susceptible in terms of shorter incubation periods and more extensive pathological 
changes.  VV homozygous mice when over-expressing the gene, were susceptible, 
but were observed not to propagate the specific biochemical vCJD strain properties 
(type 2B by Western blot) (Wadsworth et al., 2004).  Physiological expression of 
PrP in VV mice, by gene targeting methods, imparted resistance to infection (Asano 
et al., 2006).  The MV genotype transgenic mice data indicate an intermediate 
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response to vCJD transmission with less extensive pathology and longer incubation 
periods than MM mice (Asano et al., 2006, Asante et al., 2006).   
 These data are a compilation of information from many lines of mice 
produced in different ways for different research purposes.  Only the Kitamoto group 
has generated all three codon 129 genotype lines using a gene targeting 
methodology, but this group sacrifice all the mice at 75 days post inoculation (Asano 
et al., 2006).  Incubation period studies of transmitted disease, with each genotype 
line, is therefore not possible with these mouse models.   
 This leaves a significant gap in information concerning lifetime 
susceptibility to vCJD and the effect of codon 129 genotype.  The experimental 
design of this part of the thesis involves monitoring HuMM, HuMV, and HuVV 
transgenic mice over lifespan (~750 days) following inoculation with infectious 
vCJD material.  This provides a unique data set with which to assess the specific 
effect of codon 129 genotype on individual susceptibility to the vCJD agent.   
 Separate experiments were set-up with either intracerebral (i.c.) or 
intraperitoneal (i.p.) inoculation routes.  As the pathogenesis of vCJD in humans 
involves PrPSc deposition targeted to peripheral tissues outside the central nervous 
system (CNS) (including spleen, tonsils, and appendix (Ironside et al., 2000)) the 
intraperitoneal injection route may be more relevant to understanding the human 
disease.  The two infection routes could show important differences in the strain 
properties of vCJD, with pathological targeting specific to different genotype hosts.   
4.2.2  Iatrogenic Spread of vCJD Strain in the Human Population 
 In addition to identifying which codon 129 genotypes are susceptible to 
infection by the vCJD agent it is of great interest, for public health reasons, to know 
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whether infected individuals might pass on the disease to others and at what point 
during the incubation period this is possible.  Primary transmission of vCJD to these 
transgenic lines is a model of iatrogenic spread of vCJD in the UK, and also has the 
potential to assess the transmission of BSE to MV and VV genotype individuals.   
 Secondary passage from transgenic mice infected with vCJD was 
undertaken to confirm the infectious nature of the transmitted disease and to observe 
propagation of strain differences in the three codon 129 genotype mice lines.  The 
original vCJD inoculum was derived from an individual with an MM genotype at 
codon 129, but the sub-passage experiments involved material from each genotype 
of mice.  This allowed analysis of the strain transmission properties of the vCJD 
agent adapted by passage through MV and VV genotype hosts, thus modelling the 
potential spread of vCJD in the human population.   
 
4.3  EXPERIMENTAL RESULTS 
4.3.1  Intracerebral Inoculation of vCJD 
 Eighteen mice of each transgenic line (HuMM, HuMV, HuVV), and as a 
control the 129Ola wild-type line (which was used to generate these lines), were 
inoculated by the intracerebral route (i.c.) with inoculum prepared from the NIBSC 
vCJD standard (Code NHBY0/0003, see Methods).  This route of inoculation is 
commonly used when new mouse lines or new inocula are to be used.  This route 
gives the best chance of disease transmission as the infectious material is injected 
directly into the brain.  Due to the long duration of these experiments intercurrent 




were examined for markers of TSE pathology.  Table 4.T1 shows the evaluation of 
all mice in this study. 
 
 
Table 4.T1:  Data Table for Intracerebral Inoculation with vCJD 
Intracerebral inoculation with vCJD with data ordered by Survival Time.  (Protocol reference 553A-1A) 
Abbreviations: CLIN: clinical TSE signs; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: 
intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; shaded cell: positive 
score; End expt: mice that were culled when the experiment was terminated at 700 days 





















































































































103 118 ICD Neg Neg Neg 97 522 ICD Neg Neg n/d 131 462 ICD Neg Neg Neg 189 145 ICD Neg Neg n/t 
136 221 ICD Neg Neg Neg 92 542 ICD Neg Neg n/d 132 503 ICD Neg Neg Neg 207 319 ICD Neg Neg n/d 
138 333 ICD Neg Neg n/d 139 550 ICD Neg Neg Neg 129 543 ICD Neg Neg n/d 192 403 ICD Neg Neg n/d 
106 368 ICD Neg Neg Pos 98 581 ICD Neg Neg Pos 128 559 ICD Neg Neg Neg 225 405 TSE Pos Pos n/d 
122 378 ICD Neg Neg Pos 94 595 ICD Neg Neg Pos 119 578 ICD Neg Neg Neg 191 418 ICD Neg Neg n/t 
123 424 ICD Neg Neg n/d 140 595 ICD Neg Neg Pos 126 596 ICD Neg Neg Neg 221 438 TSE Pos Pos n/t 
110 497 TSE Pos Pos Pos 95 600 ICD Neg Neg Pos 118 622 ICD Neg Neg Neg 205 476 TSE Pos Pos Pos 
121 497 ICD Neg Neg Neg 143 608 ICD Neg Neg Pos 112 623 ICD Neg Neg Neg 222 483 TSE Pos Pos Pos 
135 504 ICD Neg Neg Pos 100 630 ICD Neg Neg Neg 127 649 ICD Neg Neg Neg 223 483 TSE Pos Pos Pos 
105 536 ICD Neg Pos Pos 141 665 TSE Pos Neg Pos 116 651 ICD Neg Neg Neg 193 483 TSE Pos Neg n/t 
133 545 ICD Neg Neg Pos 142 686 ICD Neg Neg Neg 130 657 ICD Neg Neg Neg 226 503 TSE Pos Pos Pos 
134 567 ICD Neg Neg Pos 144 693 End expt Neg Neg Pos 124 658 ICD Neg Neg Neg 224 508 ICD Neg Neg n/t 
137 595 ICD Neg Neg Neg 91 707 End expt Neg Neg Pos 125 686 ICD Neg Neg Neg 206 586 TSE Pos Pos Pos 
111 630 TSE Pos Pos Pos 96 707 End expt Neg Pos Pos 113 693 End expt Neg Neg Neg 208 613 ICD Pos Pos Pos 
107 651 ICD Neg Neg Pos 101 707 End expt Neg Neg Pos 115 693 End expt Neg Pos Pos       
108 693 ICD Neg Pos Pos 102 707 End expt Neg Neg Pos 120 693 End expt Neg Neg Neg       
109 707 End expt Neg Pos P  os                   
104 707 End expt Neg Pos P  os                   






4.3.1.2  Clinical TSE Findings 
 Highlighted in grey in Table 4.T1 are the mice positive for clinical signs of 
TSE, those that were confirmed by pathological analysis (either the presence of TSE 
associated vacuolation and/or those that had abnormal deposition of PrP by 
immunocytochemistry (ICC)).  Also highlighted are the vacuolation or ICC positive 
mice that were culled for other reasons (labelled ‘ICD’ or ‘End expt’) and were not 
showing clinical TSE signs.  These mice were likely to be in a subclinical phase of 
the disease which will be discussed later.  There were a number of mice culled 
because of clinical signs that suggested the TSE phenotype but were negative by 
pathological analysis.  These were not classed as positive transmissions.   
 The data table for i.c. challenge (Table 4.T1) shows that two pathologically 
confirmed clinically positive mice were seen in the HuMM line (at 497 and 630 days 
post inoculation), one in the HuMV line (at 665 days post inoculation), and none in 
the HuVV line.  A higher percentage of the 129Ola mice developed to a clinical 
disease stage (57%, 8/14) with a mean incubation period of 498 days (range 405 to 
613).   
4.3.1.3.  Survival Analysis 
 A statistical analysis of the survival rates was performed to observe any 
effects on survival due to the subclinical disease present in many of the mice.  With 
the absence of clinical disease, incubation period comparisons could not be made.  
Intercurrent deaths may be due in part to an adverse effect of the inoculum and the 
numbers vary according to the codon 129 genotype of the mouse.  To observe effects 
on overall survival rates between the three transgenic line and the wild-type mice, 
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survival curves were drawn and a Tarone-Ware test performed (SPSS v14.0) (Figure 
4.F1 and Table 4.T2).  This test was used, in preference to others, as it has an even 
bias across the lifespan of the mice.  The data show a significant difference between 
the wild-type 129Ola and the non-HuMM transgenic lines (P<0.001), between the 
HuMM and HuVV lines (P=0.04), and also between the HuMM and HuMV lines 
(P=0.012).   
Table 4.T2:  Tarone-Ware Test for Survival Analysis of Intracerebral 
Inoculation with vCJD 
Survival analysis by genotype following i.c. inoculation of vCJD shows the 
difference between the HuMM mice and the rest.  (Statistical analysis: Tarone-Ware 
Test using software SPSS v14)  Significance rating for clearer view of differences- 
*:P<0.5; **:P<0.01; ***:P<0.001; n/s: not significant. 
 
Groups Tested P value   Significance rating 
HuMM vs. HuMV vs. HuVV vs. 129Ola <0.001    *** 
HuMM vs. HuMV =0.012    * 
HuMM vs. HuVV =0.040    * 
HuMM vs. 129Ola =0.036    * 
HuMV vs. HuVV =0.615    n/s 
HuMV vs. 129Ola <0.001    *** 




Figure 4.F1:  Kaplan-Meier Survival Curve of Intracerebral Inoculation with 
vCJD 
Kaplan-Meier survival curves following i.c. challenge in HuMM (blue), HuMV 
(green), HuVV (red), and 129Ola (black) mice.  The experiment was terminated at 
700 days when the remaining mice were culled (mice alive at the end of an 
experiment are termed ‘censored’ in survival analysis and are noted as crosses in the 




4.3.1.4  Vacuolation Scoring 
 The second criteria for successful transmission after clinical TSE signs is 
post mortem assessment of the presence, location, and intensity of TSE associated 
vacuoles in the brain of each mice.  This analysis is detailed in the Methods chapter 
and is undertaken by only a handful of dedicated NPD staff trained to perform this 
task (See Acknowledgements).  They have analysed, blind to the experimental 
details and genotype of the mice, nine areas of grey matter and three areas of white 
matter, from haematoxylin and eosin stained paraffin sections.  Scores are given as 
positive / negative for the presence of TSE vacuoles, and numerically one to five for 
the intensity of the vacuoles at each of the 12 areas (zero: lowest level to five: 
highest level).  When five or six (or more) mice are scored positive means are 
generated for each region and a chart produced, a lesion profile.   
 Following i.c. challenge HuMM mice were more likely to show TSE 
associated vacuolation than the other transgenic lines, beginning at around 500 days 
post inoculation.  Six (of eighteen) were scored positive, and the mean lesion profile 
for five of the mice is shown in Figure 4.F2.  The highest scores were found in the 
dorsal medulla, thalamus, and cerebellar white matter (areas G1, G5 and W1 
respectively).  Only five of the six mice gave complete scores that could be used for 
the lesion profile but this is considered sufficient to observe the overall targeting of 
the vacuolation (Bruce et al., 2004).  By contrast, only a single mouse in each of the 
HuMV and HuVV groups scored positive for vacuolation at 707 and 693 days 
respectively post inoculation and therefore lesion profiles could not be generated.  It 
is therefore not possible to compare these single mouse profiles with the HuMM 
 123
 
data.  There are typically a number of differences in individual mouse scores with a 
single inoculum but the mean profiles highlight the strain specificity.   
 The mean lesion profile for six i.c. challenged 129Ola wild-type mice is 
shown in Figure 4.F3.  Contrasting with the HuMM mean profile which shows a 
peak in the data at position G5 (thalamus), there is a peak at position G4 
(hypothalamus) in the 129Ola mice.   
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Figure 4.F2:  Lesion Profile of vCJD Inoculated HuMM Mice 
Lesion profile for HuMM mice i.c. challenged with vCJD. (Mean score ±SEM; G1-
















Figure 4.F3:  Lesion Profile of vCJD Inoculated 129Ola Mice  
Lesion profile for 129Ola mice i.c. challenged with vCJD.  (Mean score ±SEM; G1-












 A more detailed analysis of the vacuolation present in each of the transgenic 
lines (although only single cases in the HuMV and HuVV lines) showed that areas of 
the thalamus, hippocampus, cerebellar cortex and cerebral cortex were all affected to 
varying degrees in each line.  The HuMV line showed minimal levels in all areas, 
and the cerebellar cortex was the least affected region across all lines.  The HuMM 
line showed the highest levels in the thalamus (c.f. area G5 in the lesion profile 
above) a region also targeted to the same degree in the HuVV mouse, although here 
the cerebral cortex was also involved.  The hippocampus showed less severe 
vacuolation across the three lines.   
 Plaque structures made up of aggregated PrPSc molecules, frequently in the 
form of amyloid, including the florid plaque characteristic of vCJD / BSE infection 
in humans, were commonly associated with TSE vacuolation (See Introduction, 
Figure 1.F7).  Analysis of the three genotype lines showed florid plaques only in the 
HuMM mice, in the hippocampus and the cerebral cortex (Figure 4.F4, Panel D).  
There was no evidence of plaques in the cerebellum which is one of the structures 
predominantly targeted in human vCJD cases (Ironside et al., 2000).  The HuMV 
genotype line showed no evidence of amyloid plaques in any brain region.  The 
HuVV mouse positive for TSE vacuolation showed clusters of amorphous plaque-
like features in the cerebral cortex and the thalamus but these did not have the 
structured form or the fibrillary nature of the plaques found in the HuMM mice.  
This evidence therefore points to a specific host genotype response to the vCJD 
inoculum.  This information is summarised in Table 4.T3.   
 
 HuMM HuMV HuVV 
Vacuolation* 
 
Thalamus (severe); cerebral cortex and 
hippocampus (mild); cerebellar cortex 
(minimal) 
Thalamus, cerebral cortex, 
hippocampus, and cerebellar cortex 
(minimal) 
Thalamus and cerebral cortex (severe); 





Fibrillary amyloid plaques; florid and non-
florid plaques in cerebral cortex and 
hippocampus; no evidence of plaques in 
cerebellum 
No evidence of amyloid plaques Amorphous non-fibrillary structures often 
forming into clusters in cerebral cortex and 
thalamus 
PrP deposition† Intense staining of plaques in hippocampus 
and cerebral cortex; plaque-like, 
pericellular, and amorphous deposits in the 
hippocampus;  
synaptic, perineuronal, and diffuse 
perivascular deposits in the thalamus 
Occasional small plaque-like 
deposits and pericellular deposits 
in the thalamus 
Strongly positive large amorphous deposits 
and clusters of plaques, small plaque-like 
structures, perivascular aggregates, and 
sub-pial deposits in the cerebral cortex and 
thalamus 
 
Comparison of TSE-associated neuropathology in transgenic mice inoculated with vCJD.  (*Analysed with haematoxylin and eosin staining. 
†Analysed with immunocytochemical techniques) 







4.3.1.5  Detection of PrPSc by Immunocytochemistry 
 The third criteria for positive transmission is the presence of TSE disease 
associated PrP (PrPSc).  This is generally regarded as the ‘gold standard’ for 
confirmation of TSE disease and is widely used in diagnostic tests for animal TSE.  
There are however exceptions to this rule where, for example, disease has been 
found without PrPSc and also where PrPSc has been detected without transmissible 
disease (Barron et al., 2007, Piccardo et al., 2007).   
 Immunocytochemical (ICC) detection of PrPSc on paraffin sections gave the 
positive / negative scoring seen in Table 4.T1 (column ICC) and provided data on the 
spatial distribution of this form of PrP in the brain which may be host or strain 
dependent.  With i.c. challenge, a majority of the HuMM mice (12/16) were positive 
for PrPSc and showed deposition in most areas of the brain at a relatively early stage 
(from around 370 days post inoculation), before the vacuolar pathology became 
evident (around 500 days) (Figure 4.F4, Panel A).  From 500 days post inoculation 
the appearance of vacuolation was accompanied by a significant increase in PrPSc 
deposition.  Hippocampal targeting with high levels of PrPSc deposition appeared 
only in the HuMM mice.  In this region, these mice showed intense staining of 
plaques, including the florid plaques mentioned above.  The hippocampus has a role 
in long term memory, spatial memory, and navigation.  It is one of the first regions 
of the brain to be affected in Alzheimer’s Disease, causing memory loss and 
disorientation as initial symptoms.  The hippocampus is connected via neurones to 
many areas of the brain including regions of the cortex, thalamus, and hypothalamus 
which also showed high levels of PrPSc deposition.   
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 In contrast, although PrPSc was detected in many HuMV mice (11/14), 
deposition was restricted to only a few areas (including the ventrolateral and 
ventromedial thalamic nuclei and the red nucleus of the mid-brain), even after 700 
days post inoculation (Table 4.T1 and Figure 4.F4, Panel B).  Although PrPSc 
deposition was clearly present at 581 days, the timing of the onset of deposition in 
the HuMV line could not be established as brain sections were not available from 
mice at earlier time-points.  Further studies using serial culls would be needed to 
more accurately show the appearance of PrPSc over the time-course of vCJD 
infection.   
 High levels of PrPSc deposition were seen in the brain of a single HuVV 
mouse that was also positive for TSE vacuolation, at 693 days post injection (Figure 
4.F4, Panel C).  The deposition was similar in intensity to that observed in HuMM 
mice.  The HuVV mouse showed intense PrPSc deposition in the thalamic and 
cerebral cortex regions where the amorphous plaque-like structures were found 
suggesting a link between the two pathological changes.  As there was only a single 
positive HuVV mouse it is not possible to conclude that this pathology is typical for 
HuVV mice that develop TSE from vCJD infection, but the observed distribution 
was different from both HuMM and HuMV mice.  Differences in patterns of PrPSc 
deposition among the three genotypes are described in Table 4.T3.   
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Figure 4.F4:  Histopathology of vCJD Transmission to Transgenic Mice 
Immunocytochemistry of histological sections with anti-PrP antibody 6H4 showing 
the cortex, hippocampal, and thalamic regions of the mouse brain with PrP detection 
(brown).  A: HuMM mouse (ID#108) 693 days post inoculation.  B: HuMV mouse 
(ID#101) 707 days post inoculation.  C: HuVV mouse (ID#115) 693 days post 
inoculation  (Scale bar 1250μm; Cx: cortex; Hp: hippocampus; Th: thalamus)  D: 
Florid plaques found in the hippocampus of the HuMM mouse in Panel A.  Each 
plaque has an eosinophilic core with a paler halo and is surrounded by a ring of 
vacuolation (haematoxylin and eosin stain, scale bar 25μm).  E: Florid plaques in the 




4.3.1.6  Detection of PrPSc by Western Blot 
 The detection of protease resistant fragments of PrPSc by Western blotting is 
a standard method for testing for the presence of such material, in a diagnostic or 
screening scenario, and for investigating the strain characteristics defined by the 
physical structure of the protein.  In this study the ICC method detected low levels of 
PrPSc deposition and was used for positive / negative scoring.  The Western blotting 
technique was therefore used to assess the transmission of strain characteristics 
defined by the PrPSc molecule.   
 Protease treatment of PrPSc in vCJD brain produces a Western blot profile 
that is characterised by a 19 kDa non-glycosylated fragment and a predominance of 
the fragment representing the diglycosylated form (type 2B) (Head et al., 2004a) 
(See Introduction, section 1.3.1: The Prion Protein and Figure 1.F3).  In this study 
Western blot detection of PrPSc was performed on frozen brain material set aside 
during the post mortem of each mouse (See Methods).  Both the fragment mobility 
and relative abundance, of mouse derived PrPSc are maintained when vCJD is 
transmitted to the human transgenic mice, irrespective of their codon-129 genotype 
(Figure 4.F5).   
 Densitometric analysis, using Quantity One software (Bio-Rad), measured 
the relative intensity of each of the three bands seen on x-ray film exposures (Head et 
al., 2004a).  Specific exposures were selected so that all three bands fell within the 
linear range for both the film and the densitometric analysis.  These data suggested 
that there was a relative increase in the diglycosylated form in the HuVV mouse 
compared with the HuMM mouse.  This is preliminary data as there was only one 
positive mouse tested with the VV genotype, and until more vCJD transmissions in 
 131
 
HuVV mice are achieved it cannot be concluded that this Western blot finding is 
representative of the VV genotype group.  
 Lower levels of PrPSc were seen in brain extracts from the  HuMV mice 
corresponding to the low levels observed by ICC, but the type 2B profile was 
maintained.  Further studies using more sensitive methods of PrPSc preparation, such 
as the phosphotungstic acid (NaPTA) method might improve the Western blot 
sensitivity in these mice (Peden et al., 2007).   
 
Figure 4.F5:  Western Blot Analysis of Transgenic Mice Inoculated with vCJD 
Western blots of brain extract from three transgenic lines i.c. challenged with vCJD.  
T-2B corresponds to human vCJD brain homogenate showing the typical PrPSc type 
2B, and T-1 corresponds to human sporadic CJD brain homogenate showing the 
typical PrPSc type 1 signature.  Type 2B and 1 differ in mobility of the 
unglycosylated band (~19 kDa and ~20 kDa respectively) and the degree of 
glycosylation (diglycosylated dominant and mono/unglycosylated dominant 
respectively).  All samples were treated with proteinase K.  The anti-PrP detection 




4.3.2  Secondary Inoculation of Mice with Primary Passage Material 
 To confirm the infectious nature and strain properties of TSE disease 
produced in the transgenic mice a series of three subpassage experiments was set up 
in which brain material from the initial vCJD inoculated transgenic mice was 
inoculated into further mice of all three genotypes and 129Ola wild-type mice 
(Figure 4.F6 and Table 4.T4).  The specific HuMM mouse was chosen for inoculum 
as it was clinically and pathologically positive for TSE, the HuMV mouse was one of 
the oldest surviving and had higher levels of PrPSc than the others (but no TSE 
vacuolation), and the HuVV mouse was the only one scored positive for 
transmission.  Mice were injected by the intracerebral route with brain homogenate 
at a dilution of 1% (10-2).  Because of adaptation of the infectious agent within a new 
host, these subpassage experiments were predicted to show a reduction in the 
incubation period to clinical disease, and an increase in the prevalence of 
pathological TSE features.  This adaptation occurs because the infectivity, including 
PrPSc, has been produced by the new host thereby removing any effects of between 
host transmission barriers (Lasmezas et al., 1997, Bruce et al., 2002, Kitamoto et al., 
2002, Scott et al., 2005).   
 These experiments are relevant to public health issues.  If a subclinical 
disease state is infectious in humans and is passed on iatrogenically via medical 
treatment it is important to establish whether the disease strain becomes 
progressively more infectious after each passage, and also if it retains the original 
strain phenotype in the host (so that it can be recognised by clinicians and 
pathologists).   
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Figure 4.F6:  Immunocytochemistry of Mouse Brains Selected for Second 
Passage 
Immunocytochemistry of fixed brain sections from mice inoculated with vCJD, that 
were selected for second passage inoculum sources.  Panel A: HuMM mouse ID# 
110; Panel B: HuMV mouse ID# 101; Panel C: HuVV mouse ID# 115.  (Antibody: 
6H4, scale bar 50μm) 
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Table 4.T4:  vCJD Second Passage Data 
Second passage inoculations of brain homogenates, from primary vCJD 
transmissions (experiment 553A-1A), injected by intracerebral route into transgenic 
and 129Ola wild-type mice.   
Experiment 553A-2A: Brain homogenate from HuMM mouse ID# 110 (Clin: +VE; 
Vacn: +VE; ICC: +VE; Incubation Period: 497 days) 
Experiment 553A-2B: Brain homogenate from HuMV mouse ID# 101 (Clin: -VE; 
Vacn: -VE; ICC: +VE; Survival Time: 707 days) 
Experiment 553A-2C: Brain homogenate from HuVV mouse ID# 115 (Clin: -VE; 
Vacn: +VE; ICC: +VE; Survival Time: 693 days) 



















HuMM 12 651 624 624 1/11 0/9 7/12 
HuMV 12 481 n/d n/d 0/11 0/11 2/12 




12 547 556 470-617 8/11 6/11 10/12 
HuMM 13 471 554 554 1/13 0/13 5/13 
HuMV 11 480 n/d n/d 0/10 0/9 1/11 




11 547 519 491-547 2/11 1/11 2/11 
HuMM 11 397 n/d n/d 0/11 0/11 2/11 
HuMV 10 554 n/d n/d 0/11 0/8 0/10 








4.3.2.1  Clinical Assessment 
 Of the three mice selected as tissue donors for second passage inoculum 
only the HuMM mouse was positive for clinical symptoms, and this occurred at 497 
days post injection.  It was hypothesised that the recipient HuMM mice, of this 
specific inoculum, would develop TSE clinical signs at or before this time period if 
there was strain adaptation.  However, only one HuMM mouse was scored positive 
for clinical signs (at 624 days) and six of the group of 12 mice survived beyond this 
time point.  The median survival time (the point at which 50% of mice are still alive) 
was 651 days.  One HuMM mouse also developed TSE clinical signs following 
inoculation with the HuMV derived inoculum, at 554 days.  Neither the HuMV nor 
HuVV mice developed clinical TSE with any of the three inocula, and there were no 
positive HuMM mice inoculated with the HuVV derived material.  There was no 
evidence of TSE associated vacuolation in the transgenic lines from any of the three 
second pass experiments. 
 In contrast to the transgenic results, more clinical positive results were 
obtained for the wild-type mice inoculations.  With the HuMM inoculum clinical 
TSE was observed, and confirmed by vacuolation scoring or ICC, in 8/11 mice with 
a mean incubation period of 556 days.  For comparison, primary vCJD transmission 
to these wild-type mice gave an incubation period of 498 days and 8/14 mice were 
positive (Table 4.T1).  The HuMV mouse inoculum produced clinical TSE, 
confirmed pathologically, but in only two wild-type mice at 491 and 547 days.  The 
response of the wild-type mice to HuVV mouse inoculum showed similarly high 
level of clinical disease (8/12) but a shorter mean incubation period (477 days) than 
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the HuMM mouse inoculum.  This incubation period is shorter, by about 20 days, 
than primary transmission of vCJD in wild-type mice.   
4.3.2.2  Vacuolation Scoring 
 As only the 129Ola wild-type mice had TSE vacuolation, their data were 
compared to observe any changes in the targeting of pathology following 
subpassage, this may indicate strain adaptation.  The number of wild-type mice 
positive for TSE vacuolation confirmed the clinical findings in that the HuVV 
inoculum gave the highest score (10/12) followed by the HuMM inoculum (6/11), 
and lastly the HuMV inoculum (1/11).  Lesion profiles could therefore only be 
generated for 129Ola wild-type mice inoculated with HuMM and HuVV derived 
material; these showed similar patterns.  In wild-type mice inoculated with HuMM 
derived inoculum, the lesion profile is identical to that of primary vCJD inoculation 
in wild-type mice and therefore different from the profile in the inoculum donor 
mouse. (Figure 4.F7, Panel A)   
 Comparison of the second pass lesion profiles in wild-type mice with those 
of primary pass vCJD shows close similarities (Figure 4.F7, Panels B and C).  
Primary pass vCJD at 1% concentration gave a profile with lower scores for grey 
matter and higher scores for white matter regions, whereas with 10% concentration 
inoculum the profiles were more similar.   
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Figure 4.F7:  Second Passage Lesion Profile Comparisons for 129Ola Mice  
Lesion profile comparison of 129Ola mice following second passage from two 
transgenic lines and the initial primary passage of vCJD.   
Key: 
Open Triangles: Primary pass vCJD (1% inoculum) in 129Ola 
Filled Triangles: Primary pass vCJD (10% inoculum) in 129Ola 
Open Squares: Second pass vCJD via HuMM in 129Ola 
Filled Squares: Primary pass vCJD in HuMM 
Circles: Second pass vCJD via HuVV in 129Ola 
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concentration 
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4.3.2.3  ICC Detection of PrPSc
 All transgenic mice in the three experiments were negative for vacuolation 
scoring, but PrPSc was detected by ICC in a number of mice from each experiment, 
suggesting a carrier or subclinical disease stage (Table 4.T4).  HuMM mice gave 
positive ICC scores with each of the three inocula, with the number of positives 
directly proportional to the presence of the methionine allele (HuMM inoculum: 
7/12; HuMV: 5/13; HuVV: 2/11).  HuMV mice gave positive ICC scores for only the 
HuMM (2/12) and HuMV (1/11) derived inocula.  These scores were lower than 
seen for the HuMM recipients.  No HuVV mice were positive by ICC with any of the 
three inocula.   
 It appears that regardless of the codon 129 genotype origin of the inocula 
the transmission strain characteristics are remarkably similar to that of the primary 
vCJD source.  This is also confirmed by the mice that were ICC positive (HuMM 
and HuMV), in which the brain region distribution, and type of PrPSc deposits, were 
similar to primary pass vCJD in mice that died at early time points, with mainly 
thalamic targeting, large intensely stained plaques, and no evidence of florid plaques.   
 Detection of PrPSc has confirmed positive transmission in wild-type mice 
that had clinical TSE and positive vacuolation scores.  The distribution and type of 
PrPSc deposits looked identical to that seen in primary pass vCJD, as suggested by 
the lesion profile patterns.  The number of ICC positive mice reflected the scores for 
vacuolation and clinical signs in that the codon 129 homozygous inocula resulted in 
a high proportion of positives (HuMM: 10/12; HuVV: 12/12) while the heterozygous 




4.3.3  Intraperitoneal Inoculation of vCJD 
 Twenty-four mice of each line (HuMM, HuMV, HuVV, 129Ola) were 
inoculated by the intraperitoneal (i.p.) route with 1% inoculum prepared from the 
NIBSC vCJD standard (Code NHBY0/0003, see Methods).  This alternative 
injection route to the previous intracerebral experiment was chosen as it may be a 
more relevant route.  The BSE agent is believed to have infected humans via the oral 
route and therefore the agent will have had to spread through the peripheral nervous 
system to eventually target the CNS.  VCJD pathology is different from other forms 
of human TSE, and non-TSE diseases that involve lymphoreticular tissue (such as 
human immunodeficiency virus infection), in that PrPSc deposition is found in 
peripheral tissues such as spleen and appendix (Hilton et al., 2004b).  Oral dosing of 
mice is an option, however this route can be less efficient, and the inoculated mice 
may require a thorough investigation of the gut and peripheral nervous tissues to 
observe differences between the difference mouse lines.  The aims of this thesis 
concentrate on the role of codon 129 genotype rather than modelling the route of 
BSE infection in humans.   
 Due to the long duration of these experiments intercurrent illness and death 
due to non-TSE causes were observed.  Where possible these mice were examined 
for markers of TSE pathology.  Table 4.T5 shows the evaluation of all mice in this 
study.   
 
 
Table 4.T5:  Data Table for Intraperitoneal Inoculation with vCJD 
Intraperitoneal inoculation data (protocol reference 553G-1A) 
Abbreviations: CLIN: clinical TSE signs; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: intercurrent 
death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; shaded cell: positive score 





















































































































66 238 ICD Neg Neg Neg 103 280 ICD Neg Neg Neg 59 160 ICD Neg Neg Neg 94 329 ICD Neg n/d n/t 
61 285 ICD Neg Neg Neg 45 308 ICD Neg Neg Neg 42 377 ICD Neg Neg Neg 32 427 ICD Neg Neg n/t 
29 336 ICD Neg Neg Neg 20 356 ICD Neg Neg Neg 39 471 ICD Neg Neg Neg 93 432 ICD Neg n/d n/t 
52 357 ICD Neg Neg Neg 112 378 ICD Neg Neg Neg 57 511 ICD Neg Neg Neg 36 440 ICD Neg Neg n/t 
54 364 ICD Neg Neg Neg 101 418 ICD Neg n/d Neg 37 532 ICD Neg Neg Neg 18 467 ICD Neg Neg n/t 
51 419 ICD Neg Neg Neg 105 476 ICD Neg Neg Neg 58 539 ICD Neg Neg Neg 91 476 ICD Neg Neg n/t 
78 434 ICD Neg Neg Neg 111 476 ICD Neg Neg Neg 89 567 ICD Neg Neg Neg 95 483 TSE Pos Pos Pos 
62 476 ICD Neg Neg Neg 23 481 ICD Neg Neg Neg 90 567 ICD Neg Neg Neg 82 484 TSE Pos Pos Pos 
74 476 ICD Neg Neg Neg 114 483 ICD Neg Neg Neg 98 588 ICD Neg Neg Neg 84 496 ICD Neg Neg n/t 
64 480 ICD Neg Neg Neg 116 504 ICD Neg Neg Neg 86 589 ICD Neg Neg Neg 79 508 TSE Pos Pos Pos 
65 487 ICD Neg Neg Neg 43 539 ICD Neg Neg Neg 60 603 ICD Neg Neg Neg 83 518 TSE Pos Pos Pos 
63 525 ICD Neg Neg Neg 21 545 ICD Neg Neg Neg 56 616 ICD Neg Neg Neg 81 532 ICD Neg Neg n/t 
49 531 ICD Neg Neg Neg 46 553 ICD Neg Neg Neg 88 620 ICD Neg Neg Neg 31 539 ICD Neg Neg n/t 
73 545 ICD Neg Neg Neg 106 553 ICD Neg Neg Neg 38 630 ICD Neg Neg Neg 15 540 ICD Neg Pos Pos 
76 560 ICD Neg Neg Neg 24 560 ICD Neg Neg Neg 97 637 ICD Neg Neg Neg 96 540 TSE Pos Pos Pos 
50 567 ICD Neg Neg Neg 104 574 ICD Neg Neg Neg 55 651 ICD Neg Neg Neg 80 560 TSE Pos Neg n/t 
26 630 ICD Neg Neg Neg 44 637 ICD Neg Neg Neg 85 665 ICD Neg Neg Neg 92 588 TSE Pos Pos Pos 
25 672 ICD Neg Neg Neg 115 638 ICD Neg Neg Neg 87 686 ICD Neg Neg Neg 33 601 TSE Pos Pos Pos 
77 686 ICD Neg Neg Neg 47 644 ICD Neg Neg Neg 41 714 ICD Neg Neg Neg 35 609 TSE Pos Pos Pos 
30 698 ICD Neg Neg Neg 102 679 ICD Neg Neg Neg 100 826 ICD Neg Neg Neg 13 622 ICD Neg Pos Pos 
53 700 ICD Neg Neg Neg 19 699 ICD Neg Neg Neg       16 630 ICD Neg Neg n/t 
27 730 ICD Neg Neg Neg 113 700 ICD Neg Neg Neg       14 637 TSE Pos Neg n/t 
      22 735 ICD Neg Neg Neg       34 662 ICD Neg Neg n/t 
                  17 735 ICD Neg Neg n/t 







4.3.3.1  Clinical TSE Findings 
 In the i.p. inoculation experiment there was no evidence of clinical disease, 
confirmed by pathology, in any of the three transgenic lines.  A number of mice 
displayed signs suggestive of clinical TSE, but these were negative by pathological 
analysis, and were not classed as positive for transmission.  Confirmation that the 
inoculum was infectious came from the 129Ola mice.  These mice showed confirmed 
clinical TSE in eight of the twenty-four mice with a mean incubation period of 541 
days (range 483 to 609).  Comparing this data to that obtained from the i.c. challenge 
there is a 43 day lengthening of the incubation period and an overall reduction in 
clinically positive mice (8/24 i.p. versus 8/15 i.c.).   
4.3.3.2  Vacuolation Scoring and Detection of PrPSc by ICC 
 In addition to finding no clinically positive transgenic mice there was also 
no evidence of TSE vacuolation, or detectable amounts of PrPSc by ICC, in the brains 
of these mice.  There may however be peripheral tissue deposition due to the 
inoculation route used.  Spleen material is available for future investigation of these 
mice.   
 The wild-type mice that developed clinical disease were scored positive for 
vacuolation and PrPSc detection, as expected.  The lesion profile for the wild-type 
vacuolation scores showed an identical pattern to that found for i.c. challenge, with 
the inoculum at 1% concentration (Figure 4.F8).   
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Figure 4.F8:  Lesion Profile of 129Ola Mice Following Intraperitoneal 
Inoculation with vCJD 
Lesion profile for 129Ola mice i.p. challenged with vCJD at 1% (closed circles), 
together with data for i.c. challenge at 1% (open squares) concentration. (Mean score 
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4.4  DISCUSSION 
4.4.1  A New Mouse Model for Human vCJD 
 The initial goal of this study was to assess the suitability of this transgenic 
mice model for studying the vCJD strain of TSE.   
4.4.1.1  Intracerebral Inoculation Results 
 With varying efficiency vCJD has been transmitted via the i.c. route to 
each of the three codon 129 genotype mouse lines, with success rates of 75% for 
HuMM, 79% for HuMV, and 7% for HuVV mice.  The secondary passage of brain 
material from these mice in further transgenic and wild-type mice has demonstrated 
the presence of a transmissible agent.  As these mice were generated by gene 
targeting and express the transgenic prion protein at physiological levels these data 
show that to successfully transmit disease and produce clinical TSE symptoms it is 
not essential to overexpress PrP, which may itself cause unknown effects on 
transmission.  Gene targeting has produced genetically identical lines varying only 
at codon 129 of PRNP allowing for a direct assessment of the properties of each 
line.   
 Transmission of the vCJD agent to these transgenic mice did not produce 
shorter incubation periods than the 129Ola wild-type mice which readily developed 
clinical TSE.  Replacing the mouse Prnp gene with the human version should 
hypothetically increase susceptibility to a human TSE inoculum as there would be 
homologous PrP interaction.  This is proposed to be an efficient mechanism for PrPC 
conversion (Prusiner, 1991, Horiuchi et al., 2000).  Data from transgenic mice 
expressing the methionine allele of human PrP (published since the start of this 
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thesis) have shown that the clinical phenotype is rarely observed following vCJD 
inoculation.  With three separate sources of vCJD the Kitamoto group’s KiChM (1x 
expression, MM genotype) line showed clinical TSE signs in 0/6, 1/5, and 1/5 mice, 
and with three other cases the Collinge group’s Tg35 (1-2x expression, MM 
genotype) line showed clinical TSE in 0/2, 1/5, and 0/7 mice.  Pathological analysis 
in these studies however indicated positive transmission in over 90% (27/29) of the 
mice (Asante et al., 2002, Taguchi et al., 2003).  A comparison of the data from this 
study with that available from the Kitamoto group on vCJD transmission to 
transgenic mice expressing the human PRNP gene at physiological levels, is shown 
in Table 4.T6.  Independent generation of these transgenic lines has lead to near 
identical transmission properties for the vCJD agent.   
Table 4.T6:  Comparison with Kitamoto Group Data on vCJD Transmission 
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Expression 
level 
x1 x1 x1 x1 x1 x1 
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 The most over-expressing MM line (6x) published by the Laude group is the 
only line to show 100% clinical disease with vCJD inoculation (Beringue et al., 
2008).  This line developed disease at ~500 days, indicating that significant over-
expression is required to lower the incubation period to a point shorter than the usual 
mouse lifespan.   
 Lack of clinical disease in the transgenic mice may indicate that there was a 
lengthy subclinical phase during which pathological changes were occurring, for 
example deposition of PrPSc.  Future transmission experiments aimed at determining 
the time-scale for the appearance and distribution of TSE pathology may model the 
extent of subclinical disease, or a carrier state, in humans and the spread of disease 
through different peripheral tissues.   
 Data from this study suggest that subclinical pathological changes 
associated with TSE disease are more severe in the HuMM mice compared with the 
non-HuMM lines, such as increased numbers of mice positive for TSE vacuolation 
and more widespread, more intense deposits of PrPSc.  This may manifest as a 
change in survival rate rather than directly through the appearance of a TSE clinical 
phenotype as shown by the Kaplan-Meier curves and the Tarone-Ware statistical 
tests (Section 4.3.1.3 Survival Analysis).   
 Assessment of TSE vacuolation showed differences between the HuMM 
transgenic and wild-type lesion profiles, indicating a possible effect on pathological 
targeting arising from replacing the murine Prnp gene with the human equivalent.  
Differences in the lesion profiles may also be due to data from clinically positive 
129Ola wild-type mice being compared with clinically negative HuMM mice.   
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4.4.1.2  Intraperitoneal Inoculation Results 
 Intraperitoneal inoculation did not show CNS evidence of TSE disease in 
any of the transgenic mice, compared with 33% of the wild-type mice.  Previous 
studies of BSE transmission to wild-type mice have shown that the i.p. route may be 
less efficient than the i.c. route but can produce shorter incubation times (Bruce et 
al., 1994).  This inefficiency of the i.p. route may be the reason for the results seen 
here.  As the occurrence of clinical disease was rare with i.c. route inoculation, and 
the incubation time for i.p. inoculated wild-type mice was extended, it is perhaps not 
surprising that there were no transgenic mice with clinical TSE in this experiment.  
As these experiments were set up concurrently we were not able to predict this 
potential negative result.  Although this suggests that i.p. inoculation of vCJD is not 
as efficient in these mice analysis of peripheral tissues from these mice may show 
that transmission has occurred without CNS involvement.  Spleen tissue is available 
from this experiment for such a study.   
 The similarities between the i.c. and i.p. vacuolation data for the wild-type 
mice indicate that the vCJD strain targets similar regions of the brain even when 
infection has occurred by direct injection into the brain or via a peripheral route.  It 
is, however, difficult to explain why the i.p. route in the transgenic mice was 
dramatically less efficient, with no clinical signs or pathological markers of TSE 
disease in the brain.  Lack of CNS evidence of transmission is important, as the 
propagation of human PrPSc through peripheral tissues may occur at a much lower 
rate to that of mouse PrPSc.  This could suggest one reason for the low numbers of 
vCJD cases seen.  In some individuals the disease would never progress further than 
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the peripheral nervous tissues.  This effect may vary with codon 129 genotype, with 
MM being the most susceptible to progression of the disease to the CNS.   
4.4.1.3  Replication of vCJD Pathological Features 
 In addition to the successful transmission of vCJD to the transgenic mice, 
two of the pathological characteristics of vCJD in humans have been replicated.   
 The first is the appearance of florid plaques.  These structures are not 
unique to vCJD, but are characteristic of this disease in comparison to the majority 
of other human TSEs (Kretzschmar et al., 2003).  They have only been seen in MM 
genotype vCJD cases.  Data from i.c. inoculation of transgenic mice has shown that 
these structures occur only in the HuMM line (see Figure 4.F4).  The formation of 
florid plaques in the hippocampus and immediate surrounding area of cerebral cortex 
may be due to the types of cells present or the nature of the cellular environment.  
Human vCJD cases show florid plaques in most cortical areas and predominantly in 
the occipital cortex (the rearmost lobe of the brain involved with visual processing) 
and the cerebellar cortex.  (The human cerebellum integrates sensory perception and 
motor control.)  This regional distribution of specific pathological features may be 
defined by the host and the stage of disease.  As clinical symptoms were rare in these 
HuMM mice, indicating a preclinical stage, the distribution of florid plaques may 
have been less widespread than in clinical vCJD.  The reason why only MM 
genotype humans and for this study, mice, develop these types of structures is 
unknown.  It appears to be a response of both the infectious strain and the host 
genotype.   
 The second pathological feature replicated in these mice is the type 2B 
Western blot vCJD pattern (19kDa mobility and dominance of the diglycosylated 
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fragment).  This Western blot type was found in transgenic mice of all codon 129 
genotypes suggesting that this strain property is dominant regardless of the 
genotype, and that protein typing might prove useful for the diagnosis of future 
human cases of vCJD infection in non-MM individuals, should this occur.   
 An important use of the HuMV mice infected with vCJD is to further 
understand whether there is dominance of the M allele over the V allele in 
conversion of PrPC to PrPSc.  If the V allele is protective for this strain then 
administering V-PrPC to MM genotype individuals could slow the progression of 
vCJD disease pathology.   
4.4.2  Codon 129 Genotype and Transmission Properties of the vCJD 
Agent 
 A primary aim of this study was to examine the role of codon 129 genotype 
in susceptibility to disease.   
4.4.2.1  Clinical Disease Associated with Genotype 
 Clinical symptoms of TSE disease were confirmed in only two HuMM and 
a single HuMV mice inoculated with vCJD.  This appears to reflect the relative 
rarity of secondary vCJD cases in humans.  BSE inoculation of the three transgenic 
lines showed no transmission.  In the human context this may mean that the vCJD 
agent is more infectious than BSE and may be more efficient in infecting further 
people.  The appearance of clinical TSE in only HuMM and HuMV mice confirms 
the codon 129 methionine allele dominance and that iatrogenic vCJD may only 
result in clinical disease in M allele carriers (MM and MV).  Survival analysis 
indicates a deleterious subclinical effect for the MM genotype mice only, further 
 149
 
highlighting this genotype as preferentially targeted by this TSE agent.  As the 
progressive development of CNS TSE pathology is faster in MM than MV or VV 
mice, there may also be additional early peripheral pathology in the MM mice that 
may reflect the changes in survival seen in this study.   
4.4.2.2  Vacuolation Scoring Associated with Genotype 
 TSE vacuolation was found almost exclusively in the HuMM mice and its 
appearance coincided with an increase in deposition of PrPSc.  The appearance of 
TSE associated vacuolation in similar areas in each of the three lines suggests an 
agent strain specific effect and the varying levels of vacuolation seen in the different 
genotypes indicates that the degree of pathological change is determined by the host 
genotype.  If the degree of TSE vacuolation is a predictor of the development of 
further pathological features then the host genotype may predispose an individual to 
relatively short or long incubation periods following infection.   
4.4.2.3  PrPSc Properties Associated with Genotype 
 PrPSc deposition was the most sensitive test for successful transmission 
detecting the earliest signs of TSE after inoculation.  This was seen in the HuMV 
mice in which nine of the eleven mice scoring positive had no other signs of TSE 
except for PrPPSc deposition.  Equivalent numbers of HuMM and HuMV mice were 
positive for PrPSc but the former had more widespread regions affected and a greater 
level of deposition.  PrPScP  deposition in the HuMV mice never developed further 
than a few isolated regions (Figure 4.F4), providing further evidence for the 
protective nature of the valine allele.   
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 To summarise the results of ICC detection of PrPSc, both the HuMM and 
HuMV mice were equally likely to show deposits of the abnormal protein in the 
brain over the lifespan of the mouse.  However, the HuMM mice had a significantly 
more progressive increase in the extent of the deposits over time.  The HuVV data 
suggest an extended delay before the appearance of this disease marker.  The 
appearance of PrPSc at a stage before the development of TSE vacuolation or clinical 
disease suggests that this is an important early phase in pathogenesis.  If this model 
is extrapolated to human disease there may be a lengthy subclinical stage, before 
clinical symptoms appear, following infection with BSE or vCJD.  Assuming that the 
appearance of PrPSc is associated with infectivity, this early subclinical stage could 
be a period in which human-to-human infection may occur via blood products or 
contaminated surgical instruments.   
 Western blotting has shown that each genotype mouse line has faithfully 
replicated the type 2B pattern, in terms of electrophoretic mobility and 
glycosylation, indicating that this is a dominant strain transmission characteristic 
and not dependent on host genotype.  This may aid diagnosis of human cases in 
non-MM hosts, as in the MV genotype blood transfusion transmission case (Peden 
et al., 2004).  There was a relative increase in the diglycosylated form of PrPSc in 
the single HuVV mouse.  If this is a true reflection of the VV genotype response 
then it may be due to the effect the valine amino acid has on the structure of PrPSc.  
Potentially if valine at position 129 protects the diglycosylated protein from protease 
cleavage, to a greater degree than the mono or unglycosylated forms, then the former 
will be over-represented on the Western blot.  Further analysis of the biochemical 
properties of V-PrPSc may provide insight into the folding properties of the prion 
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protein.  However, transmission of vCJD to over-expressing VV genotype mice did 
not show an increase in diglycosylation (Wadsworth et al., 2004) indicating that the 
abnormal abundance of PrPSc in these mice may lead to an alternative folding or 
aggregation state of PrPSc (Dimcheff et al., 2003).   
4.4.3  Modelling Iatrogenic Spread of vCJD 
 The data provided on vCJD transmissions give an insight into both the 
infectious nature of the vCJD agent and the potential for iatrogenic spread in 
humans (already confirmed through blood transfusion), the secondary aim of this 
study.   
 Secondary passage of brain material from vCJD infected mice of each 
codon 129 genotype was used to model more specifically the iatrogenic spread of 
vCJD originating from each genotype host.  Data from this study indicate that 
transgenic mice primarily infected with vCJD develop a transmissible disease that 
retains some properties of the original strain.  The response of the recipient mice 
showed that once again the MM genotype is the most susceptible, with the MV mice 
less so (Table 4.T4).  The VV mice showed no evidence of disease and therefore 
may have a protective genotype.  This result was the same for inocula sourced from 
MM, MV, and VV mice.   
 Positive transmission scoring in the HuMM and HuMV mice was however 
restricted to just the deposition of PrP PSc by ICC.  There was no evidence of clinical 
disease or vacuolation.  This may be suggestive of an adaptation to a less infectious 
strain, or to a difference in level of infectivity between the primary and secondary 
passage inocula.   
 152
 
4.4.3.1  Secondary Passage to Wild-Type Mice 
 Wild-type mice developed clinical and pathological signs of TSE from all 
three genotype sources of inocula.  Secondary passage of the HuMM source 
inoculum to wild-type mice produced a lengthening of the incubation period by 
approximately 50 days.  This minor effect could be due to a lower level of infectivity 
in the mouse brain tissue or due to a minor adaptation of the agent by the mouse 
host, e.g. the human PRNP expressed form of PrPSc will now have mouse derived N-
linked glycosylation compounds which may cause changes in PrPC to PrPSc 
conversion efficiency.   
 The rarity of positive transmission to wild-type mice for the HuMV derived 
inoculum may also be due to the level of infectivity as the donor mouse was negative 
for vacuolation and had only relatively small quantities of PrPPSc detectable by ICC 
(Figure 4.F6).  It is also possible that the heterozygous PrPScP  of the inoculum is 
configured or aggregated in such a way that conversion of the wild-type PrPC is less 
efficient (c.f. heterozygote ‘protection’ in kuru and iCJD (Brown et al., 1994a, Mead 
et al., 2003)).   
 The HuVV derived inoculum transmitted more efficiently at second passage 
to wild-type mice, than primary vCJD, with lower incubation period and higher rates 
of positive scoring for pathological signs.  This may be due to removal of the species 
barrier or a higher level of infectivity in the HuVV mice.  Potentially the altered 
configuration of the HuVV derived PrPSc (greater abundance of the diglycosylated 
band by Western blot) may be more efficient in converting the wild-type mouse PrPC 
which is known to be heavily diglycosylated (Chapter 3, Figure 3.F4).   
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 The lesion profiles generated for 129Ola wild-type mice from HuMM and 
HuVV derived inocula show close similarities to primary transmission of vCJD in 
these mice.  Together with the incubation period data, this suggests that the original 
vCJD strain properties have not been altered by passage through different genotype 
transgenic mice.  However, as the transgenic mice show significant differences to the 
primary transmission there is potential for some form of strain adaptation specific to 




ADAPTATION OF THE VCJD STRAIN 
FOLLOWING BLOOD TRANSFUSION 
ASSOCIATED VARIANT CJD INFECTION  
 
5.1  AIMS 
 Human-to-human transmission of vCJD, via blood transfusion, may have 
caused adaptation of the infectious agent to a form that is now more efficiently 
transmissible to humans, or may cause more rapidly progressive pathological 
changes.  This chapter aims to use data from inoculation of transgenic and wild-type 
mice, with brain material from the first case of blood transfusion associated vCJD 
infection, to determine if the vCJD strain has been modified by human-to-human 
transmission.  Comparison with the vCJD (BSE) transmission data described in 
Chapter 4 will highlight any differences that can be attributable to modification of 
the BSE agent following human-to-human passage.   
 Intracerebral inoculation of brain homogenate (at 1% concentration) was 
performed on the three transgenic lines (HuMM, HuMV, and HuVV) and the 129Ola 
wild-type control line.  These mice were assessed for clinical TSE signs, for TSE 
associated vacuolation (lesion profiling), and for targeting and biochemistry of the 
disease associated PrPSc by ICC and Western blot.   
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 Data from this study were published in 2008 in PLoS ONE (See Appendix) 
(Bishop et al., 2008).   
5.2  INTRODUCTION 
 Four cases of possible blood transfusion associated infection by the vCJD 
agent have been identified (Llewelyn et al., 2004, Peden et al., 2004, Hewitt et al., 
2006, Wroe et al., 2006, HPA, 2007).  Three of these developed clinical signs and 
were MM at codon 129 of the prion protein gene.  The fourth case died of a ruptured 
abdominal aortic aneurysm but was found by post mortem analysis to be positive for 
evidence of vCJD infection.  This individual was heterozygous, MV, at codon 129 
(Peden et al., 2004) (See Introduction, section 1.6.6.3 Variant CJD).  These four 
cases were from a small group of 28 individuals, known to have received blood 
products from vCJD donors, who survived more than five years after the transfusion.  
This rate of infection appears high compared with the few cases of vCJD that have 
arisen from a large number of infectious cattle in the food chain, and therefore places 
those others that are known to have received similar blood products, at significant 
risk of vCJD infection.  The codon 129 genotype of these vCJD blood product 
recipients is unknown.   
 It is also important to understand that all the blood donors involved with the 
above cases were in a subclinical phase of vCJD infection.  The longest period 
between blood donation and onset of clinical symptoms was 3 years and 4 months 
(the case studied in this thesis) (Llewelyn et al., 2004), suggesting that, although the 
clinical and pathological changes such as neuronal loss and deposition of PrPSc may 
not have developed the blood donor was nevertheless harbouring infectivity.   
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 The incidence of infection among blood recipients in transfusion 
transmission of vCJD suggests that human derived disease is more infectious or has a 
greater efficiency of transmission than BSE.  The alternative is that the route of 
infection is more efficient.  Blood transfusion infection was by the intravenous (i.v.) 
route whereas it is likely that BSE infection was by the oral route.  The i.v. route 
may be a more efficient route as, experimentally, a high proportion of orally 
administered PrPSc can be destroyed in the gut (Jeffrey et al., 2006).  It is also a 
possibility that a greater infectious dose was given via blood transfusion compared 
with the dose of BSE taken orally (See Introduction, section 1.6.6.3 Variant CJD).   
 In comparing vCJD and human passaged vCJD it is also important to note 
that the infectious material transmitting disease was different and that this may 
impact on the efficiency of transmission.  BSE infection of humans was likely to 
have involved consumption of meat contaminated with brain and CNS material 
whereas human-to-human infection was via labile blood products.  There is a 
possibility that PrPSc molecules present in these two very different cellular 
environments have different transmission properties.  Blood PrPSc configuration or 
even its presence is still unknown (Brown, 2005).  Blood may be infectious with 
limited levels of PrPSc.  Evidence for such disparity between low or undetectable 
levels of PrPSc and high levels of infectivity has been published for a transgenic 
mouse model of the human genetic TSE disease, GSS (Barron et al., 2007).  
 Data from vCJD infection of transgenic mice (Chapter 4) suggests that all 
three codon 129 genotype individuals are susceptible to the vCJD agent which means 
that a significant number of the UK population may be carriers of infectivity with 
some, such as those who are VV, potentially never developing clinical signs.  This 
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may lead to a large pool of infectivity which could spread via medical practice 
(Garske et al., 2006). There is currently no evidence as yet for vCJD infection via 
surgery, but, if the incubation period in those exposed is long, e.g. >20 years, then 
such cases may not yet have occurred.  Medical history taken from each vCJD case 
allows traceability of events such as surgical procedures so that future vCJD 
transmission cases can be linked to a likely point of infection. 
 Hypothetically if the vCJD agent was propagated by human-to-human 
infection within the population, then assuming long incubation periods, the agent 
could become widespread.  A self-sustaining epidemic of a human-adapted form of 
vCJD is thought unlikely as transmission would only occur in those receiving blood 
products or undergoing surgery.  This is a small fraction of the population and these 
individuals are unlikely to infect others (Clarke et al., 2007).  Deferral of individuals 
as blood donors if they themselves have had a blood transfusion is a means of 
preventing the onward spread of infection by this route (Joint UKBTS/NIBSC 
Professional Advisory Committee, Change Notification 5, 2005: 
http://www.transfusionguidelines.org.uk/docs/pdfs/change_note_2005_05.pdf).   
 Serial passage of BSE in sheep using infected sheep brain material showed 
that secondary transmission occurred, but assessment of clinical onset times and 
pathology, provided no evidence of strain adaptation (Gonzalez et al., 2007).  In 
contrast serial passage of cattle BSE in non-human primates showed strain 
adaptation with a 50% reduction in incubation period, although there were no 
differences in the intensity of pathological changes such a vacuolation (Lasmezas et 




 This chapter details work carried out to define the transmission properties of 
the infectious agent found in the first case of blood transfusion associated vCJD.  
Using data from Chapter 4 (vCJD (BSE) inoculation) a comparison was made of the 
presence of clinical disease, TSE vacuolation, and PrPSc, and mean incubation 
periods and Western blot profiles.  These parameters were assessed to determine 
whether the vCJD agent has been adapted to humans to become more infectious.   
5.3  EXPERIMENTAL RESULTS 
5.3.1  Intracerebral Inoculation with Transfusion Associated vCJD 
 Eighteen mice of each transgenic line (HuMM, HuMV, HuVV) and twelve 
wild-type 129Ola mice, were inoculated by the intracerebral (i.c.) route, with 
inoculum prepared from a sample of frontal cortex provided by Prof James Ironside 
(National CJD Surveillance Unit, Edinburgh) from the blood transfusion case 
(reference RU 03/125), here designated vCJD (transfusion).  The concentration of 
inoculum (1% (10-2)) was the same as the vCJD inoculum, here designated vCJD 
(BSE), used in previous studies.  Because of the long duration of these experiments, 
intercurrent illness and death due to non-TSE causes were observed.  Where possible 
these mice were examined for markers of TSE pathology.  Table 5.T1 shows the 
evaluation of all mice in this study.   
 
Abbreviations: CLIN: presence of clinical signs; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by 
immunocytochemistry; ICD: intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; shaded 
cell: positive score. 





















































































































47 365 ICD Neg Neg Neg 21 300 ICD Neg Neg Neg 54 162 ICD Neg Neg Neg 19 383 ICD Neg Neg Neg 
42 407 ICD Neg Neg Pos 38 302 ICD Neg Neg Neg 7 244 ICD Neg Neg Neg 16 448 ICD Neg Neg Neg 
48 483 ICD Neg Neg Pos 39 368 ICD Neg Neg Neg 12 274 ICD Neg Neg Neg 17 477 ICD Neg Neg Neg 
43 538 ICD Neg Neg n/d 22 472 ICD Neg Neg Neg 55 323 ICD Neg Neg Neg 30 547 ICD Neg Neg Pos 
44 544 ICD Neg Neg Pos 37 484 ICD Neg Neg Neg 57 477 ICD Neg Neg Neg 35 590 TSE Pos Pos Pos 
52 554 ICD Neg Neg Pos 63 519 ICD Neg Neg Neg 58 540 ICD Neg Neg Neg 15 617 ICD Neg Neg Pos 
26 618 ICD Neg Pos Pos 40 540 ICD Neg Neg Neg 3 561 ICD Neg Neg Neg 32 617 TSE Pos Pos Pos 
45 631 ICD Neg Pos Pos 62 561 ICD Neg Neg Pos 6 614 ICD Neg Neg Neg 31 638 ICD Neg Neg Pos 
49 659 TSE Pos Pos Pos 61 593 ICD Neg Neg Neg 53 624 ICD Neg Neg Neg 34 638 ICD Neg Neg Neg 
29 673 ICD Neg Pos Pos 64 596 TSE Pos Neg Pos 9 685 ICD Neg Neg Neg 18 666 TSE Pos Pos Pos 
51 680 ICD Neg Pos Pos 66 610 ICD Neg Neg Pos 1 693 ICD Neg Neg Neg 33 669 ICD Neg Neg Neg 
25 708 ICD Neg Pos Pos 60 638 TSE Pos Neg Pos 10 701 ICD Neg Neg Neg 14 680 TSE Pos Pos Pos 
41 708 ICD Neg Neg Pos 59 647 ICD Neg Neg Pos 11 701 ICD Neg Neg Neg       
50 708 ICD Neg Pos Pos 67 659 ICD Neg Neg Neg 5 701 ICD Neg Neg Neg       
24 839 ICD Neg Pos Pos 65 666 ICD Neg Neg Pos 56 750 ICD Neg Neg Neg       
      23 672 ICD Neg Neg Pos 13 764 ICD Neg Neg Neg       
      20 701 ICD Neg Neg Pos 4 869 ICD Neg Neg Pos       
                        
                        
‘Attack Rate’ 1/15 8/15 13/14  2/17 0/17 8/17  0/17 0/17 1/17  4/12 4/12 7/12 
 
Intracerebral inoculation of vCJD (transfusion) with data ordered by Survival Time.  (Protocol reference 553K-1A) 







5.3.2  Clinical TSE Findings 
 Mice scored positive for clinical signs of transmissible spongiform 
encephalopathy (TSE) were those that had pathological confirmation (either the 
presence of TSE associated vacuolation and/or the identification of abnormal 
deposition of PrP by immunocytochemistry (ICC)).  The data table shows 
pathologically confirmed clinical positives for one HuMM mouse (at 659 days post 
inoculation), two HuMV mice (at 596 and 638 days post inoculation), and none for 
HuVV mice.   
 A higher fraction of the 129Ola mice developed to a clinical disease stage 
(4/12) with a mean incubation period of 638 days (range 590 to 680).  This is longer 
than that seen for vCJD (BSE) inoculation (mean 498 days, in 8/14 mice) and with a 
reduction in the overall attack rate.  This effect could be due to the titre of infectivity 
in the inoculum and only a titration experiment (inoculating mice with a range of 
inoculum concentrations) with this material could confirm this.  There is still the 
possibility, however, that this effect is due to an alteration of strain properties.  Data 
are available from this thesis for inoculation of 129Ola mice with vCJD (BSE) 
material at both 10% and 1% dilution, and together with additional published data 
(Barron et al., 2001), the lengthening of incubation period following vCJD 
(transfusion) inoculation is clear (Figure 5.F1).  A Kaplan-Meier plot also highlights 
the differences in survival following vCJD (transfusion) and vCJD (BSE) inoculation 
(Figure 5.F2).   
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Figure 5.F1:  Incubation Period Plot for 129Ola Mice Inoculated with vCJD 
Comparison of mean incubation period (and range) for 129Ola mice inoculated with 
vCJD (BSE) at two dilutions (10% and 1%) and the vCJD (transfusion) data where 






























Figure 5.F2:  Kaplan-Meier Survival Curve for vCJD Inoculated 129Ola Mice 
Survival curves for 129Ola mice inoculated with 10% (green line) and 1% (red line) 
dilution vCJD (BSE) inoculum and 1% vCJD (transfusion) inoculum (blue line).  
Statistically significant differences (Tarone-Ware test): vCJD (transfusion) vs. vCJD 
(BSE) 1%: P=0.001; vCJD (transfusion) vs. vCJD (BSE) 10%: P<0.001. (No 




5.3.3  Survival Analysis 
 As seen before with vCJD (BSE) transmission there is little evidence of 
clinical TSE symptoms and so survival analysis was used to determine whether the 
variation in rate of intercurrent deaths was specific to the different codon 129 
genotypes of the mice.  Survival curves were drawn and a Tarone-Ware test 
performed which has an even bias across the lifespan of the mice, using software 
SPSS v14.0 (Figure 5.F3 and Table 5.T2).  The data show no significant differences 
between any of the lines, in contrast to vCJD (BSE) inoculation that significantly 
affected both HuMM and 129Ola mice compared with HuMV and HuVV (See 
Chapter 4, section 4.3.1.3).  The 129Ola mice developed clinical symptoms more 
readily that the transgenic mice, but, as the incubation time had been extended 
compared to vCJD (BSE), the curves have become superimposed.   
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Figure 5.F3:  Kaplan-Meier Curve for Inoculation with vCJD (transfusion) 
Kaplan-Meier survival curves following i.c. challenge of vCJD (transfusion) in 
HuMM (blue), HuMV (green), HuVV (red), and 129Ola (black) mice.   
 
Table 5.T2:  Tarone-Ware Test Data for Inoculation with vCJD (transfusion) 
Survival analysis by genotype following intracerebral inoculation of vCJD 
(transfusion).  (Statistical analysis: Tarone-Ware Test using software SPSS v14)  ns: 
not significant 
 
Groups Tested P value  (significance rating) 
HuMM vs. HuMV vs. HuVV vs. 129Ola =0.283  (ns) 
HuMM vs. HuMV =0.100  (ns) 
HuMM vs. HuVV =0.962  (ns) 
HuMM vs. 129Ola =0.257  (ns) 
HuMV vs. HuVV =0.168  (ns) 
HuMV vs. 129Ola =0.630  (ns) 
HuVV vs. 129Ola =0.305  (ns) 
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5.3.4  Vacuolation Scoring 
 HuMM mice were the only transgenic line to show disease-associated 
vacuolation, initially detectable at around 600 days post inoculation, approximately 
100 days later than HuMM mice challenged with vCJD (BSE) (Chapter 4, Table 
4.T1).  The number of vacuolation positive mice was higher (8/15 – 53%) than for 
the vCJD (BSE) inoculum (6/18 – 33%).  This may be due to extended survival 
times for the former mice providing time for development of the vacuolation.  The 
HuMM mice that were scored positive showed a similar distribution of vacuolation 
in the brain, with the highest levels found in the thalamus and cerebellar white 
matter, but overall the intensity of vacuolation was less than seen for vCJD (BSE) 
inoculation, as shown in the lower lesion profile scores.  The mean lesion profile 
from six HuMM mice is shown in Figure 5.F4, compared with the vCJD (BSE) data.   
 The mean lesion profile for four 129Ola mice is shown in Figure 5.F5 
together with data from the vCJD (BSE) experiment.  Although routinely five or six 
mice are required for generating the mean lesion profile these four clinically positive 
mice gave a profile very similar to that found for vCJD (BSE) transmission and this 
analysis is therefore included.   
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Figure 5.F4:  Lesion Profile for HuMM Mice Inoculated with vCJD 
(transfusion) 
Vacuolation scoring (mean lesion profile) of HuMM mice i.c. challenged with vCJD 
(transfusion) (open triangles, ±SEM), and vCJD (BSE) (open squares; ±SEM).  (G1-














Figure 5.F5:  Lesion Profile for 129Ola Mice Inoculated with vCJD 
(transfusion) 
Vacuolation scoring (mean lesion profile) of 129Ola mice i.c. challenge with vCJD 
(transfusion) (open triangles; ±SEM) and vCJD (BSE) (open squares; ±SEM).  (G1-


















5.3.5  Detection of PrPSc by Immunocytochemistry 
 Immunocytochemical (ICC) detection of disease associated PrP (PrPSc) on 
paraffin sections of mouse brain was found to be a sensitive method of detecting 
positive transmission for the vCJD (BSE) inoculum.  This was seen again in this 
experiment.  The positive / negative transmission scoring is shown in Table 5.T1 
(column ICC) and gave a similar attack rate to that found for vCJD (BSE) 
transmission.  A majority of the HuMM mice (13/14) showed PrPSc deposition in 
most areas of the brain at a relatively early stage (from around 400 days post 
inoculation), before the vacuolar pathology became evident around 600 days.  The 
regional distribution of PrPSc in the brain and the types of deposits seen showed clear 
similarities to that found for vCJD (BSE) transmission (Figures 5.F6 and 5.F7).  
Florid plaques were seen only in the HuMM mice confirming the specific vCJD / 
BSE strain nature of this blood transfusion case (Figure 5.F7).  The thalamus was 
targeted for the most intense deposition (see ‘Hippocampus’ images in Figure 5.F6, 
panels 2 and 7) and the ‘Forebrain’ sections (panels 1 and 6) showed that the cortex 
contained many intensely stained plaques, many of which were located near the outer 
surface (sub-pial).  The brain stem was only mildly affected, whereas the cerebellum 
had PrPSc deposition targeted to the white matter and granular layer regions (panels 
4,5,9, and 10).   
 One HuMM mouse with survival time of 365 days was examined but was 
negative for PrPSc deposition.  A positive score at 407 days suggested that 350-400 
days was the approximate timescale for the onset of PrPSc deposition for the HuMM 
mice.  The first ICC positive HuMM mouse was found at 368 days for the vCJD 




 PrPSc deposition was identified in approximately half of the HuMV mice 
(8/17), first appearing at around 550 days, with seven mice negative by ICC between 
300 and 540 days.  There appears to be a 150 day lengthening of time to onset of 
PrPSc deposition in the HuMV mice compared to the HuMM mice.  If 550 day 
survival time was used as a cut-off point for calculating the attack rate then there 
were 8/10 positives which was similar to the data for vCJD (BSE) inoculation with 
the same cut-off time (11/13).  PrPSc deposition was targeted to the thalamic nuclei 
as seen in the vCJD (BSE) data.   
 Only a single HuVV mouse showed evidence of PrPSc deposition, at 869 
days post inoculation, with very limited deposition found only in the cerebellum.  
Sixteen mice were negative for deposition at survival times ranging from 162 to 764 
days.  The single positive HuVV mouse at 869 days suggested an increase in the 
time period before appearance of this CNS pathology, compared with HuMM and 
HuMV mice.   
 ICC positive 129Ola wild-type mice were first found at approximately 550 
days concurrent with the appearance of vacuolation.  The majority of this group of 
mice were positive (7/12) as was seen for vCJD (BSE) inoculation (6/6 tested that 
survived >450 days).  A characteristic of 129Ola mice inoculated with vCJD 
material was the targeting of PrPSc deposition to the CA2 region of the hippocampus 
(Brown et al., 2003).  This was seen for both vCJD (BSE) and vCJD (transfusion) 
inoculum (Figure 5.F8).   
 
Immunocytochemistry with anti-PrP antibody 6H4 (brown deposits) on progressive sections through HuMM mouse brains from front to 
rear.  vCJD (BSE) images from HuMM mouse (ID#108) 693 days post inoculation. vCJD (transfusion) images from HuMM mouse 
(ID#50) 708 days post inoculation. (Images at 1.6x magnification.)  Key: Cx: cerebral cortex; Hp: hippocampus; Th: thalamus; CbW: 
cerebellar white matter; GL: cerebellum granular layer; ML: cerebellum molecular layer; BS: brain stem 
 











Figure 5.F7:  ICC Detection of PrPSc in Hippocampus of HuMM Mice with 
vCJD 
PrPSc detection by ICC in the hippocampus and thalamus (lateral posterior nucleus) 
region of the brain, showing close similarities between the vCJD (BSE) (panel A) 
and vCJD (transfusion) (panel B) inocula, and the identification of florid plaques 
(40X magnification of florid plaque structure, see box lower left).  (Scale bar 




Figure 5.F8:  ICC Detection of PrPSc in Hippocampus of 129Ola Mice with 
vCJD 
PrPSc targeting to the CA2 region (arrowed) of the hippocampus in 129Ola mice 
challenged i.c. with A: vCJD (BSE) and B: vCJD (transfusion).  (Panel A mouse ID# 





5.3.6  Detection of PrPSc by Western Blot 
 The detection and characterisation of protease resistant fragments of PrPPSc 
by Western blotting can provide further evidence to define strain properties of the 
vCJD (transfusion) agent.  In addition to analysis of incubation periods and 
vacuolation scoring. PrPScP  found in the brain of this blood transfusion associated 
vCJD case and the case from which the blood donation originated were both 
characterised by a 19kDa non-glycosylated fragment and the predominance of the 
diglycosylated form (type 2B), typical of all vCJD cases (Head et al., 2004a, 
Llewelyn et al., 2004).   
 Western blot detection of PrPSc was performed on frozen brain material set 
aside during the post mortem of each mouse.  Both of the biochemical properties of 
vCJD strain PrPSc, discussed above, are maintained when vCJD (transfusion) is 
transmitted to the HuMM transgenic mice (Figure 5.F9).  Very low levels of PrPSc 
were seen in HuMV and HuVV mice by ICC and therefore future analysis of the 
frozen tissue will be by high sensitivity methods such a sodium phosphotungstic acid 




Figure 5.F9:  Western Blot of HuMM Mice Inoculated with vCJD (BSE) and 
vCJD (transfusion) 
Western blot of brain material from HuMM mice i.c. challenged with vCJD (BSE) 
and vCJD (transfusion) showing the same type 2B profile.  ‘T2B’: control vCJD 
brain homogenate.  Anti-PrP detection antibody: 6H4.  (D: diglycosylated, M: 
monoglycosylated, U: unglycosylated) 
 
 
5.4  DISCUSSION 
 The aim of this study was to find evidence for adaptation of vCJD 
transmission properties following human-to-human infection via blood transfusion, 
as this would have public health implications for the continuing spread of the 
disease.   
5.4.1  Evidence for Strain Adaptation from Clinical Findings and 
Survival Analysis 
 The number of transgenic mice scored positive for clinical TSE symptoms, 
HuMM (1/15) and HuMV (2/17), was as low as found previously with the vCJD 
(BSE) inoculum (HuMM: 2/18; HuMV: 1/17).  Once again there were no HuVV 
mice positive for clinical signs.  The 129Ola mice developed clinical TSE after a 
longer incubation period (mean 638 days) and in fewer mice (4/12) than seen for 
vCJD (BSE) (mean 498 days; rate 8/14).   
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 The transgenic data for the presence of clinical signs suggest that there has 
been no major adaptation of the infectious agent after passage from human-to-
human.  However, unlike vCJD (BSE) inoculation, survival analysis showed no 
difference between the HuMM mice and the other transgenic lines.  It was proposed 
that HuMM mice developed deleterious subclinical effects from the vCJD (BSE) 
inoculation, manifesting in a lower survival rate (See Chapter 4, section 4.4.2.1).  As 
HuMM mice inoculated with vCJD (transfusion) do not show the same effect this 
may point towards a minor change in the strain transmission properties.   
 The wild-type mice data also showed that the vCJD (transfusion) inoculum 
was less efficient in transmission to these mice.  This could suggest that either the 
inoculum is at a lower titre of infectivity, or there has been an adaptation of the agent 
by human passage.  There could have been a form of adaptation of the agent due to 
the intravenous route of infection (blood transfusion), rather than the oral route of 
BSE infection.  Alternative PrPPSc configuration or binding by chaperone proteins 
specific to the blood environment may alter the infectivity levels of the agent, 
although currently there is no evidence for this as disease associated forms of blood 
PrP have not been isolated and characterised.  The presence of PrPSc in hamster 
blood has been shown by the protein misfolding cyclic amplification (PMCA) 
method (Castilla et al., 2005).   
 If adaptation has occurred due to human passage, making it less 
transmissible to wild-type mice, then it would be expected that vCJD (BSE) 
transmission would give longer incubation periods than transmission of BSE derived 
from cattle.  Unpublished data from Dr P Hart (NPD) showed the mean incubation 
period of BSE inoculation in 129Ola wild-type mice (at 10% concentration) from six 
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independent experiments to be 405 days.  This was very similar to the 392 day mean 
incubation period from vCJD (BSE) inoculum at 10% concentration, suggesting that 
the initial cattle-to-human passage had not caused adaptation of the agent.  However, 
129Ola wild-type transmission data from this study indicated longer incubation 
periods found with vCJD (transfusion) inoculum.  Therefore a form of strain 
adaptation may have occurred following human-to-human transmission.  This effect 
could also be due to a lower titre of infectivity in the vCJD (transfusion) inoculum 
(Figure 5.F1).   
 If a lower titre of infectivity is the reason for the longer incubation period 
seen in 129Ola mice, and the shifted survival curve for the HuMM mice, inoculated 
with vCJD (transfusion) material, then possible reasons for this are: 
1. The two inocula were prepared differently.  The vCJD (BSE) inoculum was 
sourced from a preparation created as an international standard, in which a 
large amount of brain tissue (10 pieces of 10g each) was homogenised.  The 
vCJD (transfusion) inoculum was prepared from 1-2g of tissue sourced 
specifically for this experiment.  A 1% homogenate made of these two tissue 
preparations may therefore contain different amounts of PrPSc or infectivity 
dependent on the distribution of cells or tissue types included.   
2. Titre is likely to depend on the level of pathological change in the brain 
tissue selected for the inoculum.  Although both the vCJD (BSE) and vCJD 
(transfusion) cases developed clinical vCJD with similar disease durations 
(11 and 13 months respectively) they were of very different ages at onset (19 
and 68 respectively).  The older brain from the vCJD (transfusion) case is 
likely to have age related degeneration which may have reduced the levels of 
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infectivity.  In addition, this case did not have the characteristic magnetic 
resonance imaging (MRI) pattern in the brain, which was present in the 
vCJD (BSE) case.  This may also indicate distinct pathological features in 
this case, which could be associated with a reduced the titre of infectivity.   
 If the reason for changes in vCJD (transfusion) transmission properties was 
due to a minor strain adaptation this may have arisen because: 
 1. The intravenous route of exposure in human-to-human vCJD 
transmission may produce a less transmissible TSE than the original oral 
route of exposure to BSE.   
 2. Infectivity, including PrPSc, in vCJD (transfusion) material is of 
human and not bovine origin.   
 3. Humans may be an inefficient, or ‘dead-end’ host, for propagating 
the BSE strain resulting in a TSE disease strain that is less transmissible to 
further individuals.   
5.4.2  Evidence for Strain Adaptation from Vacuolation Scoring 
 The number of transgenic mice scored positive for TSE vacuolation, HuMM 
(8/15), HuMV (0/17), and HuVV (0/17) was approximately equal to that found 
previously for the vCJD (BSE) inoculum (HuMM: 6/18; HuMV: 1/16; HuVV: 1/16).  
The HuMM mice clearly develop this type of pathological change at an earlier time 
than the other genotypes suggesting an increased susceptibility with this genotype.  
The HuMM transgenic line showed a slight difference in attack rate; 8/15 (53%) for 
vCJD (transfusion) compared with 6/18 (33%) for vCJD (BSE).  However, this may 
be due to the difference in survival rate, as discussed in the previous section.  More 
HuMM mice inoculated with vCJD (transfusion) survived past 600 days, the point at 
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which vacuolation became more prominent with both inocula.  If the positive scoring 
rates are calculated for those mice that survived past 600 days then the results are: 
8/9 (89%) for vCJD (transfusion) and 4/5 (80%) for vCJD (BSE).   
 In accordance with the variation in levels of clinical positive scoring and 
mean incubation period, the number of wild-type mice found positive for vacuolation 
showed a difference between the two inocula.  The numbers were equal to those with 
clinical symptoms as each vacuolation positive mouse was also clinically positive 
(vCJD (transfusion) 4/12; vCJD (BSE) 8/14) (Table 5.T1).   
 Vacuolation scoring produced the lesion profiles shown in Figure 5.F4 and 
Figure 5.F5 for the HuMM and 129Ola wild-type mice.  These data suggest the 
reverse of the findings above, in that there are differences for the HuMM mice and 
close similarities for the wild-type mice, between each inoculum.  As the two lesion 
profiles for the wild-type mice were both generated from clinically positive animals 
it can be assumed that these mice had reached a similar pathological end-point.  In 
contrast, both groups of HuMM mice were at an undefined subclinical stage of 
disease development which may have affected the degree of vacuolation.  The 
difference seen for the HuMM mice (lower scores but similar pattern of targeting for 
the vCJD (transfusion) inoculum) indicate more strongly a titre effect rather than a 
strain adaptation as the regional targeting has not changed.  Comparing lesion 
profiles for sCJD and vCJD transmission in wild-type mice shows these regional 
differences associated with strain (Bruce et al., 1997).   
 Vacuolar pathology data outlined here shows differences between the vCJD 
(transfusion) data and that produced for vCJD (BSE) in Chapter 4, with respect to 
mice scored positive for TSE vacuolation, and the degree of vacuolation seen.  
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Whether these are attributable to changes in the TSE strain or infectivity titre are 
difficult to distinguish, but on this evidence it is likely that there has not been a 
significant adaptation of the infectious agent.   
5.4.3  Evidence for Strain Adaptation from Detection of PrPSc
 The number of transgenic mice scored positive for PrPSc detection by ICC 
(HuMM: 13/14, HuMV: 8/17, and HuVV: 1/17) was similar to that shown in 
Chapter 4 for vCJD (BSE) inoculum (HuMM: 12/16; HuMV: 11/14; HuVV: 1/15).  
This method gave many more positive scores than vacuolation scoring, especially for 
the HuMV line, and was therefore a good marker for detecting early signs of TSE 
disease transmission.  There were slightly less positive HuMV mice in the vCJD 
(transfusion) experiment, but this effect appears to be due to the loss of mice due to 
intercurrent deaths from non-TSE related causes.  Survival analysis did not indicate 
that there was a significant difference in this genotype line between inocula. (Figure 
5.F3)  The 550 day time-point is when deposition of PrPSc first becomes detectable 
by this method and this time-point was similar for both vCJD (BSE) and vCJD 
(transfusion) in the HuMV mice.  The timing for onset of detectable levels of PrPSc 
was similar for all three genotype transgenic lines with either inoculum, suggesting 
no evidence of strain adaptation.  The number of 129Ola wild-type mice positive for 
PrPSc shows no difference between the two inocula.   
 Regional distribution of PrPSc throughout the brain shows no evidence of 
differences between the two inocula.  There are clear similarities including the 
detection of florid plaques in the hippocampal region of HuMM mice only, the low 
levels only in the thalamus for HuMV mice, and the specific targeting of the CA2 
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region of the hippocampus for the 129Ola mice, all of which are indicative properties 
of typical vCJD / BSE transmissions (Figure 5.F7 and Figure 5.F8).   
 Western blotting of brain material from HuMM mice infected with vCJD 
(transfusion) inoculum shows the characteristic type 2B profile, giving further 
supportive evidence that this material contains the same strain as vCJD (BSE), as 
defined by the biochemical properties of PrPSc and its conversion of host PrPC.   
 The deposition and biochemical properties of PrPSc in the brains of 
transgenic mice inoculated with vCJD (transfusion) showed no evidence that human 
passage of vCJD has caused adaptation of the agent strain.   
5.4.4  Summary 
 In conclusion, this study indicates that the strain transmission characteristics 
of vCJD have not been significantly altered by secondary transmission through blood 
transfusion in an individual that was MM at codon 129 of PRNP.  This suggests that 
adaptation of the infectious agent to humans following secondary passage has not 
increased the risk of onward iatrogenic transmission of vCJD through routes such as 
blood transfusion, although this route of infection may increase the efficiency of 
transmission.  Data in this chapter suggest that human-to-human transmission of 
vCJD may even produce a strain with longer incubation periods, a lower infectious 
titre, or one that would not be sustained through serial passage.  MM genotype 
individuals are still likely to be the most susceptible in relation to those that are MV 
or VV. 
 The characteristics of the infectious vCJD agent from different genetic 
backgrounds (MV and VV) has not yet been defined.  Data in Chapter 4 (section 
4.3.2) indicate that regardless of the inoculum source genotype, sub-passage of the 
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vCJD strain will still preferentially affect MM over other genotypes.  Post mortem 
material from the sub-clinical MV genotype, blood transfusion associated, case has 
been inoculated into these transgenic mice, however the results were not available 
for inclusion in this thesis.  It is hoped that use of these mice lines will be of 





IDENTIFYING THE UNIQUE TRANSMISSION 
PROPERTIES OF SPORADIC CJD SUBGROUPS 
DEFINED BY THE PRNP CODON 129 
GENOTYPE AND PRPSC TYPE 
 
6.1  AIMS 
 In sporadic CJD patients the PRNP genotype at codon 129 and the PrPSc 
Western blot type combine to form six subgroups (MM1, MM2, MV1, MV2, VV1, 
and VV2) that has formed a basis for defining typical cases of sCJD since the 
publication in 1999 (Parchi et al., 1999) (See Introduction, section 1.6.1 Sporadic 
CJD).  Should each of the six subtypes show unique transmission properties to the 
panel of three transgenic lines, then these data can be used as a comparative tool for 
investigating atypical forms of sCJD, or novel forms of acquired human TSE, for 
example from atypical BSE or atypical scrapie.   
 To define the role of codon 129 genotype in transmission of sCJD, each of 
the three transgenic mouse lines (HuMM, HuMV, and HuVV) were inoculated with 
infectious material from sCJD sources also from each of the three genotypes.  
Understanding how the host codon 129 genotype influences susceptibility may 
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provide evidence for individual risk in humans from iatrogenic infection via sCJD 
sources.   
 Intracerebral inoculation of sCJD brain homogenate from six typical cases 
was performed on the three transgenic lines and the 129Ola wild-type line.  These 
mice were assessed clinically for signs of TSE disease, and pathologically for TSE 
associated vacuolation (lesion profiling), and targeting and biochemistry of the 
disease associated PrPSc.  Brain material from HuVV mice that developed TSE after 
inoculation with sCJD(MV2) was also inoculated into further transgenic and wild-
type mice to confirm the infectious nature of the transmitted TSE disease and 
observe strain adaptation in the transgenic host.  This was the only subpassage that 
could be performed during the timescale of this thesis because of the fast incubation 
period seen in the HuVV mice with sCJD(MV2).   
 
6.2  INTRODUCTION 
6.2.1  Characterisation of sCJD Subgroups as Unique Transmissible 
Strains 
 Sporadic CJD is, as the name suggests, the idiopathic form of Creutzfeldt-
Jakob disease.  There is much that remains to be understood about how and why this 
disease occurs and the specific biochemical and cellular pathogenesis that leads to 
the neurodegenerative phenotype.  Most frequently sCJD is a rapidly progressive 
dementia that occurs in elderly people between 60 and 70 years of age, and has a 
short clinical duration of weeks to a few months.  The ‘classical’ clinical 
presentation of sCJD that is most often observed occurs in individuals who are 
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homozygous for methionine (MM) at codon 129 of the prion protein gene, and 
following post mortem, biochemical analysis shows the type 1, monoglycosylated 
dominant, Western blot profile of protease treated prion protein (PrPres or PrP PSc) (See 
Introduction section 1.3.1, Figure 1.F3.).  The clinical presentation and variation in 
neuropathological features has allowed sCJD cases to be grouped according to the 
codon 129 genotype and PrP Western blot profile (type 1 or 2) (Parchi et al., 1999, 
Hill et al., 2003, Cali et al., 2006).   
6.2.2  Role of Codon 129 Genotype and PrPPSc Type in Transmission of 
sCJD 
 For the purpose of this study of sCJD transmission properties, six cases 
were selected, each of which showed the typical characteristics of the subgroup: 
MM1, MM2, MV1, MV2, VV1, and VV2 (See Introduction, section 1.6.1 Sporadic 
CJD).  Inoculation of HuMM, HuMV, and HuVV mice that are genetically identical, 
except for the polymorphism at codon 129 of their transgene, allowed direct 
comparisons to be made, to determine the influence of both inoculum and host 
genotype, and the effect of inoculum PrPSc type.   
 
6.3  EXPERIMENTAL RESULTS 
6.3.1  Primary Intracerebral Inoculation of sCJD 
Eighteen mice of each line (HuMM, HuMV, HuVV, 129Ola) were 
inoculated by the intracerebral (i.c.) route.  As these were primary inoculations, the 
i.c. route was chosen to provide the best chance of infection and the group size was 




transgenic mouse life-span (~700-800 days).  Inoculum was prepared from frontal 
cortex provided by Prof. James Ironside and Ms. Chris-Anne McKenzie (National 
CJD Surveillance Unit - NCJDSU) from typical sCJD cases of each subgroup as 
confirmed by clinical investigation and pathological analysis carried out by staff at 
NCJDSU.   
Case references are: 
sCJD(MM1):  CJDSU reference RU 98/088  (NPD Protocol: 553D-1A) 
sCJD(MM2):  CJDSU reference RU 98/073  (NPD Protocol: 553L-1A) 
sCJD(MV1):  CJDSU reference RU 99/072  (NPD Protocol: 553N-1A) 
sCJD(MV2):  CJDSU reference RU 98/123  (NPD Protocol: 553C-1A) 
sCJD(VV1):  CJDSU reference RU 96/027  (NPD Protocol: 553M-1A) 
sCJD(VV2):  CJDSU reference RU 94/083  (NPD Protocol: 553E-1A) 
 
6.3.1.1  Mouse Data Tables 
Intercurrent illness and death reduced the total mice available for studying 
transmission properties over the lifespan of the mice but sufficient mice survived to 
observe clinical and pathological signs of disease transmission.  Tables 6.T1 to 6.T6 
show the evaluation of all mice in this study.  Highlighted in grey in these Tables are 
the mice positive for clinical signs of transmissible spongiform encephalopathy 
(TSE) confirmed by pathology (either the presence of TSE associated vacuolation 
and/or the identification of abnormal deposition of PrP by immunocytochemistry 
(ICC)).  Also highlighted are the vacuolation or ICC positive mice that were culled 
for other, non-clinical TSE reasons (intercurrent deaths).   
 
 
Table 6.T1:  Data Table for sCJD(MM1) Inoculation 
Intracerebral inoculation data (protocol reference 553D-1A) for sCJD(MM1) 
Abbreviations: CLIN: clinical score; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: 
intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; End expt: 


























































































































59 345 ICD Neg Pos Pos 44 279 ICD Neg Pos Pos 136 233 ICD Pos Neg Neg 122 394 ICD Neg Neg n/t 
58 352 ICD Neg Pos Pos 46 366 ICD Neg Pos Pos 41 236 ICD Neg Neg Neg 125 471 ICD Neg Neg n/t 
108 401 ICD Neg Pos Pos 42 387 TSE Pos Pos Pos 132 485 ICD Neg Pos Pos 120 531 ICD Neg Neg n/t 
109 436 TSE Pos Pos Pos 146 387 ICD Neg Pos Pos 36 513 TSE Pos Pos Pos 98 548 ICD Neg Pos Pos 
111 436 TSE Pos Pos Pos 43 447 TSE Pos Pos Pos 133 527 ICD Neg Pos Pos 75 562 TSE Pos Pos Pos 
112 436 TSE Pos Pos Pos 147 448 ICD Neg Pos Pos 135 541 TSE Pos Pos Pos 72 569 ICD Neg Pos Pos 
171 442 TSE Pos Pos Pos 144 454 TSE Pos Pos Pos 28 548 TSE Pos Pos Pos 99 580 ICD Neg n/d n/t 
174 442 TSE Pos Pos Pos 154 454 TSE Pos Pos Pos 134 555 TSE Pos Pos Pos 121 597 ICD Neg Neg n/t 
55 447 TSE Pos Pos Pos 159 454 TSE Pos Pos Pos 26 563 ICD Neg Pos Pos 77 604 ICD Neg Pos Pos 
110 447 TSE Pos Pos Pos 145 456 TSE Pos Pos Pos 137 583 ICD Neg Neg Pos 73 611 TSE Pos Pos Pos 
56 454 TSE Pos Pos Pos 143 478 TSE Pos Pos Pos 30 584 ICD Pos Pos Pos 101 612 ICD Neg n/d n/t 
57 454 TSE Pos Pos Pos 158 484 TSE Pos Pos Pos 37 611 ICD Neg Pos Pos 100 630 ICD Neg Pos Pos 
170 466 TSE Pos Pos Pos 155 487 ICD Neg Pos Pos 29 625 TSE Pos Pos Pos 74 702 End expt Neg Pos Pos 
      47 499 TSE Pos Pos Pos 27 667 TSE Pos Pos Pos 97 730 End expt Neg Pos Pos 
            40 667 TSE Pos Pos Pos 102 730 End expt Neg Pos Pos 
            25 702 End expt Neg Pos Pos 123 737 End expt Neg Pos Pos 
                        
                        
                        




Table 6.T2:  Data Table for sCJD(MM2) Inoculation 
Intracerebral inoculation data (protocol reference 553L-1A) for sCJD (MM2) 
Abbreviations: CLIN: clinical score; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: 
intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; End expt: 

























































































































153 232 ICD Neg Neg n/t 132 322 ICD Neg Neg n/t 114 147 ICD Neg Neg n/t 188 486 ICD Neg Neg n/t 
146 244 ICD Neg Neg n/t 138 358 ICD Neg Neg n/t 62 259 ICD Neg Neg n/t 189 512 TSE Pos Neg n/t 
69 280 ICD Neg Neg n/t 79 434 ICD Neg Neg n/t 137 268 ICD Neg Neg n/t 187 537 ICD Neg Neg n/t 
64 337 ICD Neg Neg n/t 98 438 ICD Neg Neg n/t 131 364 ICD Neg Neg n/t 186 589 ICD Neg Neg n/t 
63 403 ICD Neg Neg n/t 112 466 ICD Neg Neg n/t 147 384 ICD Neg Neg n/t 193 617 ICD Neg Neg n/t 
154 504 ICD Neg Neg n/t 130 497 ICD Neg Neg n/t 129 402 ICD Neg Neg n/t 158 629 ICD Neg Neg n/t 
72 511 ICD Neg Neg n/t 75 510 ICD Neg Neg n/t 51 423 ICD Neg Neg n/t 195 631 ICD Neg Neg n/t 
85 538 ICD Neg Neg n/t 111 522 ICD Neg Neg n/t 66 493 ICD Neg Neg n/t 159 634 ICD Neg Neg n/t 
134 546 ICD Neg Neg n/t 60 525 ICD Neg Neg n/t 110 493 ICD Neg Neg n/t 161 658 ICD Neg Neg n/t 
117 560 ICD Neg Neg n/t 102 558 ICD Neg Neg n/t 155 536 ICD Neg Neg n/t 81 665 ICD Neg Neg n/t 
100 567 ICD Neg Neg n/t 65 560 ICD Neg Neg n/t 61 539 ICD Neg Neg n/t 192 673 ICD Neg Neg n/t 
113 593 ICD Neg Neg n/t 68 560 ICD Neg Neg n/t 67 565 ICD Neg Neg n/t 191 687 ICD Neg Neg n/t 
71 616 ICD Neg Neg n/t 76 588 ICD Neg Neg n/t 78 627 ICD Neg Neg n/t 160 721 ICD Neg Neg n/t 
135 637 ICD Neg Neg n/t 77 602 TSE Pos Neg n/t 74 654 ICD Neg Neg n/t 190 750 ICD Neg Neg n/t 
101 651 ICD Neg Neg n/t 80 602 ICD Neg Neg n/t 73 658 ICD Neg Neg n/t 83 784 TSE Pos Neg n/t 
84 658 ICD Neg Neg n/t 70 614 ICD Neg Neg n/t 52 678 ICD Neg Neg n/t 82 805 ICD Neg Neg n/t 
      136 651 ICD Neg Neg n/t 103 735 ICD Neg Neg n/t       
      53 678 ICD Neg Neg n/t             
                        




Table 6.T3:  Data Table for sCJD(MV1) Inoculation 
Intracerebral inoculation data (protocol reference 553N-1A) for sCJD(MV1) 
Abbreviations: CLIN: clinical score; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: 
intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; End expt: 

























































































































20 400 TSE Pos Pos n/t 3 232 ICD Neg Pos n/t 93 162 ICD Neg Neg n/t 82 314 ICD Neg Neg n/t 
21 407 ICD Neg Pos n/t 117 298 ICD Neg Neg n/t 140 241 ICD Neg Neg n/t 52 380 ICD Neg Neg n/t 
172 429 TSE Pos Pos n/t 60 338 ICD Neg Pos n/t 5 260 ICD Neg Neg n/t 53 413 ICD Neg Neg n/t 
174 429 TSE Pos Pos n/t 1 414 TSE Pos Pos n/t 141 303 ICD Neg Pos n/t 51 455 ICD Neg Neg n/t 
161 436 TSE Pos Pos n/t 118 436 TSE Pos Pos n/t 8 323 ICD Neg Pos n/t 115 457 TSE Pos Neg n/t 
170 436 TSE Pos Pos n/t 119 436 TSE Pos Pos n/t 64 360 ICD Neg Pos n/t 54 498 ICD Neg Neg n/t 
171 436 TSE Pos Pos n/t 154 436 TSE Pos Neg n/t 144 435 TSE Pos Pos n/t 113 499 ICD Neg Neg n/t 
164 443 TSE Pos Pos n/t 58 443 TSE Pos Pos n/t 92 449 ICD Neg Pos n/t 83 534 ICD Neg Neg n/t 
162 450 TSE Pos Pos n/t 4 449 TSE Pos Pos n/t 142 457 ICD Neg Pos n/t 168 548 ICD Neg Neg n/t 
163 450 TSE Pos Pos n/t 2 470 TSE Pos Pos n/t 143 497 ICD Neg Pos n/t 84 554 ICD Neg Neg n/t 
166 450 TSE Pos Pos n/t 150 478 TSE Pos Pos n/t 94 499 ICD Neg Pos n/t 111 555 ICD Neg Neg n/t 
18 456 TSE Pos Pos n/t 151 478 TSE Pos Pos n/t 7 515 TSE Pos Pos n/t 167 561 ICD Neg Neg n/t 
16 464 TSE Pos Pos n/t 56 513 TSE Pos Pos n/t 176 583 ICD Neg Pos n/t 55 575 ICD Neg Neg n/t 
165 464 TSE Pos Pos n/t 57 513 TSE Pos Pos n/t 62 645 TSE Pos Pos n/t 85 584 ICD Neg Neg n/t 
17 470 TSE Pos Pos n/t 59 513 TSE Pos Pos n/t 175 647 ICD Pos Pos n/t 112 639 ICD Neg Pos n/t 
19 470 TSE Pos Pos n/t 61 513 TSE Pos Pos n/t 6 659 TSE Pos Pos n/t 114 660 ICD Neg Neg n/t 
      153 513 TSE Pos Pos n/t 9 659 TSE Pos Pos n/t 116 716 ICD Neg Neg n/t 
      152 520 TSE Pos Pos n/t 63 660 TSE Pos Pos n/t       
                        





Table 6.T4:  Data Table for sCJD(MV2) Inoculation 
Intracerebral inoculation data (protocol reference 553C-1A) for sCJD(MV2) 
Abbreviations: CLIN: clinical score; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: 
intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; End expt: 

























































































































69 258 TSE Pos Neg Neg 55 223 ICD Neg Neg Neg 106 247 ICD Neg Pos Pos 86 314 TSE Pos Neg n/t 
118 295 ICD Neg Neg n/d 174 341 ICD Neg Neg Pos 96 267 TSE Pos Pos Pos 27 342 ICD Neg Neg n/t 
119 479 ICD Neg Pos Pos 209 394 ICD n/s Neg Pos 102 271 ICD Pos Pos Pos 28 406 ICD Neg n/d n/t 
170 496 ICD Neg Neg n/d 206 398 ICD Neg Neg Neg 214 279 TSE Pos Pos Pos 87 427 ICD Neg Neg n/t 
170 496 ICD Neg Neg Pos 159 426 ICD Neg Neg Pos 103 279 ICD Pos Pos n/d 73 503 ICD Neg Neg Neg 
171 521 ICD Neg Pos Pos 160 426 ICD Neg Neg Pos 104 279 TSE Pos Pos Pos 25 509 ICD Neg Neg Neg 
111 545 ICD Neg Pos Pos 157 479 ICD Neg Neg Pos 107 279 TSE Pos Pos Pos 30 534 ICD Neg Neg Neg 
109 559 TSE Pos Pos Pos 176 503 ICD Neg Pos Pos 97 280 TSE Pos Pos Pos 84 545 ICD Neg Neg Neg 
70 565 TSE Pos Pos Pos 60 538 ICD Neg Neg Pos 215 290 ICD Pos n/d Pos 88 559 ICD Neg Neg Neg 
67 566 TSE Pos Pos Pos 156 538 TSE Pos Neg Pos 101 290 TSE Pos Pos Pos 26 565 ICD Neg Neg Neg 
168 577 ICD Neg Pos Pos 207 559 ICD Neg Pos Pos 211 293 ICD Pos Pos n/d 77 668 ICD Neg Neg Neg 
169 584 ICD Neg Pos Pos 178 566 ICD Neg Neg Pos 164 293 TSE Pos Pos Pos 89 692 ICD Neg Neg Neg 
173 643 ICD Neg Pos Pos 161 612 TSE Pos Neg Pos 167 293 TSE Pos Pos Pos 75 717 End expt Neg Neg Neg 
      57 714 End expt Neg Pos Pos 163 299 TSE Pos Pos Pos 76 720 End expt Neg Neg Neg 
      59 714 End expt Neg Pos Pos 98 300 TSE Pos Pos Pos       
      205 714 End expt Neg Pos Pos 100 306 TSE Pos Pos Pos       
      208 714 End expt Neg Pos Pos 99 308 TSE Pos Pos Pos       
                        
                        




Table 6.T5:  Data Table for sCJD(VV1) Inoculation 
Intracerebral inoculation data (protocol reference 553M-1A) for sCJD(VV1) 
Abbreviations: CLIN: clinical score; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: 
intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; End expt: 
mice that were culled when the experiment was terminated at 700 days; shaded cell: positive score 
 
 





















































































































102 260 ICD Neg Neg n/t 3 239 ICD Neg Neg n/t 57 315 ICD Neg Neg n/t 158 379 ICD Neg Neg n/t 
67 267 ICD Neg Neg n/t 109 343 ICD Neg Neg n/t 78 337 ICD Neg Neg n/t 153 442 ICD Neg Neg n/t 
71 462 ICD Neg Neg n/t 63 379 ICD Neg Neg n/t 112 384 ICD Neg Neg n/t 161 456 ICD Neg Neg n/t 
99 481 ICD Neg Neg n/t 5 428 ICD Neg Neg n/t 54 400 ICD Neg Neg n/t 155 477 ICD Neg Neg n/t 
103 504 ICD Neg Neg n/t 106 546 TSE Pos Pos n/t 113 430 ICD Neg Pos n/t 30 491 ICD Neg Neg n/t 
100 533 ICD Neg Neg n/t 107 568 TSE Pos Pos n/t 76 505 ICD Neg Neg n/t 33 561 ICD Neg Neg n/t 
49 536 ICD Neg Neg n/t 110 575 ICD Neg Pos n/t 111 526 ICD Neg Pos n/t 154 588 ICD Neg Neg n/t 
51 540 ICD Neg Neg n/t 108 603 ICD Neg Neg n/t 56 540 ICD Neg Neg n/t 157 596 ICD Neg Neg n/t 
70 559 ICD Neg Neg n/t 105 610 ICD Neg Pos n/t 59 568 TSE Pos Pos n/t 31 611 ICD Neg Neg n/t 
53 603 ICD Neg Neg n/t 60 644 ICD Neg Pos n/t 75 568 TSE Pos Pos n/t 156 630 ICD Neg Neg n/t 
52 609 ICD Neg Neg n/t 2 651 ICD Neg Pos n/t 58 575 ICD Neg Neg n/t 32 638 TSE Pos Neg n/t 
101 610 ICD Neg Neg n/t 4 651 ICD Neg Pos n/t 74 610 ICD Neg Pos n/t 34 659 ICD Neg Neg n/t 
68 618 ICD Neg Neg n/t 104 676 ICD Neg Pos n/t 79 631 ICD Neg Pos n/t 169 694 ICD Neg Neg n/t 
66 639 ICD Neg Neg n/t 6 694 ICD Neg Pos n/t 72 635 ICD Neg Pos n/t 171 729 ICD Neg Neg n/t 
50 644 ICD Neg Neg n/t             168 778 ICD Neg Pos n/t 
69 687 ICD Neg Neg n/t             160 785 ICD Pos Neg n/t 
                        
                        
                        





Table 6.T6:  Data Table for sCJD(VV2) Inoculation 
Intracerebral inoculation data (protocol reference 553E-1A) for sCJD(VV2) 
Abbreviations: CLIN: clinical score; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: 
intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; End expt: 
mice that were culled when the experiment was terminated at 700 days; shaded cell: positive score 





















































































































157 278 ICD Neg Neg Neg 111 330 ICD Neg Neg Neg 165 258 ICD Neg Pos n/t 22 231 ICD Neg Neg n/t 
180 337 ICD Neg Neg Neg 80 416 ICD Neg Neg n/t 46 259 TSE Pos Pos Pos 130 245 ICD Neg Neg n/t 
177 355 ICD Neg Neg Pos 106 450 TSE Pos Neg Pos 54 261 TSE Pos Pos Pos 19 325 ICD Neg Neg n/t 
181 400 TSE Pos Neg n/t 112 538 ICD Neg Neg Pos 47 261 TSE Pos Pos Pos 127 378 ICD Neg Neg n/t 
94 436 ICD Neg Neg Pos 110 562 ICD Neg Neg Neg 167 261 TSE Pos Pos Pos 132 409 ICD Neg Neg n/t 
160 436 ICD Neg Neg Pos 104 580 ICD Neg Neg Pos 48 268 TSE Pos Pos Pos 128 422 ICD Neg Neg n/t 
179 447 TSE Pos Neg Pos 113 595 ICD Neg Neg Pos 164 268 TSE Pos Pos Pos 134 422 ICD Neg Neg Neg 
176 455 ICD Neg Neg Pos 109 599 ICD Neg Neg Pos 166 268 TSE Pos Pos Pos 129 485 ICD Neg Neg Neg 
183 462 ICD Neg Neg Pos 81 611 ICD Neg Neg Pos 45 272 TSE Pos Pos Pos 138 524 ICD Neg Neg Neg 
96 469 ICD Neg Neg Pos 105 618 ICD Neg Pos Pos 44 279 ICD Neg Pos Pos 131 562 ICD Neg Neg Neg 
174 482 ICD Neg Neg Pos 85 629 ICD Neg Neg Pos 162 282 TSE Pos Pos Pos 136 618 ICD Neg Neg Neg 
182 491 ICD Neg Neg Pos 82 723 End expt Neg Pos Pos 59 284 ICD Neg Pos Pos 137 625 ICD Neg Neg Neg 
159 581 TSE Pos Pos Pos 84 723 End expt Neg Pos Pos 56 288 TSE Pos Pos Pos 133 660 ICD Neg Neg Neg 
158 646 TSE Pos Pos Pos 108 729 End expt Neg Pos Pos 57 289 TSE Pos Pos Pos 20 709 End expt Neg Neg Neg 
161 653 TSE Pos Pos Pos 115 730 End expt Neg Pos Pos 55 293 TSE Pos Pos Pos 21 709 End expt Neg Neg Neg 
92 710 ICD Neg Pos Pos       58 293 TSE Pos Pos Pos 23 709 End expt Neg Neg Neg 
93 723 End expt Neg Pos Pos             24 709 End expt Neg Neg n/t 
97 723 End expt Neg Pos P  
 
 
os                   
                        
                        
                        




6.3.1.2  Survival Analysis to Investigate Clinical and Subclinical TSE 
An analysis of the survival rates was performed because of the absence of 
clinical TSE signs in many groups of inoculated mice and the large number of mice 
that died or were culled on animal welfare grounds (intercurrent deaths), during the 
course of the experiments.  These deaths may be due in part to an underlying effect 
of the inoculum and the numbers may vary according to the codon 129 genotype of 
the mouse.  To observe the effects on overall survival rates between the different 
inocula and mice lines Kaplan-Meier survival curves were drawn and Tarone-Ware 
tests performed (Software: SPSS v14.0).  Tarone-Ware tests have even bias across 
the lifespan of the mice whereas Log Rank (Mantel-Cox) tests apply more weight to 
late time points and Breslow (Generalised Wilcoxon) tests apply more weight to 
early time points.   
Figure 6.F1 shows Kaplan-Meier survival curves for all the experiments in 
this study.  The majority of mice survived until approximately 300-400 days then 
were lost gradually, but uniformly over time, with 50% alive at 500-600 days and 
all dead by 700-800 days (some experiments were terminated at around 700-750 
days with the remaining few mice culled).  The panel of ‘uninfected’ mice, that 
were left to age naturally, showed a similar pattern.  Therefore the majority of mice 
in this study, although inoculated with TSE material followed the normal pattern of 
aging. 
6.3.1.2.1  Effect of Inoculum Source on Survival 
Figure 6.F1 shows the Kaplan-Meier curves for each inoculum used and 
Table 6.T7 highlights the statistically significant comparisons.  These data have been 
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prepared to provide a clearer method of understanding which sCJD source of 
infectivity has a dominant role in the transmission to the transgenic mice, and 
whether each sCJD subgroup has specific effects.  Those mice groups that developed 
clinical TSE signs showed near vertical survival curves, compared to other groups 
whose curves were less steep  (For examples, see Figure 6.F1, Panels sCJD(MV2) 
and sCJD(VV2)).  These latter mice may have developed subclinical TSE or may be 
unaffected, and statistical comparisons can highlight the degree to which subclinical 
disease is present and in what genotypes of mice.  As an example, for sCJD(MM2) 
inoculation both the wild-type and transgenic mice were all negative clinically and 
for TSE vacuolation indicating that there did not seen to be an effect attributable to 
expression of the human prion protein.  However, the Tarone-Ware test showed a 
significant difference between survival in the wild-type line compared with each of 
the transgenic mice lines (P<0.01).   
A difference in the response of the HuVV mice to the sCJD(MM1) and 
sCJD(MV1) inocula was also detected by the Tarone-Ware test, showing a more 
detrimental effect from the sCJD(MV1) inoculum (no difference between the HuVV 
mice and the other transgenic lines).   
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Table 6.T7:  Tarone-Ware Analysis by sCJD Inoculum 
Statistical analysis of survival data by inoculum group, significant findings only 
(Tarone-Ware Test; *: P<0.05; **: P<0.01; ***: P<0.001). 
 
Inoculum Groups Tested P value  (significance rating) 
sCJD(MM1) HuMM and/or HuMV vs. 
HuVV and/or 129Ola 
P<0.001         *** 
sCJD(MM2) 129Ola vs. Rest 
 
P<0.01             ** 
sCJD(MV1) HuMM vs. 129Ola 
HuMV vs. 129Ola 
P=0.001           ** 
P=0.004           ** 
sCJD(MV2) HuVV vs. Rest 
 
P<0.001        *** 
sCJD(VV1) HuVV vs. 129Ola 
 
P=0.026            * 
sCJD(VV2) HuVV vs. Rest 
 
P<0.001        *** 
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Figure 6.F1:  Kaplan-Meier Survival Curves for Primary sCJD Inoculation 
Kaplan-Meier survival curves of uninfected mice, and primary i.c. challenge of sCJD 
to investigate effects of the inoculum. (HuMM (blue squares), HuMV (green 
diamonds), HuVV (red triangles), 129Ola (black open circles) mice, x-axis: days 




























































6.3.1.2.2  Effect of Mouse Codon 129 Genotype on Survival 
In addition to each individual inoculum having an effect on transmission 
properties, there could be a more dominant role for the host mouse codon 129 
genotype.  To test this, survival analysis was performed on data grouped according to 
codon 129 genotype.  If there were effects due to the host genotype then it would be 
expected that all inocula would produce similar survival curves in one genotype line.  
Figure 6.F2 shows the Kaplan-Meier curves grouped for each mouse line genotype 
and Table 6.T8 highlights the statistically significant comparisons.   
The data in Table 6.T8 show that there were differences between the inocula 
(as shown below) but that these were specific to the genotype of the mice.  The 
HuMM data show that there were differences between both sCJD(MM1) and 
sCJD(MV1) inocula and the others, and uninfected mice.  Similarly the HuMV data 
show these differences for the sCJD(MM1) and sCJD(MV1) inoculations.  The 
HuVV data highlighted the clear differences seen between inocula from sCJD(MV2) 
and sCJD(VV2) sources, and the rest of the inocula and the uninfected mice.   
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Figure 6.F2:  Kaplan-Meier Survival Curves Grouped by Mouse Line 
Kaplan-Meier survival curves following primary i.c. challenge of sCJD grouped by 
mouse line.  (Blue square sCJD(MM1), green diamond sCJD(MM2), red triangle 
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Table 6.T8:  Tarone-Ware Analysis Grouped by Mouse Genotype 
Primary sCJD transmissions, pairwise survival analysis by genotype. (Tarone-Ware 
Test -  only data with significance P<0.05 shown.) 
 
HuMM MM1 MM2 MV1 
MM2 0.016 / / 






HuMV MM1 MM2 MV1 
MM2 =0.001 / / 
MV1   0.002 / 
MV2  0.016 0.037
VV1  0.005 0.003
VV2  <0.001 0.047 <0.001
 
 
HuVV MM1 MM2 MV1 MV2 VV1 VV2 
MM1 / / / / / / 
MM2  / / / / / 
MV1  / / / / 
MV2 <0.001 <0.001 <0.001 / / / 
VV1  <0.001 / / 
VV2 <0.001 <0.001 <0.001 0.016 <0.001 / 




6.3.1.3  Incubation Period Variation Determined by Codon 129 Genotype of 
Inoculum and Host 
Survival analysis can determine an effect of the inoculum or host without 
clinical signs of TSE being present.  There were however, some inoculated groups of 
transgenic mice that developed clinical TSE signs, and therefore an assessment was 
made of the mean incubation time across the different inocula and genotype of hosts.   
A direct comparison of the incubation time data for the mice showing 
clinical TSE symptoms is shown in Table 6.T9.  The presence / absence, and time of 
onset, of clinical manifestation of TSE disease was dependent on both the genotype 
of the host mouse and the inoculum.  No two primary transmission experiments gave 
the same result suggesting that each source of sCJD is a separate strain, although 
there were some similarities.  SCJD types MM1 and MV1 which are combined by 
the Parchi classification (Parchi et al., 1999), both being the ‘classical’ form of 
sCJD, showed very similar incubation time data for the transgenic lines and only 
differed in that the MM1 type produced clinical TSE in the wild-type mice.  The 
other similar grouping was between the MV2 and VV2 inocula.  Both produced 
clinical disease with relatively short incubation times (<300 days) in the HuVV 
mice, but long incubation times in a few HuMM and HuMV mice.  There was no 
evidence of a difference between these two inocula.  Although the HuMV mice 
showed different incubation periods between MV2 and VV2 inocula these data were 
limited to too few mice to compare accurately.   
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Table 6.T9:  Incubation Period Data for sCJD Inoculation 
Incubation periods for clinically positive mice shows variation between inocula and 
mouse lines.  (mean (range); ‘attack rate’ and percentage; n/d: no clinical disease) 
 
Inoculum HuMM HuMV HuVV 129Ola 











n/d n/d n/d 































6.3.1.4  Vacuolation Scoring 
Examination of the neuropathology of these mice allowed further dissection 
of the similarities and differences in transmission.  All mice in this study were scored 
blind for the degree and location of TSE vacuolation according to the lesion profiling 
methods used on all mice at NPD, by their trained staff (Aileen Boyle, Wing-Gee 
Lui, and Sandra Mack).  Presence of TSE associated vacuolation gave the positive 
scores found in Tables 6.T1 to 6.T6 (column VACN).  In general there was a higher 
rate of positive scores than for clinical positives.  Further examination can be made 
of the differences and similarities between the sCJD inocula, and the effect of host 
codon 129 genotype.  Table 6.T10 shows the comparison of these data.   
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Wild-type 129Ola mice data have been included as there was a clear 
difference between the number of positive mice for the sCJD(MM1) and 
sCJD(MV1) inocula (71% versus 6% respectively).  These two inocula were 
otherwise identical for vacuolation scoring in the transgenic lines, with ~100% of 
HuMM and HuMV mice, and ~80% of HuVV mice positive.  Sporadic CJD cases of 
the MM1 and MV1 types are group together as the ‘classical’ form, with similar 
clinical and pathological features, and so the apparent close similarities in 
transmission properties in the transgenic mice may be expected.   
Inocula from sCJD(MV2) and sCJD(VV2) showed similar responses from 
the different mice lines.  The short incubation periods seen in the HuVV mice were 
reflected in 100% scores for vacuolation, and the HuMV mice gave equal scores of 
33% positive.  There was some variation for the HuMM mice with 69% positive with 
sCJD(MV2) inoculum compared with 33% with the sCJD(VV2) source.  129Ola 
wild-type mice were negative for both inocula.   
The sCJD(VV1) inoculum showed no evidence of vacuolation in the 
HuMM mice and only a single positive wild-type mouse, and ~50% were positive 
for the other two transgenic lines.  Lastly, the sCJD(MM2) inoculum showed no 
evidence of TSE vacuolation in any of the four mouse lines.   
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Table 6.T10:  Vacuolation Scoring Data for sCJD Inoculation 
Summary and comparison of positive scores (attack rates) for TSE vacuolation 
assessment. 
 
Inoculum HuMM HuMV HuVV 129Ola 
MM1 13/13 100% 14/14 100% 13/16 81% 10/14 71%
MM2 0/16 - 0/18 - 0/17 - 0/16 - 
MV1 16/16 100% 16/18 89% 15/18 83% 1/17 6% 
MV2 9/13 69% 6/17 35% 16/16 100% 0/13 - 
VV1 0/16 - 9/14 64% 7/14 50% 1/16 6% 
VV2 6/18 33% 5/15 33% 16/16 100% 0/17 - 
 
6.3.1.5  Lesion Profile Comparison 
 In addition to the positive / negative scoring for TSE vacuolation, each 
mouse was scored for the degree of vacuolation (ranked 1 to 5 with 1 the least 
affected) found in nine grey matter regions and three white matter regions, combined 
to produce a mean lesion profile (See Methods).  Figure 6.F3 shows the lesion 
profiles generated.  SCJD(MM2) is absent as there were no mice positive for 
vacuolation.   
 Comparing the data between mouse lines for each inoculum and also 
between the separate inocula should provide evidence for the role each is playing 
with respect to the targeting and intensity of TSE vacuolation.  There were close 
similarities, as found previously, between sCJD(MM1) and sCJD(MV1), and all 
three transgenic lines appeared to have similar lesion profiles for either inoculum.   
 The sCJD(MM1) inoculum was the only one to give positive scores in the 
wild-type mice.  The lesion profile from these mice is included in Figure 6.F3 and 
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showed clear differences, including a greater intensity of vacuolation at grey matter 
region three, the superior colliculus.  Pathological targeting of this region, associated 
with processing sensory information and corresponding head and eye movements, 
may have triggered earlier onset of clinical TSE symptoms in these mice.   
Lesion profiles produced for transmission of sCJD(MV2) and sCJD(VV2) 
showed close similarities for the HuMM and HuVV mice whereas the HuMV data 
were different.  The data for sCJD(VV1) transmission gave profiles for HuMV and 
HuVV only and these were different from the other inocula.  These data provided 
some evidence that a combination of both inoculum source and host codon 129 
genotype can affect the overall transmission properties of each subgroup of sCJD to 
the transgenic mice.  A statistical approach to lesion profile comparison was made to 




Figure 6.F3:  Lesion Profile Data for sCJD Inoculations 
Lesion profile variation according to inoculum, in HuMM (blue squares), HuMV 
(green diamonds), HuVV (red triangles), and 129Ola (black circles) mice. (Error 



































6.3.1.6  Hierarchical Cluster Analysis of Lesion Profile Data 
Comparative analysis can be achieved ‘by eye’ for the lesion profiles that 
show close similarities, such as the HuVV mice inoculated with sCJD(MV2) and 
sCJD(VV2).  However in assessing the full dataset a statistical approach is more 
objective, and less subject to operator bias.  Hierarchical Cluster Analysis (using 
software SPSS v14.0) was used to test the lesion profile data.  This method is a 
means of classification of experiments into groups (clusters) that have similarities in 
the data.  The degree of similarity was determined by a distance measure (in this case 
the Chebyshev interval) that was calculated from the differences between the lesion 
profile mean scores at each of the twelve brain regions.  The hierarchical nature of 
this analysis builds successive clusters from those already established (containing the 
most similar data) to form a branching dendrogram.  Using Hierarchical Cluster 
Analysis each of the twelve data points of the lesion profile were tested for similarity 
between different genotype mice and inocula used, and these similarities in the data 
were visualised in a dendrogram, the branching tree structure where the most similar 
lesion profiles are clustered together (Figure 6.F4).  The more branches there are 
between data sets the less similar they are.   
Data for lesion profiles from the primary transmissions showed branching of 
the dendrogram into three main clusters, as follows: 
 6.3.1.6.1  ‘Type 1’ cluster 
All codon 129 genotype mice inoculated with three type 1 PrPPSc subgroups of sCJD 
(MV1, MM1 and VV1), but not sCJD (MM1) in HuVV mice. 
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HuVV mice inoculated with type 2 PrPSc sCJD containing at least one valine allele at 
codon 129, that show relatively ‘fast’ incubation periods of <300 days post injection.   
 6.3.1.6.3  ‘Fast’ cluster 
All codon 129 genotype mice inoculated with type 2 PrPSc sCJD cases (including 
MV2 and VV2).  The exception is HuVV mice inoculated with sCJD (MM1).   








Hierarchical Cluster Analysis to assess variation in vacuolation intensity and location. (SPSS v14.0: within-groups linkage and the 
Chebyshev interval measure (which checks the absolute difference between the values)) 




6.3.1.7  Detection of PrPSc by Immunocytochemistry 
Immunocytochemical (ICC) detection of disease associated PrP (PrPSc) in 
transgenic mouse models is commonly used as the standard method to confirm 
transmitted TSE disease in transgenic mice (Asano et al., 2006).  For this study, ICC 
gave the positive / negative scoring seen in Tables 6.T1 to T6 (column ICC), and 
provided a means of demonstrating PrPSc pathological targeting differences that 
could be attributable to an effect of the inocula or the codon 129 genotype of the 
transgenic mice.   
The positive scores have been summarised in Table 6.T11.  In mice already 
scored positive for clinical signs and vacuolation, detection of PrPSc confirmed 
positive transmission.  However, in some mice negative for clinical signs or TSE 
vacuolation, ICC detected PrPSc deposition (For example, see Table 6.T4, HuMV 
data.).  This suggested that variation in timing of appearance of pathological signs 
may be inoculum or host genotype dependent.   
 The positive scoring obtained by ICC detection of PrPSc showed that all 
three transgenic lines were ~100% positive for the three inocula tested (types MM1, 
MV2, and VV2).  It was only wild-type mice with sCJD(MV2) and sCJD(VV2) 
inocula that showed no evidence of PrPSc.  The remaining experiments will be 
analysed in the near future as there was insufficient time during this study to 
complete this work. 
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Table 6.T11:  ICC Scoring Data for sCJD Inoculations 
Summary of positive ICC scores compared between inocula and mouse lines.  (N/T: 
not tested) 
Inoculum HuMM HuMV HuVV 129Ola 
MM1 13/13 100% 14/14 100% 14/16 87% 10/10 100%
MM2 N/T - N/T - N/T - N/T - 
MV1 N/T - N/T - N/T - N/T - 
MV2 10/11 91% 15/17 88% 15/15 100% 0/10 0% 
VV1 N/T - N/T - N/T - N/T - 




6.3.1.8  Distribution of PrPSc as Detected by ICC 
Defining the variation of type and location of PrPSc deposits, by qualitative 
and quantitative analysis of the ICC slides, in brains of the transgenic mice will 
hopefully allow further examination of whether it is the individual sCJD inocula, or 
the codon 129 genotype of the mice, that determines this pathology.  This will be the 
goal of future analysis as there was insufficient time during this thesis to carry out 
such a detailed study.  The differences in PrPSc deposition for the six subgroups of 
sCJD are discussed in the Introduction; some of those features may be replicated in 
the transmission to transgenic mice.  Limited analysis of PrPSc deposition variation 
has been carried out and some differences and similarities have been observed. 
(Figure 6.F5)  ICC slides from all mice in each inoculated group were checked to 
give an overall representation of the specific targeting of deposition seen, as 
discussed below.  The degree of within-group variation appeared to depend on the 
incubation time of the mice, with an increase in deposition over time.  The targeted 
regions did not change over this time period.  The specific brain regions mentioned 
are outlined in diagrammatical form in Figure 6.F6.   
6.3.1.8.1  sCJD(MM1) PrPSc Deposition 
The sCJD(MM1) inoculated mice of each genotype showed similar overall 
patterns of staining: in the thalamic region with discrete, punctate, deposits; 
hippocampal targeting of the stratum lacunosum moleculare; and occasional larger 
deposits in deep layers of the cerebral cortex.  The cerebellum was spared with only 
very little evidence of PrPSc deposition.   
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The sCJD(MV2) and sCJD(VV2) inoculated mice showed very similar 
patterns of PrPSc deposition, which were different from that found with sCJD(MM1).  
The same thalamic regions were targeted as for sCJD(MM1), but as well as the 
punctuate deposits, there was an increase in more diffuse staining.  The HuMM and 
HuMV lines showed a similar degree of staining concentrated in the ventral 
posteromedial, and posterolateral, thalamic nuclei.  For the HuVV line this area 
extended to include the lateral dorsal nucleus, the posterior thalamic nuclear group, 
and the medial dorsal and ventromedial thalamic nuclei.  Outside the thalamic region 
the HuVV mice again showed differences to the other lines.  The cerebral cortex was 
heavily stained with distinctive banding associated with the cell type layers present.  
Band 6 showed the densest deposits.  These HuVV mice developed clinical TSE 
following a significantly shorter incubation time and therefore the more widespread 
pathological change may be the cause of this phenotype.  Intensely stained 
aggregates were seen in the white matter of the corpus callosum in both HuMM and 
HuVV mice, and not in the HuMV mice.  The cerebellum shows similar staining 
patterns, targeted to the granular layer, for all mouse lines and both inocula. 





Immunocytochemistry with anti-PrP antibody 6H4 (brown staining) on representative histological sections of transgenic mouse brains, 
specifically the hippocampus and cerebellum, following i.c. inoculation with three subtypes of sCJD.  (Images at 2.5x magnification.)   




Figure 6.F6:  Brain Map Reference Diagrams 
Diagrammatic representation of the brain sections used in Figure 6.F5, highlighting 
the regions mentioned in the text.  (Areas within hippocampal section: hippocampus: 
dark green region, thalamus: pink region, cerebral cortex: light blue)  Images 




6.3.1.9  Detection of PrPSc by Western Blot 
Western blot detection of PrPSc was performed on frozen brain material set 
aside during the post mortem of each mouse.  As there was variation of protein type 
in the inoculum it could be that the PrPSc type determined the transmission strain 
characteristics, as was seen in the Hierarchical Cluster Analysis of the lesion profile 
data.   
The PrPSc type produced by each of the three genotype host mice as a 
response to the inoculum in shown in Figure 6.F7.  The appearance of type 2 PrPSc 
was restricted to the ‘Fast’ group (defined by the Cluster Analysis) of HuVV mice 
inoculated with either sCJD(MV2) or sCJD(VV2).  These mice also showed a 
dominance of the diglycosylated fragment, a Western blot profile similar to vCJD 
(see adjacent lanes in Figure 6.F7).  All the other mice / inoculum combinations in 
which PrPSc has been detected showed the usual sCJD type 1, monoglycosylated 
dominant, profile even if the inoculum was type 2.  Very low levels of PrPSc were 
seen in the sCJD(VV1) experiment and for HuVV mice inoculated with sCJD(MV1).   
No variation has been found in human PrPPSc fragment mobility or 
glycosylation by using addition antibodies and it was therefore not deemed necessary 
to further analyse the mouse brain extracts (Head et al., 2004a, Yull et al., 2006).   
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Figure 6.F7:  Western Blot Images for sCJD Inoculations 
Western blots of brain extract from transgenic mice i.c. challenged with sCJD.  (T1 
and T2B human control samples of sCJD(MM1) and vCJD respectively; red number 
is test sample assigned type.  Upper of three bands is the diglycosylated form, middle 
is monoglycosylated and lower is unglycosylated.  Antibody: 6H4) 
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The number of mice injected was less (12) than the 18 used for primary 
inoculation as secondary passage material is less likely to be toxic as it is mouse 
instead of human derived, and should transmit more efficiently.  Intercurrent illness 
and death reduced the total mice available for studying transmission properties over 
lifespan but sufficient mice survived to observe clinical and pathological signs of 
disease transmission.  Where possible intercurrent deaths were also examined for 
markers of TSE pathology.  Tables 6.T12 to 6.T13 show the evaluation of all mice in 
this study. 
To generate duplicate data for confirmation of the results, two HuVV mice 
clinically and pathologically positive for transmission of sCJD(MV2) (protocol 
553C-1A, see Table 6.T4) were selected for sub-passage of brain homogenate into 
further groups of 12 transgenic and wild-type 129Ola mice.  
Following primary inoculation of sCJD(MV2) all the HuVV mice 
developed clinical disease after much shorter incubation times than seen for other 
genotypes of mice and other experiments.  This provided an opportunity to perform a 
secondary passage during the course of this study.  Transmission data from 
secondary passage can provide evidence that the primary passage generated a disease 
in the mice that is infectious, and also whether there has been any host adaptation of 
the strain transmission properties.  For instance the removal of a species barrier 
effect, on second passage, is suggested by a decrease in incubation period.   
6.3.2  Secondary Inoculation of Mice with Primary Passage Material 
 
Protocol: 553J-1A:  HuVV mouse ID# 97 (Incubation period 280 days) 




Table 6.T12:  Data Table for Second Passage sCJD(MV2) Inoculation via HuVV Mouse 
IC inoculation data (protocol reference 553H-1A) for secondary passage of sCJD(MV2) primary pass in HuVV 
Abbreviations: CLIN: clinical score; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: 
intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; End expt: 
mice that were culled when the experiment was terminated at 700 days; shaded cell: positive score 
 





















































































































51 127 ICD Neg Neg n/t 29 265 ICD Neg Neg n/t 4 225 TSE Pos Pos Pos 12 358 ICD Neg Neg Neg 
54 420 ICD Neg Neg Pos 25 362 ICD Neg Neg Pos 43 225 TSE Pos Pos n/t 7 414 ICD Neg Neg Neg 
16 489 ICD Neg Pos Pos 30 442 ICD Neg Neg Pos 44 226 TSE Pos Pos Pos 35 421 ICD Neg Neg Neg 
14 529 ICD Neg Pos Pos 58 503 ICD Neg Pos Pos 45 226 TSE Pos Pos Pos 36 526 TSE Pos Neg Neg 
17 554 ICD Neg Pos Pos 57 540 ICD Neg Pos Pos 47 226 TSE Pos Pos Pos 31 620 ICD Neg Neg n/t 
50 606 ICD Neg Pos Pos 27 559 ICD Neg Neg Pos 3 238 TSE Pos Pos Pos 10 673 ICD Neg Neg Neg 
15 610 ICD Neg Pos Pos 59 582 ICD Neg Neg Pos 6 238 ICD Neg Pos n/t 34 680 ICD Neg Neg Neg 
52 638 TSE Pos Pos Pos 55 589 ICD Neg Pos Pos 2 239 TSE Pos Pos Pos 32 702 ICD Neg Neg Neg 
49 658 TSE Pos Pos Pos 60 670 ICD Neg Neg n/t 46 239 TSE Pos Pos Pos 33 783 ICD Neg Neg n/t 
13 673 ICD Neg Pos Pos 56 678 ICD Neg Pos Pos 48 243 TSE Pos Pos Pos 8 812 End expt Neg Neg n/t 
18 719 ICD Neg Pos n/t 26 722 ICD Neg Neg Pos 5 246 TSE Pos Pos Pos 9 812 End expt Neg Neg n/t 
      28 754 ICD Neg Neg Pos 1 253 TSE Pos Pos Pos       
                        






Table 6.T13:  Data Table for Duplicate Second Passage sCJD(MV2) Inoculation via HuVV Mouse 
IC inoculation data (protocol reference 553J-1A) for secondary passage of sCJD(MV2) primary pass in HuVV 
Abbreviations: CLIN: clinical score; VACN: presence of TSE vacuolation; ICC: presence of abnormal PrP by immunocytochemistry; ICD: 
intercurrent death or culled for animal welfare reasons; n/d: no data available as tissue not testable; n/t: not tested at this time; End expt: 
mice that were culled when the experiment was terminated at 700 days; shaded cell: positive score 
 





















































































































19 264 ICD Neg Neg n/t 4 335 ICD Neg Neg n/t 40 224 TSE Pos Pos n/t 17 426 ICD Neg Neg n/t 
33 320 ICD Neg Neg n/t 5 448 ICD Neg Neg n/t 42 225 TSE Pos Pos n/t 58 440 ICD Neg Neg n/t 
36 410 ICD Neg Neg n/t 46 455 ICD Neg Neg n/t 38 231 TSE Pos Pos n/t 59 502 ICD Neg Neg n/t 
23 473 ICD Neg Neg n/t 44 553 TSE Pos Pos n/t 9 238 TSE Pos Pos n/t 56 567 ICD Neg Neg n/t 
35 539 TSE Pos Pos n/t 43 623 ICD Neg Pos n/t 37 238 TSE Pos Pos n/t 15 601 ICD Neg Neg n/t 
24 576 ICD Neg Pos n/t 45 655 ICD Neg Pos n/t 39 243 TSE Pos Pos n/t 57 663 ICD Neg Neg n/t 
31 595 ICD Neg Pos n/t 47 655 ICD Neg Pos n/t 7 244 TSE Pos Pos n/t 55 670 ICD Neg Neg n/t 
22 636 ICD Neg Pos n/t 1 679 ICD Neg Pos n/t 8 245 TSE Pos Pos n/t 14 721 ICD Neg Neg n/t 
20 662 ICD Neg Pos n/t 48 686 ICD Neg Pos n/t 11 245 TSE Pos Pos n/t 18 721 ICD Neg Neg n/t 
34 679 ICD Neg Neg n/t 3 695 ICD Neg Neg n/t 10 246 TSE Pos Pos n/t 13 791 ICD Neg Neg n/t 
32 694 ICD Neg Pos n/t 2 770 ICD Neg Neg n/t 12 246 TSE Pos Pos n/t 16 811 End expt Neg Neg n/t 
21 735 TSE Pos Pos n/t                   
                        





6.3.2.1  Summary of Second Passage Data 
The results of clinical and pathological scoring of mice from the duplicate 
secondary passage experiments are presented in Table 6.T14 and show only slight 
variation between the two data sets.  The main conclusion from this work was that 
the transmission properties of the HuVV brain and original human source inocula 
showed remarkable similarities in incubation period, targeting of vacuolation, and 
efficiency of transmission to the three genotype hosts.   
6.3.2.1.1  Clinical Features of Transmission 
Primary and secondary passage to the HuMM and HuMV mice showed 
similar low levels of clinical disease, even though the second passage inoculum was 
derived from a mouse brain.  This was remarkable considering that the inocula 
produced mean incubation periods in HuVV recipient mice of 235 and 239 days for 
the two experiments.  The primary passage gave an incubation time in HuVV mice 
of 288 days, therefore there had been a reduction for second passage of 
approximately 50 days, suggesting adaptation of the infectious agent.   
6.3.2.1.2  Pathological Features of Secondary Passage Mice 
The number of mice scored positive for the presence of TSE vacuolation 
and PrPSc by ICC confirmed that the secondary passage transmission properties 
were identical to that of the primary passage.  Approximately one-third of HuMV 
mice developed vacuolation compared with two-thirds of HuMM mice and 100% of 
HuVV mice.  Almost all mice regardless of codon 129 genotype were positive for 
PrPSc deposition in the brain.  There was no evidence that the spatial distribution or 
type of deposits were different from that found in the primary passage mice.   
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Lesion profile data comparison for vacuolation scoring further confirmed 
the high degree of similarity between primary and secondary passage, with the 
distribution and intensity of vacuolation in the latter mirroring that seen in the former 
(Figure 6.F8).  The pathological transmission properties of the original sCJD(MV2) 
human inoculum strain had therefore been propagated by brain tissue inoculum 
derived from HuVV mice.   
 
Table 6.T14:  Summary of Data for Primary and Secondary sCJD(MV2) 
Inoculation 
Summary of experimental data for primary and secondary inoculation (via HuVV 
mice) of sCJD(MV2).  (Incubation period for clinically positive mice (mean 
(range)); positive scores out of mice tested; n/t: not tested) 
 






































































Figure 6.F8:  Lesion Profile Similarities for Primary and Secondary 
sCJD(MV2) Inoculation 
Lesion profiles from sCJD(MV2) primary (solid lines and symbols) and 
sCJD(MV2)-HuVV secondary (dashed lines and open symbols) transmissions.  
(HuMM: blue squares; HuMV: green diamonds; HuVV: red triangles; error bars 
omitted) 
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6.4  DISCUSSION 
Following inoculation of the six subtypes of sCJD, segregated according to 
codon 129 genotype and PrP type, in the four mouse lines, data for multiple 
pairwise comparisons determined whether characteristics of the host or the 
inoculum were the major factors for successful transmission.  The significant 
variability, within and between inocula and mouse lines, in the dataset generated by 
this study has provided evidence, discussed below, that the subtypes of sCJD 
behave like separate transmissible strains, and that there are dominant effects 
attributable to the codon 129 genotype and PrPSc type of the host and inoculum.  
Table 6.T15 summarizes the data currently available from this study for the six sCJD 




Table 6.T15:  Summary of sCJD Transmission Data 
Overall transmission attack rate from positive scores for vacuolation and ICC (%), 
mean incubation time if clinical signs present, and PrPSc type by Western blot.  
(Green: clinical TSE in majority of mice; Yellow: subclinical TSE disease in 




INOCULUM HuMM HuMV HuVV 129Ola 
MM1 
100%   Type 1 
 
446 days 
100%   Type 1 
 
457 days 







94%   Type 1 
 
446 days 
89%   Type 1 
 
475 days 







91%   Type 1 
 
Subclinical 
89%   Type 1 
 
Subclinical 







88%   Type 1 
 
Subclinical 
86%   Type 1 
 
Subclinical 










60%   Type 1 
 
Subclinical 




















6.4.1  Characterisation of sCJD Subgroups as Unique Transmissible 
Strains 
 One main aim of this study was to use transmission data from each of the 
six subgroups of sCJD to understand further the individual strain characteristics.  
Using survival analysis, incubation times, vacuolation scoring, and detection of PrPSc 
by ICC and Western blot, similarities and differences have emerged.  Overall the 
data suggested that each of the subgroups, represented here by a single typical case, 
had unique transmission properties, although some subgroups were similar.  The 
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following paragraphs discuss each subgroup in turn to highlight their unique features 
when inoculated into human transgenic mice and the wild-type 129Ola line.   
6.4.1.1  SCJD(MM1) 
The majority of sCJD cases (~70%) fall into this category (Parchi et al., 
1999, Pocchiari et al., 2004); it is the ‘classical’ / myoclonic form of the disease.  
Successful transmission to all three transgenic lines and the 129Ola wild-type mice 
made this the most efficiently transmitted subgroup.  If transmission efficiency was 
comparable to the probability of a human being developing the disease then this is 
consistent with the prevalence of this subgroup.  As the aetiology of sCJD is still a 
matter of debate there remains a possibility that it is an acquired disease with the 
MM1 subgroup being the disease caused by the most transmissible / infectious agent.   
There was little difference in the number of mice positive for clinical signs, 
or the incubation periods, for the three transgenic mouse lines inoculated with both 
sCJD(MM1) and sCJD(MV1).  The Tarone-Ware results, however, indicated that 
the survival rate of the HuVV mice was different between the inocula.  The 
sCJD(MV1) inoculum appeared to have had a more detrimental effect on the HuVV 
line than the sCJD(MM1) inoculum, with more early intercurrent deaths.  This 
effect may be due to the presence of valine allele associated PrPSc in the inoculum 
which may more efficiently convert the valine allele PrPC of the VV genotype mice.  
A comparison of solely the HuVV mice data between the two inocula did not 
support this finding (Table 6.T8).   
SCJD(MM1) transmission produced clinical TSE symptoms in all three 
transgenic lines.  This was also seen with sCJD(MV1) inoculum but this differed 
from any of the other four subgroups.  There was a methionine allele dominance in 
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the mean incubation time, with little observable gene dosage effect (i.e. HuMM mice 
did not have shorter incubation periods than HuMV mice), with HuMM and HuMV 
mice developing TSE signs at ~450-470 days and HuVV mice at ~600 days post 
inoculation.   
SCJD(MM1) lesion profiles for the transgenic mice showed consistency 
across the lines, however, Hierarchical Cluster Analysis suggested that the 
vacuolation distribution in the HuVV mice was different from the others, and more 
like transmissions from PrPSc type 2 associated subgroups (Figure 6.F3 and Figure 
6.F4).  This infers a dominance effect of the VV host genotype over the sCJD(MM1) 
inoculum strain characteristics.   
Detection of PrPSc by ICC confirmed that when TSE associated vacuolation 
was present there was also deposition of PrPSc, with no suggestion of a subclinical 
disease state where PrPSc was present without vacuolation.  The pattern of PrPSc 
distribution in the brain appeared similar for all transgenic lines, with more punctate 
appearance and less cerebellar involvement than sCJD(MV2) or sCJD(VV2) (Figure 
6.F5).  This suggested a more dominant role for the sCJD(MM1) inoculum over host 
genotype in determining the pathological targeting.   
100% subclinical disease (presence of TSE vacuolation and / or PrPSc 
detection without clinical signs) in 129Ola wild-type mice distinguished this 
subgroup from all the others.  Only the MV1 and VV1 subgroups showed evidence 
of wild-type transmission with <10% of mice showing subclinical disease.  Western 
blot analysis showed the PrPSc formed in each transgenic line to be type 1 and 
monoglycosylation dominant, as per standard sCJD(MM1) brain material.   
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Together these data indicate that the sCJD(MM1) subgroup strain 
transmission characteristics were different from the other five studied here. 
6.4.1.2  SCJD(MV1) 
Approximately 5% of sCJD cases are of this subgroup (Parchi et al., 1999, 
Pocchiari et al., 2004) and are grouped with the MM1 cases as the ‘classical’ form of 
the disease.  Consistent with these clinical and pathological findings in humans the 
transmission properties of sCJD(MV1) showed few differences to sCJD(MM1).  The 
main difference found compared to sCJD(MM1) was the much lower transmission 
efficiently to the 129Ola wild-type mice.   
Survival analysis and Tarone-Ware statistical tests confirmed that the HuVV 
line was more adversely affected by this inoculum compared with sCJD(MM1) 
(Table 6.T7 and Figure 6.F1).  This difference was also seen in the lesion profile 
pattern of the HuVV line.  Hierarchical Cluster Analysis of the lesion profile scores 
grouped the HuVV data with the other two genotype lines, in contrast to the 
sCJD(MM1) data (Figure 6.F4).  This difference may be attributable to the presence 
of valine allele PrPSc in the inoculum and host.   
ICC data was not available for mice injected with this inoculum.  Western 
blot analysis showed each transgenic line propagated the type 1 sCJD profile as seen 
in patients typical of the sCJD(MV1) subgroup.   
The sCJD(MV1) strain transmission properties had close similarities to 
sCJD(MM1) however the differences discussed above indicated that this strain is 
unique within the 6 subgroups.   
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6.4.1.3  SCJD(VV2) and SCJD(MV2) 
The sCJD(VV2) subgroup is the second most common form of sCJD 
occurring in ~15% of cases, with sCJD(MV2) the third most common at ~10% 
(Parchi et al., 1999, Pocchiari et al., 2004).  These subgroups shared near identical 
transmission properties and have therefore been discussed together.  For both inocula 
the HuMM and HuMV mice showed a predominance of subclinical infection, and 
HuVV mice rapidly developed clinical TSE signs at ~280 days posts inoculation.  
These data were unlike any of the other 4 sCJD subgroups.   
Neither data from survival analysis, presence of clinical symptoms, nor 
mean incubation periods could distinguish the data sets from sCJD(MV2) and 
sCJD(VV2) subgroup inocula.   
Hierarchical Cluster Analysis of lesion profiling data grouped the 
sCJD(VV2) data together with the sCJD(MV2) data and therefore there was no 
evidence to distinguish the two strains.  However, the attack rate for positive 
vacuolation scoring was higher (approximately double) in the HuMM mice with 
sCJD(MV2) at 69%, compared to the sCJD(VV2) inoculum, at 33% (Table 6.T10).  
Codon 129 genotype may be the cause of this effect with the MM mouse more 
rapidly developing TSE pathology with an inoculum containing a methionine allele.  
This was the only evidence to distinguish between these two sCJD strains.   
ICC data for the number of mice positive for PrPSc, and distribution of PrPSc 
in the brain, showed nothing to separate sCJD(MV2) and sCJD(VV2) inocula.  The 
appearance of type 2 PrPSc by Western blot was only found in HuVV mice 
challenged with these two inocula, suggesting a specific response from VV hosts to 
inoculum containing type 2, valine allele PrPSc.  Type 2 PrPSc from the HuVV mice 
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had also been shown to be predominantly diglycosylated, similar to the Western blot 
pattern characteristic of vCJD.  This finding highlighted the possibility that if a VV 
individual was infected by material from a sCJD(MV2) or sCJD(VV2) patient then 
typing of the PrPSc present in the brain may suggest vCJD.  Two cases of young (<45 
years old) VV sCJD patients have been reported with Western blot types indicative 
of vCJD (Head et al., 2001, Mead et al., 2007).  The 2007 publication suggested that 
patient may represent a novel form of vCJD.  No reference was made to a possible 
iatrogenic cause of infection in those two cases.   
 Secondary passage of brain material from two HuVV mice, initially 
inoculated with sCJD(MV2), into the three transgenic lines, produced scores for 
clinical TSE and vacuolation that were identical to the original transmission (Table 
6.T14).  Also the lesion profiles when overlaid onto the primary data showed near 
identical profiles (Figure 6.F8).  There was no possibility of residual inoculum being 
present from the initial injection as it would be significantly diluted by the time the 
brains were prepared as inocula.  The chance of contamination was very small as the 
primary and secondary experiments were set up approximately one year apart and 
other tissues had been injected in the intervening time with different transmission 
results.   
 Although there were a number of similarities between these two sCJD 
subgroup strains the relative increase in TSE vacuolation positive HuMM mice with 
sCJD(MV2) inoculum allowed for discrimination from sCJD(VV2).  The rapid 
transmission and type 2 PrPSc found in HuVV mice clearly distinguished these two 
strains from the other 4 subgroups.  
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6.4.1.4  SCJD(VV1) 
This subgroup of sCJD occurs in <5% of cases (Parchi et al., 1999, 
Pocchiari et al., 2004) and is therefore one of the rarer forms of this disease.  There 
was no evidence of transmission to the HuMM mice and only 50-60% subclinical 
disease in the other mice lines.  This strain was the only one to produce subclinical 
TSE in the HuVV mice (MM1, MV1, MV2, and VV2 produced a majority of mice 
with clinical TSE, and MM2 showed no evidence of transmission).  The survival 
curve for these HuVV mice was statistically different from that of the wild-type 
mice (P=0.026), unlike the other two transgenic lines.  Only two of the HuVV and 
HuMV mice developed clinical TSE at ~550 days, but the survival analysis showed 
that the former may be more affected subclinically by the inoculum.  This may be 
due to the 100% genotype homology between mouse and inoculum.  There was no 
increase in vacuolation for the HuVV mice and ICC data is not currently available, 
which may allow further examination of this effect.  These data show that this strain 
had different transmission properties to all other five subgroups.   
Lesion profiling and Hierarchical Cluster Analysis placed the HuMV and 
HuVV data with others in the ‘Type 1’ group (sCJD(MM1) and sCJD(MV1)) 
suggesting a common pathological response from all genotype mice to the type 1 
configuration of PrPSc in inocula.  These inocula could be of any codon 129 
genotype.  The presence of a single 129Ola mouse positive for vacuolation indicated 
some similarity with the sCJD(MV1) inoculum.  In fact only type 1 PrPSc inocula 
showed evidence of transmission to the wild-type 129Ola mice.   
Western blot data indicated low levels of type 1 PrPSc in the HuMV and 
HuVV mice.  The presence of type 1 PrPSc in both mouse lines was the same as that 
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found for the other type 1 inocula, indicating a response to the inocula rather than a 
host genotype effect.   
ICC data is unavailable at present but is likely to improve the attack rate 
based on the findings of the other inocula.  Even without this data there was clear 
segregation of this subgroup of sCJD, as shown above, compared to all others 
examined.   
6.4.1.5  SCJD(MM2) 
Approximately 5% of sCJD cases are in this subgroup.  Two types exist 
described as ‘cortical’ or ‘thalamic’, the former is the more common and was used in 
this study.  No evidence of transmission was observed in either of the four mouse 
lines, although ICC data is unavailable, the most sensitive test for confirming 
transmission.  There was some evidence however from the survival analysis that this 
inoculum was more detrimental to the transgenic lines than to the wild-type.  The 
Tarone-Ware test showed that there was a small statistical difference between the 
wild-type mice and the transgenics (P<0.01) suggesting that the inoculum 
preferentially affected the transgenic lines.  Use of additional aliquots of this 
inoculum in experiments outside this study showed that it was infectious so possibly 
PrPSc deposition may be the only indication of successful transmission.  The 
combination of type 2, and MM genotype PrPSc may also be a barrier to propagation 
or PrPSc conversion in the host animals and therefore this ‘negative’ experiment was 
important.  Should an individual become infected with sCJD (MM2) then the risk of 
developing iCJD is the least for any form of sCJD.   
The absence of evidence of transmission in any mouse line showed this 
subgroup of sCJD to be different from all five others investigated here.   
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6.4.2  Role of Codon 129 Genotype and PrPPSc Type in Transmission of 
sCJD 
 The second aim of this study was to observe the effects on transmission of 
codon 129 genotype and PrPSc type, defined in both host and inoculum.  Methionine 
or valine at codon 129 was the only genetic variation between the three lines of 
transgenic mice and therefore the effect of genotype can be observed in the 
differences between the lines.  Inoculation with sCJD material from patients with 
each of the three codon 129 genotypes, and either PrPSc type, allowed for further 
observation of how each mouse line responded to inocula with different genotypes 
and type 1 or 2 PrPSc.   
 Transmission properties were determined by the genotype of both transgenic 
mouse line and sCJD inoculum, and by the PrPSc type.  This meant that no generic 
rules could be defined for the three genotype hosts.  The human response to a source 
of infection is likely therefore to depend on both their own genotype and the 
genotype and PrPSc type (the subgroup) of sCJD.   
There were some characteristics within the dataset that suggested specific 
combinations of genotype and PrPSc type were more dominant, such as the 
observation that the HuVV genotype line developed clinical TSE features with most 
inocula.  HuVV mice also had the shortest incubation periods, seen for sCJD(MV2) 
and sCJD(VV2) inocula.  These data predict that for human iatrogenic spread of 
sCJD, this genotype may be the most susceptible or may show shorter incubation 
periods.  An overabundance of iCJD cases in VV genotype recipients of 
contaminated human growth hormone in the UK would support this hypothesis 
(Collinge et al., 1991, Brown et al., 2000a).  It is also of interest that there is an 
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increased prevalence of young (<50 years) VV genotype sCJD cases across 
European countries (UK, Germany, Italy and France) (Alperovitch et al., 1999).   
The second common characteristic amongst the data was that HuMM and 
HuMV mice had similar levels of clinical disease, and mean incubation periods, for 
four of the six inocula (excluding sCJD(MM2) and sCJD(VV1)).  This suggests that 
the methionine allele PrPPC in the heterozygous HuMV mice may have had a 
dominant effect over the valine allele PrPC with regards to the transmission 
properties.   
 The most significant effect of the inoculum PrPSc type was seen in the 
targeting of vacuolar pathology.  Hierarchical Cluster Analysis of the lesion profile 
data clearly indicated that there was closer similarity between those profiles 
produced from inoculum with a specific type of PrPSc than for groups of mice or 
inocula with the same codon 129 genotype (Figure 6.F4).  As PrPSc type is closely 
associated with specific pathology in the sCJD patients, these data would indicate 
that pathological changes in the tissue selected for inocula had potentially the most 
dominant role in determining transmission properties.   
 The transgenic mice produced PrPSc of only two confirmations that matched 
the type 1 mobility and predominance of monoglycosylation as seen in type 1 sCJD 
patients, and the type 2 mobility and predominance of diglycosylation as seen in 
vCJD patients.  Figure 6.F7 shows that type 2 PrPPSc was seen in the HuVV mice that 
had short incubation periods, after inoculation with sCJD(MV2) and sCJD(VV2). All 
other mice genotype / inoculum combinations produced type 1 PrPSc.  This would 
indicate a specific link between inocula with valine allele type 2 PrPSc, and the valine 
homozygous mouse host.   
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 Type 1 PrPSc was found in mice of each codon 129 genotype and following 
inoculation with material of each genotype and either PrPSc type.  The main 
conclusion that can be drawn from the widespread appearance of type 1 PrPSc, even 
if the inoculum is type 2, is that this type is the dominant type produced by these 
mice following TSE challenge.  Finding type 1 PrPSc in mice inoculated with type 2 
sCJD inocula indicated that the PrPPC-to-PrPScP  conversion is controlled by the 





7.1  AIMS 
 The aims of this thesis were to investigate the transmission of a number of 
different forms of human transmissible spongiform encephalopathy (TSE) to gene 
targeted transgenic mice that express the human prion protein with variation in 
genotype at codon 129.  This allowed detailed examination of the role of codon 129 
genotype in susceptibility and the identification of unique strain properties amongst 
the types of human TSE.  The hypotheses discussed below were tested from the data 
generated.   
7.2  HYPOTHESES 
7.2.1  Codon 129 Genotype is the Key Factor in Defining Susceptibility 
to Human TSE Transmission 
 Susceptibility is generally defined as whether an infected individual 
develops any evidence of TSE such as clinical signs, vacuolation, or PrPSc 
deposition.  However a more common usage is the degree to which an individual is 
affected, for example the relative progression of pathological changes and the level 
and distribution of PrPSc deposition in the brain.   
 Data from this thesis indicate that both inoculum and recipient codon 129 
genotype play significant roles in defining aspects of susceptibility to human TSE 
such as incubation period and pathological response in the host, and transmission 
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efficiency of the inocula.  The most significant importance of this mouse model is 
that the specific effects of codon 129 genotype on transmission can be assessed 
independently of the influence of alternative genetic backgrounds or the location of 
the transgene.  For primary vCJD transmission, variation in codon 129 genotype 
could not be studied as the source of inoculum, clinical vCJD, has only been detected 
in MM patients.  However, second passage from each genotype transgenic line has 
shown the influence of non-MM vCJD strains on transmission.   
 The codon 129 genotype of recipient mice significantly affected the 
outcome of primary vCJD transmission with the most efficient host being MM 
followed by MV and then VV.  The MM and MV mice had similar frequency of 
positive scores suggesting equivalent susceptibility, but the MM line more readily 
developed vacuolar pathology and widespread deposits of abnormal PrP, together 
with the appearance of florid plaques, which developed only in this line.  
Pathological changes in the MV mice did not progress further than limited thalamic 
deposition of PrPSc, suggesting that the heterozygous genotype may restrict the 
progression of TSE pathology.  That there was only a single HuVV mouse positive 
for vCJD transmission indicated that this genotype appeared to be the most resistant 
to infection.  Transmission data from the blood transfusion vCJD agent strain 
showed near identical findings in the three codon 129 genotype hosts indicating that 
the TSE agent has not been significantly adapted by passage through a second MM 
genotype human.   
 Second passage transmission data from the primary vCJD inoculations of 
each genotype mouse line showed an overall decrease in the pathological changes, 
but the ranking of codon 129 genotypes in the recipient lines was unchanged.  
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Regardless of the inoculum source genotype, the MM recipients were the most 
susceptible to infection followed by the MV mice, with all VV mice negative.  The 
vCJD agent strain transmission characteristics appear to be stable regardless of the 
genotype of the host.   
 The robust nature of the vCJD agent transmission properties, seen in this 
mouse model, with specific targeting of MM hosts and resilience to adaptation by 
passage is important for assessing individual risk following known exposure and for 
modelling possible future epidemics of vCJD associated with human-to-human 
infection.  The replication of pathological and biochemical features of human vCJD 
disease in mice provides an in-vivo model system which may allow further 
investigation into pathogenic mechanisms and therefore may provide an 
understanding of individual susceptibility and novel targets for therapeutic 
intervention.   
 The data from sporadic CJD transmissions showed a complex relationship 
between the codon 129 genotype of inoculum and recipient mice.  However 
differences in the response between the three mouse lines indicated that the recipient 
genotype had a major role in determining the transmission properties.  An 
individual’s risk of iatrogenic infection from sCJD may therefore be determined 
primarily by the host codon 129 genotype.   
 With sCJD the VV genotype mice were the most susceptible overall in 
terms of the number of mice positive for transmission and had the shortest incubation 
periods (for transmission of sCJD(MV2) and sCJD(VV2)).  One implication is that 
VV individuals may be the most susceptible to infection following iatrogenic 
transmission of sCJD, with relatively short incubation times, if the infectious 
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material originated from sCJD(MV2) or sCJD(VV2) cases.  This host targeting is 
very different from that seen for vCJD transmission.  The reason may be that the 
vCJD agent strain is of bovine origin, is restricted to MM genotype hosts, is 
characterised by type 2B PrPSc, and has markedly different neuropathology 
compared to sCJD.   
 Sporadic CJD subgroup MM1 is by far the most common form of CJD 
because of as yet undefined factors (such as non-PRNP genetic polymorphisms) that 
may increase the susceptibility of these individuals.  It is therefore likely that this 
subgroup would represent the major source for secondary infection.  All three 
genotype mouse lines were 100% susceptible to sCJD(MM1) infection, but the 
HuVV mice had longer incubation periods than HuMM and HuMV mice.  The 
predicted prevalence of MM and MV iatrogenic TSE cases may therefore be higher 
than VV cases.  However, data published in 2000 show that overall, for all types of 
iCJD combined, there was an increase in MM and VV patients compared with the 
normal population genotype frequencies (Brown et al., 2000a).  As this does not fit 
the predicted prevalence of cases from the transmission studies, the source of 
infectivity for the iCJD patients may have included sCJD subgroups that target VV 
genotype hosts with short incubation periods, such as sCJD(MV2) or sCJD(VV2).   
 In summary, for human TSE diseases, the codon 129 genotype of both the 
infectious agent and the host (in this study mice) determine the transmission 
characteristics.  The inoculum genotype acts as one of the determinants of the strain 
but in addition the infected hosts show specific features dependent on their genotype.  
Data for the MV genotype recipient mice showed that these responded more like 
MM than VV mice, suggesting that the methionine allele may have a dominant role 
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in determining the transmission properties of the heterozygote host.  The data from 
this thesis will hopefully allow for better risk analyses for patients exposed to human 
TSE by predicting the outcome of infection dependent on the sCJD subgroup and the 
codon 129 genotype of the patient.  The availability of this in-vivo model expressing 
human PrP with codon 129 genotype variation may also allow research into the 
protein structural effects of codon 129 during pathogenesis and specifically during 
PrPC conversion.   
7.2.2  The Agent Strain Responsible for vCJD is Transmissible to 
Humans with Codon 129 MV and VV Genotypes 
 Data from this thesis provide strong support for this hypothesis and this 
important finding was published in 2006 in Lancet Neurology (See Appendix) 
(Bishop et al., 2006).  As discussed above the MV genotype was found to be as 
susceptible as MM to the vCJD agent, with equivalent numbers of mice positive for 
transmission.  However the pathological changes in the brain were significantly less 
severe than in the MM mice (see the next hypothesis below).  HuVV mice appeared 
relatively resistant to infection with only a single mouse positive at a late stage of 
normal lifespan.  The benefit of a mouse model truly comparable between codon 129 
genotypes is clearly shown here, highlighting the relative efficiency of transmission.   
 In the Lancet Neurology article it was reported that BSE did not transmit to 
the human transgenic mice suggesting a significant species barrier between cattle and 
humans.  This may explain the relatively low number of vCJD cases identified to 
date.  However the vCJD transmission data indicate that this agent can infect MV 
and VV mice, and suggests that there may be significant subclinical infection present 
in the human population with these genotypes.  This theory has been supported by a 
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national screening program of UK lymphoreticular tissues (Hilton et al., 2004a, 
Ironside et al., 2006).   
 The slow progression of vCJD infection in the MV and VV mice indicated 
that humans infected with the vCJD agent strain from another human would likely 
have a long subclinical phase.  This phase could last for many years, if not decades, 
during which time there may be high levels of infectivity present in peripheral tissues 
and latterly in the CNS.  Even in the absence of clinical disease during normal 
lifespan, the agent could still be transmitted from person-to-person through blood 
transfusion or surgery, leading to a potentially silent epidemic.  Routine screening of 
blood products, transplant material, or surgical instruments would help to protect 
public health but currently there are no applicable tests available for this purpose.   
 In summary, this model of human-to-human vCJD infection predicts 
successful secondary transmission of this agent strain to non-MM genotype hosts.  
As transmission data for primary and secondary vCJD material has indicated no 
significant adaptation of this TSE agent, overcoming the species barrier for BSE 
infection of MM individuals may have modified the agent into a stable human strain.  
As BSE material did not transmit to these mice we can only speculate that primary 
BSE infection of humans might affect non-MM hosts, although it is of note that these 
experiments all used i.c. inoculation and the current absence of human BSE infection 
in non-MM hosts may be related to the route of exposure or some other, yet to be 




7.2.3  The Pathology in the Central Nervous System Following vCJD 
Infection in Individuals of Codon 129 MV and VV Genotype is Different 
from that of MM Cases 
 The observation that susceptibility to the vCJD agent is different between 
MM and non-MM genotype mice, is supported by neuropathological findings.  The 
MM and MV mice developed similar early signs of TSE disease with PrPSc 
deposition in the thalamus, but pathology never progressed beyond this stage in the 
MV mice.  In contrast, the MM mice developed extensive PrPPSc deposition and TSE 
vacuolation throughout the brain, and also showed evidence of florid plaques which 
are characteristic of vCJD (in an MM genetic background).  TSE vacuolation was 
present in the HuMM mice but only in single HuVV and HuMV mice.  Because of 
this no mean lesion profile analysis comparison could be undertaken.   
 These differences may be important for the identification of vCJD 
transmission in non-MM individuals.  The brain of an infected MV individual may 
have low levels of detectable PrPSc concentrated in the thalamus, and therefore a 
biopsy of the cerebral cortex may be negative.  This type of scenario was observed in 
the MV patient who became infected with vCJD by blood transfusion.  The brain 
was negative for PrPSc whereas the spleen and lymph nodes were positive (Peden et 
al., 2004).   
 The single VV mouse positive for vCJD transmission showed pathological 
differences, including extensive PrPSc deposition throughout the brain, unlike the 
MV line.  The type of deposition was also different from the MM mice with no 
evidence of PrP antibody stained florid plaques and less targeting of the 
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hippocampus.  This comparison is limited by the availability of only the single 
positive HuVV mouse.   
 Western blot typing of the PrPSc present in the MV and VV mice showed 
the type 2B pattern, as in the HuMM mice.  Protein typing may therefore be useful as 
a diagnostic tool when assessing humans who are suspected of being infected with 
vCJD.   
 In summary the prediction for CNS pathology in non-MM human 
individuals following infection by vCJD, or BSE, is that it will be different in some 
aspects such as florid plaque development and degree of PrPSc deposition but similar 
in the Western blot profile.  This may lead to misdiagnosis of such cases as atypical 
sCJD (see reference (Mead et al., 2007)) and therefore confirms the need for 
continued active surveillance with extensive post mortem analysis of both brain and 
peripheral tissues.  The differences seen here in in-bred lines of mice should provide 
useful tools for understanding the effect of codon 129 genotype on the progression of 
pathological changes.  If the HuMV and HuVV mice restrict the progression of 
disease, with this specific strain, then understanding the underlying mechanism may 
be useful in designing therapies for humans.   
 
7.2.4  There is an Increase in Incubation Period for vCJD in Codon 129 
MV and VV Individuals 
 The pathological differences seen between the three genotype mouse lines 
predict that the onset of clinical disease following vCJD infection is likely to be 
delayed for non-MM individuals because of extended incubation periods.  If the 
BSE strain behaves in a similar fashion it may be that non-MM individuals will 
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develop vCJD after longer incubation periods, leading to a biphasic (MV and VV 
cases occurring at the same time) or triphasic (MV cases occurring then VV cases at 
a later stage) epidemic curve.  The length of the incubation period in BSE or vCJD 
infection is unknown, but the evidence from kuru points to a maximum time for 
onset of disease in some individuals at nearly 50 years from exposure (Collinge et 
al., 2006).  It is difficult to predict incubation times from this mouse model as few 
mice had clinical signs.  However, differences in the pathological features between 
lines provided clues to how different codon 129 genotype humans may respond to 
infection.   
 Clinical TSE disease in the HuMM mice was a rare occurrence (2 out of 18 
mice) even though there was extensive PrPSc deposition in the brains of older mice.  
This indicates a disparity between overall pathological change and the presence of 
clinical TSE disease, suggesting that the pathology had not yet targeted those 
regions responsible for the TSE clinical phenotype, such as the motor cortex 
neurons or the cerebellum.  There was only a single HuMV mouse positive for 
clinical TSE and no HuVV mice.  Understanding the relationship between clinical 
TSE and pathology may be an important future use of these mouse lines.   
 The majority of MV genotype mice developed pathological features of TSE 
disease but this was considerably less extensive than seen in HuMM mice.  Only a 
single VV mouse developed TSE pathology.  If the development of pathological 
TSE is used to predict the development of human clinical vCJD disease, then the 
incubation period is likely to be ranked in the order shortest to longest: MM, MV, 
VV.   
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 In summary vCJD infection is likely to result in longer incubation periods 
for non-MM individuals.  This longer incubation period may provide a window of 
opportunity for potential treatment to halt the progression of disease before the CNS 
is irrevocably damaged.  The ethics of providing a screening test for infection (if 
this were available) are complex especially as the incubation period may be greater 
than the normal lifespan of the individual.   
 
7.2.5  Adaptation of the vCJD Agent Following Human Passage will 
Produce a More Infectious Strain. 
 The identification of vCJD infection in four individuals via blood 
transfusion, has lead to the hypothesis that human passage may have resulted in 
adaptation of the agent.  This may in turn lead to an increase in the infectivity of the 
strain in the human population and to more secondary cases than have arisen from 
primary BSE infection.  Data from this thesis does not support this hypothesis.  The 
transmission properties of material from the first case of blood transfusion 
associated vCJD (codon 129 genotype MM) were remarkably similar to that of BSE 
associated vCJD.  This finding has now been published in PLoS ONE together with 
supportive evidence from wild-type mouse studies (Bishop et al., 2008).   
 The human passaged agent showed a similar preference for the MM mouse 
host, a decrease in efficiency in the MV host, and rare transmission to the VV host, 
with evidence of a subclinical phase in methionine carriers.  The pathological 
features (lesion profile and plaque formation) and biochemical PrPSc profile were 
very similar to that seen for transmission of BSE associated vCJD.   
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 Although there is little evidence of strain adaptation, the intravenous route 
of blood transfusion associated vCJD infection is more efficient than the oral route 
of BSE infection.  There is therefore the possibility that even without an adaptation 
of the vCJD agent the human population may be at greater risk than for BSE 
because of more efficient human-to-human routes of infection.  The predicted long 
subclinical phase in all genotypes, with associated infectivity, may therefore provide 
the source of future vCJD cases following secondary infection by blood transfusion, 
surgery, or organ transplant.  These conclusions are based on transmission data from 
an MM genotype vCJD patient and an MM blood transfusion recipient.  It remains 
unknown whether there could be more substantial strain adaptation in MV or VV 
genotype hosts.  Second passage of vCJD (from BSE) in these mice indicates that 
the original strain properties are likely to remain the same regardless of host 
genotype.  This knowledge may allow statistical predictions of future human-to-
human disease transmissions to use the same modelling criteria associated with 
codon 129 genotype that have been used for primary vCJD.   
 
7.2.6  The Risk of Iatrogenic Infection from sCJD Varies According to 
the Codon 129 Genotype of Source and Recipient 
 With the exception of sCJD(MM2) in all three codon 129 genotype 
recipients, and sCJD(VV1) in HuMM mice, all other sCJD subgroups can infect each 
codon 129 genotype host.  There are a wide range of clinical and pathological 
responses which may correlate with the risk of infection for example the sCJD(MV2) 
and sCJD(VV2) subgroups infect 100% of VV mice with short incubation periods 
for clinical disease, whereas only subclinical disease is seen in MM and MV mice.  
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Subclinical disease in the majority of mice was seen in nearly half the transmission 
experiments suggesting that there may be undetected cases of iatrogenic sCJD 
transmission.  This may not be of major concern as onward human-to-human 
transmission from these cases of iatrogenic sCJD is likely to be limited to 
neurosurgical events, as the pathology of sCJD is usually restricted to CNS tissues.   
 The appearance of clinical TSE signs in mice may have a direct relationship 
to the risk of iatrogenic infection leading to clinical disease in humans.  If this is the 
case then the sCJD(MM1) and sCJD(MV1) human strains carry the highest risk for 
human-to-human transmission.  Unlike the other inocula these two produced clinical 
TSE in the majority of mice for each genotype line.  It may be that the commonest 
form of sCJD (MM1 subgroup) is also one of the most infectious, an important 
consideration for modelling iatrogenic spread of human TSEs.   
 Looking at the relative risk between each codon 129 genotype mouse line, 
for all types of inocula, the data suggest that the VV genotype is the most at risk of 
iatrogenic infection from sCJD.  The HuVV line was the only one that had positive 
scores for the presence of clinical disease with at least four of the six inocula.  There 
is no evidence of heterozygote protection in the HuMV line as seen in kuru 
(Cervenakova et al., 1998) and French growth hormone associated iCJD (d'Aignaux 
et al., 1999, Brandel et al., 2003).  The HuMV line appears to be more susceptible 
than the HuMM line as the former shows subclinical signs with sCJD(VV1) and the 
latter has no evidence of transmission.   
 The variation in host response to inocula of different codon 129 genotype 
may predict that similar differences may appear in human iCJD cases infected with 
sCJD strains.  It is assumed that the majority of iCJD cases were due to sCJD 
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infection as this is the most common human TSE.  As tracing the source of 
contamination is difficult, the available evidence relates to codon 129 genotype 
frequency and incubation periods for iCJD patients.  French human growth hormone 
associated iCJD patients had a higher incidence of MM (MM: 62%, MV: 22%, VV: 
16%, n=77) than UK cases in which there was a higher frequency of VV genotypes 
(MM: 4%, MV: 52%, VV: 44%, n=27).  Amongst the French cases the MV patients 
had longer incubation periods, with onset for the first case 5 years later than the first 
homozygous case (Brandel et al., 2003).  Production and treatment methods were 
similar in both countries so the reason for these differences is likely to be the source 
of infectivity, the sCJD strain.  Based on the results of this thesis the UK iCJD cases 
may have been caused by infection with material from a sCJD subgroup with valine 
at codon 129 and type two PrPSc (which produces shorter incubation periods in 
HuVV mice), and the French cases with MM1 or MV1 subgroup sCJD (that 
produces clinical TSE in all three genotype transgenic mice).   
 As cadaveric human growth hormone was produced from large pools of 
pituitary glands there may have been infectivity from multiple sCJD strains, which 
may have influenced the host response.  This could be tested in this mouse model by 
infecting with pooled sCJD samples from different subgroups.  Additionally, 
peripheral route challenge rather than the intracerebral inoculation used here may 
more accurately model susceptibility in human iCJD cases, which developed via 




7.2.7  The Currently Defined Subgroups of sCJD are Unique Strains of 
Human Disease, with Individual Transmission Properties 
 For approximately 40 years research groups have attempted to define sheep 
scrapie strains.  Initially this involved assessing the pathology and clinical features 
found in the ovine host and this progressed to observing the transmission properties 
in sheep and goats and then in laboratory mice (Zlotnik and Rennie, 1958, Zlotnik 
and Rennie, 1962, Dickinson, 1970).  Use of mice lead to a definition of strain that 
was dependent on both agent source and experimental host factors.   
 The definition of TSE strains was based on incubation period, vacuolation 
scoring (lesion profile), and serial passage in mouse models, and more recently on 
genetics, biochemistry and CNS deposition of PrP.  Incubation period and 
vacuolation scoring were the core variables examined in early studies, and are still 
used today. The original research highlighted some important considerations when 
using these variables to determine differences between strains.  Incubation period is 
useful only if titre, dose, and inoculation route are constant.  Lesion profiles of 
vacuolation scoring will be the same for clinical disease resulting from variable 
doses, but will increase in intensity during the course of pathogenesis (Fraser and 
Dickinson, 1968, Dickinson and Meikle, 1969).  Further definition of TSE strains 
and the response of the host has benefited from the subsequent characterisation of 
prion protein genetics and biochemistry, and the distribution of disease associated 
PrPSc in tissues of an infected animal.  Panels of wild-type mice were successfully 
used to define scrapie strains but have been of very limited use in understanding 
sCJD.  This was due to the absence of clinical disease for most subgroups and the 
similarities in lesion profiles within mouse lines infected with different sCJD 
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subgroups.  This thesis discusses the generation and use of transgenic mice 
specifically manufactured to define sCJD strains.   
 Subgroups of sCJD have been defined by the codon 129 genotype and PrPSc 
Western blot type leading to classification into six subgroups (MM1, MM2, MV1, 
MV2, VV1, and VV2) (Parchi et al., 1999, Hill et al., 2003, Cali et al., 2006).  The 
data in this thesis has distinguished these six subgroups as unique strains as they 
exhibit differences in transmission properties, such as incubation period to clinical 
disease, TSE vacuolation, PrPSc distribution, and PrPSc type by Western analysis.  
This thesis has shown that the codon 129 genotype plays a significant role in 
transmission properties, and that inoculum PrPSc Western blot type is a significant 
determinant of TSE vacuolation intensity and distribution (the lesion profile) in the 
infected host.   
 Four major patterns have been identified within the subgroups leading to 
two pairs with similar attributes and two distinct single types.  The first pair is 
sCJD(MM1) and sCJD(MV1), which are usually grouped together in the sCJD sub-
classification as the ‘classical’ form of sCJD, and could be predicted to have shown 
similar transmission properties.  Incubation period data for onset of clinical TSE 
signs in the transgenic mice cannot distinguish between these two inocula.  
Comparison of the lesion profile data by Hierarchical Cluster Analysis points to a 
difference in the HuVV data.  The lesion profile from the sCJD(MM1) inoculum is 
more like those seen with inocula derived from sCJD cases with type 2 PrPSc 
whereas the sCJD(MV1) inoculum lesion profile is more like those seen with type 1.  
This is the only evidence from the transgenic mice that distinguishes these two 
inocula.  However, in the wild-type transmissions ICC detection of PrPSc was 
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positive in all wild-type mice inoculated with sCJD(MM1) but in only 6% of mice 
with sCJD(MV1).  These two sCJD subgroups therefore have different transmission 
properties.   
 The second pairing of inocula with similar transmission properties are 
sCJD(VV2) and sCJD(MV2).  These two are the second and third most frequent 
types of sCJD found but, unlike the above pairing, patients show widespread clinical 
and pathological differences.  There are no differences in the appearance of clinical 
TSE in the mice with both HuMM and HuMV mice showing only subclinical TSE 
and the HuVV mice developing symptoms after a short incubation period of <300 
days.  There was also no difference in wild-type mouse transmission, or PrPSc typing, 
or lesion profile cluster analysis.  The HuMM and HuMV mice produced type 1 
PrPSc whereas the HuVV mice produced type 2 (with both inocula).  The latter were 
the only mice in this sCJD study to show this protein type.  This may have been due 
to a specific biochemical response of PrP only seen in VV genotype mice to 
inoculum from sCJD patients also with valine allele, type 2 PrPPSc.  It may also have 
been a consequence of the specific pathological targeting to the cerebral cortex in 
these HuVV mice, which may itself have been a cause of the relatively fast 
incubation period (as seen in Chapter 6, Figure 6.F5, Panels 15 and 17).   
 The number of mice positive for TSE vacuolation provided the only 
evidence of a difference between the inocula as HuMM mice inoculated with 
sCJD(MV2) were more likely to be positive than those inoculated with sCJD(VV2) 
(69% versus 33% respectively).  This suggests that there was more compatibility 
between the MV inoculum and the MM mice than for the VV inoculum, leading to a 
faster development of pathology.  This may be due to the methionine allele PrPPC in 
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the host mice.  Although the rate may differ, the cluster analysis shows that the final 
intensity of vacuolation and the distribution was equivalent.  Evidence to separate 
these two sCJD subtypes is limited and could be investigated further, for example, by 
comparing PrPSc deposition in different brain regions.   
The remaining two inoculum sources, sCJD(VV1) and sCJD(MM2) showed 
different transmission properties from the two pairings above and to each other.  
These are the least common forms of sCJD comprising 1-2% of cases.  These were 
the only inocula not to produce significant levels of clinical TSE in any of the 
transgenic or wild-type mice lines.  SCJD(VV1) showed no evidence of transmission 
to the HuMM mice but showed high levels of subclinical TSE in both the HuMV and 
HuVV mice, suggesting that with type 1 PrPSc in a VV genotype inoculum there is a 
valine dominant codon 129 genotype effect.  SCJD(VV2) transmits to the HuMM 
mice indicating an important effect of the PrPSc type between these inocula.   
 There was no evidence of transmission to transgenic or wild-type mice for 
the sCJD(MM2) inoculum.  ICC data is unavailable for these mice, because with no 
TSE vacuolation, the levels of PrPSc, if present, are likely to be very low or non-
existent (as seen for sCJD(VV1) inoculation of HuMM mice).  It may be important 
for further investigation why sCJD(MM2) material does not transmit whereas 
sCJD(MM1) transmission is highly efficient as the only difference with respect to 
PrP is the protein configuration.   
These last two sCJD inocula have unique transmission properties and 
therefore, overall, the six defined subgroups can be distinguished to varying degrees 
by transmission to this panel of mice.  Understanding the reasons for these 
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differences in strain transmission, and attempting to identify atypical sCJD cases by 
transmission to this panel, may be key future uses of this mouse model.   
 
7.3  CONCLUDING REMARKS 
 The overall goal of this PhD thesis was to use a novel panel of gene targeted 
transgenic mice expressing the human prion protein, in understanding further some 
of the human TSE strains, and specifically the role of codon 129 genotype in disease 
transmission and pathogenesis.   
7.3.1  The Transgenic Mouse Model 
 Aside from examining the specific transmission properties of different 
human TSE this thesis also aimed to set out the benefits of a gene targeted approach 
to understanding TSE transmission and the effects of codon 129 genotype the most 
important factor in human PRNP genetics.   
 At the outset of this thesis the three transgenic mouse lines, HuMM, HuMV, 
and HuVV, were unique in the prion research field.  These inbred mice were 
genetically identical except for the single base change required to code for either 
methionine or valine at codon 129 of the inserted human PRNP gene.  The new gene 
having directly replaced the original mouse copy and therefore under the correct 
gene expression regulatory processes.  Since the start of this thesis Professor 
Kitamoto’s group has also published a similar model however most of their work 
centres on using the mice as bioassays, rather than lifespan susceptibility, with 
positive transmission results based on detection of PrPSc in the spleen at 75 days post 
injection.   
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 The most significant benefit of this model is the ability to determine the true 
effect of codon 129 genotype.  With other lines of mice developed via the random 
genomic insertion method there is always the possibility that either the insertion 
points, or the expression levels, are affecting the data.  Gene targeting for insertion of 
new genetic elements ensures that from birth to death of each mouse the prion gene 
is expressed in the right place, at the right time, and at the right level.  Therefore, if 
the same inoculum is injected into these three codon 129 genotype lines the relative 
differences in transmission are due directly to the host genotype.   
 The uses for this mouse model are varied.  This thesis outlines the starting 
point with transmission of standard cases of human TSE.  From this point atypical 
cases can be analysed to observe how different or how similar they are to specific 
typical cases.  For example, it will be important in the future to be able to classify 
novel forms of vCJD, such as those with long incubation periods, or those in MV or 
VV genotype patients, and to differentiate these from atypical forms of sCJD.  There 
may also be novel forms of animal TSE that might pose a threat to humans via the 
food chain and therefore these mice could be used to understand the potential risks.   
 As a laboratory tool these mice could be the source of material such as cell 
lines or tissues with which it may be possible to understand further the pathological 
processes of prion disease, the biochemistry of PrPC conversion (Jones et al., 2007), 
or the potential of therapeutic approaches to halt this invariably fatal disease.   
7.3.1  Summary of Results 
 Chapter 4 details the findings of vCJD transmission which were published 
in 2006 in Lancet Neurology (Bishop et al., 2006).  This was the first report of a 
direct comparison of transmission properties of this strain in hosts of each of the 
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three codon 129 genotypes.  The data indicated that all three genotypes were 
susceptible with a hierarchy of reducing transmission efficiency from MM to MV to 
VV, and that there was evidence of a lengthy infectious subclinical phase.  The 
implications of these findings were that MM individuals were not the only 
susceptible genotype to infection by BSE, and although the number of clinical cases 
of vCJD has been falling since 2000 there may still be significant numbers of 
individuals of each genotype harbouring infectivity.  A second wave of human-to-
human infection via blood products or surgery is therefore a possibility, together 
with clinical cases occurring in non-MM patients after much longer incubation 
periods than seen already in MM patients.   
 Chapter 5 outlines the data obtained from transmission of the first case of 
blood transfusion associated vCJD infection which were published in 2008 (Bishop 
et al., 2008).  In comparison with the data obtained from vCJD transmission it was 
shown that material from this patient contained a strain of TSE that had remarkably 
similar properties.  This implied that significant adaptation of the BSE strain to a 
more highly infectious agent to humans, would not occur via human passage and 
therefore the individual risk of developing vCJD remained low.  This was also 
confirmed by secondary passage of material from the primary vCJD transmission 
experiment.  Clinical presentation of vCJD infection via human passage may be 
similarly limited to a low number of MM genotype individuals, but a lengthy 
subclinical phase in all genotypes would be of concern to future surveillance and risk 
assessment of disease transmission.   
 Chapter 6 contains the dataset obtained following transmission of typical 
cases of each of the six subgroups of sCJD to understand further the strain nature of 
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the commonest type of human TSE.  Although there were a number of similarities 
between the six experiments, overall it was possible to identify unique properties for 
each subgroup and therefore they could be described as six individual strains of 
sCJD.  As each sCJD subgroup was shown to be different the inocula clearly had the 
dominant role in determining the transmission properties.  This was confirmed by 
sub-passage via the HuVV mice where the original human sCJD strain properties 
were propagated by the mouse host, and by analysis of the mouse lesion profile data 
which was shown to be primarily affected by the inocula PrPSc type.  The response of 
the three mouse lines provided much of the data for observing differences between 
each inoculum.  The HuVV mice were the most efficient host overall for 
transmission and produced the fastest incubation times, with sCJD(MV2) and 
sCJD(VV2).  In contrast, these two inocula produced clinical TSE in only a few 
HuMM and HuMV mice, with the majority surviving with subclinical infections.   
 With transmission variation due to the codon 129 genotype of both inocula 
and host mouse it was difficult to draw an overall conclusion about the role of this 
polymorphism however this dataset now provides a standard to which atypical sCJD 
case can be compared, and from which detailed research on the mechanisms of sCJD 
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